SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 1997

COMMISSION FILE NUMBER 0-22333

NANOPHASE TECHNOLOGIES CORPORATION
(Exact name of registrant as specified in its charter)

            DELAWARE                                  36-3687863
  (State or other jurisdiction                     (I.R.S. Employer
of incorporation or organization)                 Identification No.)

453 COMMERCE STREET, BURR RIDGE, ILLINOIS 60521
(Address of principal executive offices) (zip code)

Registrant's telephone number, including area code: (630) 323-1200

Securities registered pursuant to Section 12(b) of the Act: NONE

Securities registered pursuant to Section 12(g) of the Act:
COMMON STOCK, PAR VALUE $.01 PER SHARE
(Title of Class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X]

The aggregate market value of the registrant's voting stock held by non-affiliates of the registrant, based upon the last reported sale price of the registrant's Common Stock on March 27, 1998 was $51,205,444.

The number of shares outstanding of the registrant's Common Stock, par value $.01, as of March 27, 1998 was 12,277,467.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant's Definitive Proxy Statement in connection with the registrant's 1998 Annual Meeting of Stockholders are incorporated by reference into Part III of this Report on Form 10-K.


PART I

ITEM 1. BUSINESS

Because Nanophase Technologies Corporation ("Nanophase" or the "Company") wants to provide investors with more meaningful and useful information, this Annual Report on Form 10-K (the "Form 10-K") contains, and incorporates by reference, certain "forward-looking statements" (as such term is defined in
Section 21E of the Securities Exchange Act of 1934, as amended), that reflect the Company's current expectations regarding the future results of operations, performance and achievements of the Company. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends" and similar expressions. These statements reflect the Company's current beliefs and are based on information currently available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies, which could cause the Company's actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and contingencies include, without limitation, demand for, and acceptance of, the Company's nanocrystalline materials; changes in development and distribution relationships; the impact of competitive products and technologies; and the factors set forth under "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations -- Risk Factors." The Company undertakes no obligation to update or revise any such forward-looking statements that may be made to reflect events or circumstances after the date of this Form 10-K or to reflect the occurrence of unanticipated events.

GENERAL

Nanophase develops and markets nanocrystalline materials for use as ingredients and components in a wide range of commercial applications. The Company began manufacturing nanocrystalline materials in commercial quantities in the fourth quarter of 1996. Nanocrystalline materials are metallic and ceramic materials that generally consist of particles that are less than 100 nanometers (billionths of a meter) in diameter and contain only a few thousand or tens of thousands of atoms, rather than the millions or billions of atoms in particles of most conventional materials. By processing materials in this near-atomic size range, the Company is able to engineer the structure of particles and exploit the properties of their surface atoms to enhance the performance of basic raw materials such as aluminum, iron, titanium and zinc, as well as to molecularly engineer new composite materials. Compared to conventional materials, the Company believes its nanocrystalline materials generally exhibit superior chemical, mechanical, electronic, magnetic and optical properties. The Company believes that through its extensive proprietary research and development programs, combined with its proprietary and patented production processes, it has established new standards for high-performance commercially produced nanocrystalline materials.

The Company is in the advanced materials industry and has identified initial commercial applications for its nanocrystalline materials in four primary markets: electronics, structural ceramics and composites, cosmetics and skin-care, and industrial catalysts. The Company believes each of these markets provides numerous commercial applications in which its nanocrystalline materials will have significant competitive advantages based on product performance. Commercial applications which have been developed or are currently being developed in these markets include the following:

- Electronics. Abrasives for chemical/mechanical polishing of semiconductor wafers, anti-radiation coatings for cathode ray tubes and thin-film materials for semiconductor manufacturing.

- Structural Ceramics and Composites. Ceramic mechanical seals, components for continuous steel casting, abrasion-resistant polymers for oil drilling sensors and ceramic armor.

- Cosmetics and Skin-Care. Topical health-care products, transparent ultraviolet blockers and colorants for cosmetics.

- Industrial Catalysts. Chemical-process catalysts.

2

In each of these markets, the Company's strategy is to establish collaborative relationships with industry leaders in order to validate the capabilities of its materials and coordinate the development and commercial introduction of product applications. These relationships generally include specific milestones and a development path that is intended to lead to significant commercial product revenues. The Company is currently collaborating with, among others, AG Industries ("Acutus Gladwin"), The Dow Chemical Company ("Dow"), E.I. Dupont & de Nemours & Co. ("DuPont"), Pacific Safety, Inc. ("Pacific Safety") and Philips Electronics N.V. ("Philips"). As a result of its collaborative relationships, the Company entered into commercial supply contracts with EKC Technology, Inc. ("EKC"), a subsidiary of ChemFirst Corporation ("ChemFirst"), a manufacturer of semiconductor polishing slurries; with Schering-Plough Corporation ("Schering-Plough") pursuant to which the Company is supplying its nanocrystalline zinc oxide to Schering-Plough for use in topical health-care products; and with LWT Instruments, Inc. ("LWT") for anti-abrasive polymers used in oil drilling applications. To gain access to foreign markets, Nanophase has entered into a license agreement which enables C.I. Kasei Co., Ltd. ("CIK"), a subsidiary of Itochu Corporation ("Itochu"), formerly C. Itoh, to manufacture, use and sell the Company's nanocrystalline materials in broad-based industrial markets throughout various Asian countries.

The Company believes that its nanocrystalline materials have broad and enabling potential beyond the product applications it is currently developing with its customers. In 1995, the Battelle Memorial Institute, a leading contract research organization, identified "molecularly engineered" materials (i.e., nanocrystalline materials) as "super materials" which represent one of the ten most important technologies for the coming decade. Nanophase was organized in 1989 to commercialize technologies that are based on principles developed at Argonne National Laboratories ("Argonne"), and believes that it is the only company to successfully transition the production of high-performance nanocrystalline materials from laboratory to commercial scale. In 1995, the Company's patented physical-vapor-synthesis ("PVS") process for producing these materials received the R&D 100 Award, given each year by R&D Magazine to recognize the 100 most technologically significant new products and processes in the world.

NANOCRYSTALLINE MATERIALS

All matter is composed of atoms, or molecules that are combinations of atoms. Most solid materials, such as ceramics and metals, are polycrystalline in nature, i.e., they consist of microscopic particles, or crystals, the atoms or molecules of which are stacked in orderly patterns. The attributes of a polycrystalline material, including strength, flexibility, color and electronic conductivity, depend upon the composition, shape and size of the material's individual crystals, the organization of atoms in the individual crystals, and the relationships and interactions among the crystals. The particles of conventional crystalline materials generally have irregular shapes and sizes. The organization of a crystalline material's atoms or molecules, however, can be manipulated to form particles that are much smaller and more uniform. Particles that are less than 100 nanometers (billionths of a meter) in diameter are generally called nanocrystals and contain only a few thousand or tens of thousands of atoms, rather than the millions or billions of atoms in particles of most conventional materials. Through molecular engineering, the shape and size of such particles in nanocrystalline materials can be manipulated to produce materials with superior properties. These nanocrystalline materials behave in enhanced and novel ways because the properties of, and interactions among, their ultra-small particles have been significantly altered.

The potential of nanocrystalline materials has been known for decades and such materials have been produced by a variety of other processes. However, these other processes are more limited in their ability to engineer the materials for high-performance applications. Mechanical and chemical processes are the two most common methods for producing nanocrystalline materials. In mechanical processes, fine powders are commonly made from large particles through the use of crushing techniques such as a high-speed ball mill. The resulting fragmented powders contain particles of inconsistent shapes and sizes, are relatively coarse, and are not adequate for many high-performance commercial applications. Nanocrystalline materials can also be made through chemical processes, which utilize chemicals to create a reaction that precipitates particles of varying size and shape. Chemical processes, like mechanical processes, often produce nanometric particles of inconsistent shapes and sizes that are difficult to engineer for high-performance applications. Chemical

3

processes also tend to leave chemical residues on the particle surfaces, making it difficult to precisely engineer the mechanical, chemical and electronic properties of the materials. Historically, high-quality nanocrystalline materials have been difficult to consistently produce in other than laboratory-scale quantities and have not been produced at commercially affordable costs. The Company believes that these traditional methods of producing nanocrystalline materials do not provide the means to realize the full potential of such nanocrystalline materials.

ADVANTAGES OF THE COMPANY'S NANOCRYSTALLINE MATERIALS

The Company has developed new technologies for the engineering and high-volume production of high-quality nanocrystalline materials that it believes cannot be accomplished by the traditional methods described above. At the core of the Company's technologies is its patented PVS process, whereby metallic or ceramic materials are vaporized into atoms that are mixed with a gas to form nanometric particles.

The following attributes of the particles produced by the Company's PVS process enable it to produce significant quantities of nanocrystalline materials which it believes to be superior, for a range of high-performance applications, to both conventional materials and nanocrystalline materials produced by other means:

SPHERICAL SHAPES AND SMALL SIZES enable particles to slide over each other, which allows the Company's ceramic materials to become more ductile and more easily formed. This enables the Company to rapidly mold variously shaped ceramic components without the costly and time-consuming machining which is typically used for conventional ceramics.

CLEAN SURFACES enable particles to exhibit consistent surface chemistry, which facilitates the Company's ability to coat its nanocrystalline materials. The Company's coatings enhance certain commercial applications of its nanocrystalline materials, such as cosmetic dispersions.

NARROW SIZE DISTRIBUTION of nanometric particles ensures that nanocrystalline materials are virtually free of large particles, which facilitates engineering of the chemical, mechanical, optical and electronic properties of the material because these properties vary according to particle size. For example, the Company produces titanium dioxide with particles that are large enough to block ultraviolet rays but are consistently smaller than the wave length of visible light, which enables sunscreens formulated with these particles to provide high SPF protection and transparency.

AGGREGATION CONTROL results in loosely agglomerated and uniformly small particles that can be readily and uniformly dispersed in a variety of media. For example, the Company produces ultra-fine abrasives for slurries used to polish the surfaces of semiconductors, which results in significantly smoother surfaces and faster and more selective removal of material.

DIALABLE CONTROL OF PARTICLE SIZE enables precise engineering of particles through subtle modifications of the Company's PVS process. By controlling the evaporation rate of a material's atoms or the type or pressure of gas used in the production process, the Company can alter, enhance and tailor the performance of its basic raw materials for specific product applications. For example, further decreasing the particle size of a metal oxide increases its number of surface atoms, which enables the Company to produce metal oxides with enhanced catalytic performance.

The Company has developed related technologies to further enhance the materials produced by its PVS process. Because the PVS process produces particles that, in contrast to particles of conventional materials, are (i) nearly spherical, (ii) virtually free of chemical residues, (iii) uniformly small, (iv) not strongly agglomerated, and (v) easily engineered, the Company can apply its other proprietary technologies to further process these particles to set new standards for a range of additional high-performance commercial applications. For example, certain product applications require surface treatments for nanocrystalline particles so they can be dispersed in a variety of media. To enable the incorporation of its materials in dispersions, the Company developed its proprietary discrete-particle-encapsulation ("DPE") process that prevents particles from agglomerating by completely coating each individual particle. The coating process also enables the Company to alter the optical, chemical and electronic behavior of particles to meet the requirements of

4

particular applications. In addition, certain product applications require nanocrystalline materials to be formed into structural ceramics of a precise shape and tolerance. As part of its strategy to enter markets for structural ceramics, the Company developed its net-shaping technology that enables the rapid fabrication of dimensionally precise, high tolerance structural ceramic components without costly machining.

CUSTOMERS AND APPLICATIONS

The Company is in the advanced materials industry and has identified four primary markets -- electronics, structural ceramics and composites, cosmetics and skin-care, and industrial catalysts -- each of which offers the Company significant potential for revenue growth. In addition, the Company believes these markets provide opportunities to achieve competitive advantages based on product performance. The Company's strategy is to collaborate with industry leaders in these markets in order to validate the capabilities of its materials and coordinate the development and commercial introduction of product applications. The collaborative relationships pursued by the Company include (i) agreed-upon specifications for the proposed commercial application of the Company's materials; (ii) confirmation by the customer that the proposed application appears to be commercially viable and valuable; (iii) a significant commitment of developmental resources; (iv) agreed-upon developmental milestones, and (v) a development path that is intended to lead to significant commercial revenues from the customer.

Following is a more detailed description of the Company's targeted markets and its activities in certain material product applications.

ELECTRONICS

Electronics is one of the world's largest and fastest growing markets, fueled in part by rising demand for increased computing power and information storage requirements and the rapid growth of communications technologies. The new levels of performance in electronics that are necessary to meet these requirements depend, in large part, on advanced materials, especially advanced ceramics, that enable higher performance and further miniaturization. Increasingly, critical dimensions and performance criteria for high-speed electronic pathways and dense platforms are measured in nanometers and angstroms (tenths of nanometers). It is at this level of performance that Nanophase believes its engineered nanocrystalline materials demonstrate advantages for electronics applications.

Nanophase's primary focus in this market has been directed toward two product applications: (i) semiconductor polishing and (ii) coatings for electromagnetic radiation protection. The Company believes that the uniformly small particle size, nearly spherical particle morphology and clean particle surface of the Company's materials allow such materials to provide innovative, value-added benefits for these and other product applications in the electronics market.

Semiconductor Polishing

Increases in computing power require increased memory capacity, which is achieved by fabricating smaller circuits on smoother semiconductor wafer surfaces. These smoother surfaces are obtained by a technique called chemical/mechanical polishing ("CMP"), in which an abrasive slurry is used to polish semiconductor surfaces to a very fine finish.

Polishing slurries utilizing the Company's nanometer-sized aluminum oxide ("alumina") and cerium oxide ("ceria"), with their nearly spherical particle shapes and uniformly small particle sizes, provide semiconductor polishing that results in (i) significantly smoother surfaces, (ii) more selective removal of material, and (iii) easier cleaning during the manufacturing process, compared to slurries utilizing conventional materials. The Company believes that these attributes will be an important element in the production of semiconductor wafers with smaller geometries that will result in increased memory capacity, faster processing speeds and lower production costs.

In December 1997, Nanophase entered into a seven-year supply agreement with EKC, a subsidiary of ChemFirst, pursuant to which the Company will supply its nanocrystalline alumina and ceria and provide

5

related research and customer and technical support to EKC. This agreement supersedes the Company's five-year requirements contract with Moyco Technologies, Inc. ("Moyco") and was entered into after Moyco sold its CMP intellectual property, technologies and certain other intangible assets to EKC in December 1997. Sales to, and fees from, Moyco pursuant to such contract constituted approximately 42% of the Company's revenue in 1997. The Company has agreed to sell its nanocrystalline alumina and ceria to EKC for use in the production and sale of slurries and other materials used in CMP on an exclusive basis so long as EKC purchases certain annual minimum dollar amounts specified in the agreement. If EKC fails to purchase such minimum dollar amounts, the Company may terminate EKC's exclusivity. In addition, if EKC does not purchase certain other minimum dollar amounts specified in the agreement, the Company may terminate the entire agreement or its obligation to supply nanocrystalline materials to future customers of EKC. The minimum dollar amounts specified in the agreement which EKC must purchase over the term of the agreement to maintain exclusivity, avoid termination of future supply obligations or avoid termination of the agreement are approximately $50 million, $25 million or $5 million, respectively, of the Company's nanocrystalline materials.

Electromagnetic Radiation Protection

Cathode ray tubes ("CRTs") utilized in television and computer monitors emit electromagnetic radiation due to the high voltages used to generate light. In the past, little attention was paid to the potential harmful effects of this radiation. Recent European Economic Community regulations scheduled to go into effect over the next several years, however, place more stringent limits on the quantity of radiation that can be emitted by television and computer monitors. In response to such regulations, CRT manufacturers require transparent, conductive coatings that meet the new electromagnetic radiation standards.

The materials currently used for conductive coating of CRTs have not been proven to meet all of the new radiation requirements. Nanophase can produce a proprietary metal oxide mixture, which has a narrower particle-size distribution and cleaner particle surfaces than currently used materials. The Company's nanocrystalline metal oxide mixture is highly conductive and easily dispersed and, when applied as a coating to CRTs, is expected by the Company to meet the increased radiation shielding regulatory requirements, while maintaining the transparency required for quality video images. The Company has developed a coating for CRTs which meets the conductivity and transparency requirements of Philips and is actively working with their manufacturing group to introduce this product into production for CRTs manufactured by Philips.

Thin-Film Materials for Semiconductor Manufacturing

Nanophase has begun an early stage development program with a leading electronic materials company for developing advanced materials for use in semiconductor manufacturing. The objective is to develop advanced materials which can be used to fabricate thin-films on the surfaces of semiconductors to enable the production of semiconductor wafers with increased memory capacity, faster processing speeds and lower production costs. Nanocrystalline materials are used because the products require a uniform and fine-grained structure. This product application is in an early stage of development and investigation.

STRUCTURAL CERAMICS AND COMPOSITES

Structural ceramics are advanced compounds that offer hardness, high strength and inertness for a broad range of industrial applications involving harsh chemical and thermal environments. The free-flowing nature and weak agglomeration of the Company's nearly spherical nanocrystalline particles enable the Company to rapidly fabricate high-tolerance, dimensionally precise structural ceramic parts without costly machining. Because the conventional methods for forming structural ceramics involve the use of high temperatures, high pressures or lengthy machining operations, the high costs of fabrication have limited the usage of dimensionally precise ceramics to only the most critical applications. Through its net-shaping process, the Company can mold nanocrystalline ceramic materials into fully dense ceramic parts with little or no machining. This process makes it possible to fabricate a variety of dimensionally precise structural ceramic components in a significantly shorter period of time and at significantly lower temperatures and pressures than conventional fabrication methods.

6

Composites, like structural ceramics, are engineered structures that consist of diverse elements and are geared toward high-stress product applications that require durable, resistant materials. Composites combine the advantageous qualities of their constituent materials. The properties of these composites depend heavily on the nature and amount of the materials that are incorporated into the composites. For example, incorporating a hard material like alumina into a flexible and lightweight plastic can increase the plastic's resistance to abrasion and wear. Such an increase is related to the number of particles of the constituent alumina. Because there are more particles in one pound of nanocrystalline materials than in one pound of more commonly used micron-sized particles, properties such as abrasion resistance are enhanced by substituting nanocrystalline materials for conventionally used materials.

Composite Polymer for Oil Drilling Machinery

Nanophase has entered into a contract with LWT, a supplier of instrumentation to the oil drilling industry, for the supply of abrasion-resistant composite polymers to protect down-hole data logging equipment. In this application, instrumentation is lowered into a drilled shaft in order to provide information to the drill operator on a continuous basis. Because drilled shafts often pass through hard rock formations, or very abrasive layers of sandstone, the data logging instruments must be protected from potential wear. A protective housing, or collar, is used to protect the data logging equipment. These collars are conventionally coated with a commercially available ceramic-filled polymer. Conventional fabrication of these collars is difficult because the polymer is thick and must be applied by hand. LWT requires a polymer, which can be applied by automatic machinery, has a long service life and is abrasion-resistant. Initial tests performed by LWT using the Company's composite materials indicate that such materials can meet these requirements. The Company is currently developing composite materials which meet LWT's particular product specifications.

Ceramic Components for Continuous Steel Casting

The Company is collaborating with Acutus Gladwin, a leading supplier of services and products in the steel industry, to produce a ceramic component for use in continuous steel casting. Continuous steel casting is performed by pouring molten steel from a ladle through a funnel-shaped nozzle into a mold, which is several hundred feet long. Current nozzles are made of a porous alumina/graphite material and require frequent replacement due to wear. During replacement, steel-casting lines using these nozzles must be shut down for 15 to 45 minutes while new components are installed, resulting in down-time costs which could approximate up to $25,000/hour and several tons of second-quality steel which must be remelted or downgraded for use in lower-quality products. Nanophase believes that its denser net-shaped ceramics in this application will substantially increase wear resistance, resulting in significant cost savings due to decreased downtime and less wasted or sub-standard steel. Under a development agreement with Acutus Gladwin, the Company has successfully completed laboratory testing of its material and prototypes are scheduled to be field tested during the second quarter of 1998.

Ceramic Mechanical Seals

Nanophase has fabricated prototype ceramic mechanical seals which are designed for use in harsh applications to prevent abrasive particles from entering mechanical joints and to prevent oil from leaking from the joints. Conventional seals used in these applications are commonly made of plastic composite materials and either wear or corrode, requiring replacement after only a few thousand hours of operation. Ceramic seals, because of their improved abrasion and corrosion resistance, are believed by the Company to be more reliable and durable than conventional seals. Customer-laboratory tests of prototype seal designs have shown that Nanophase's ceramic seals can increase the service life compared to currently-used seal materials, resulting in a reduction of equipment downtime and associated costs. In addition, Nanophase's net-shaping process reduces or eliminates the costly diamond grinding that normally would be required to fabricate other ceramic seals. The Company believes that reduced manufacturing costs make its ceramic seals cost-effective for a number of high-volume mechanical-seal applications. The Company is marketing its ceramic seals for potential commercial sales to various equipment and machinery manufacturers.

7

Ceramic Armor

The Company is currently fabricating net-shaped ceramic armor plates under a development agreement with Pacific Safety, a leading Canadian armor producer. Ceramic-based armor is highly desirable because of its strength and weight advantage over steel. It can provide the same protection at a significantly reduced weight. However, current ceramic armor materials, made from hot-pressed alumina or boron carbide, are either not durable enough or very costly to fabricate, and thus have limited markets. Based on preliminary studies, the Company believes that it will be able to produce denser, fine-grained ceramic armor tiles that will have greater durability and impact resistance than hot-pressed alumina tiles and offer a significant economic advantage over boron carbide.

COSMETICS AND SKIN-CARE

The cosmetics and skin-care market is a substantial consumer of particulate materials as active ingredients and pigments. The Company has targeted three of its nanocrystalline materials, titanium dioxide ("titania"), iron oxide and zinc oxide, for applications in the cosmetics and skin-care market, including sunscreens, cosmetic colorants and topical health-care applications. The Company
(i) is selling its titania to several cosmetics companies for use in sunscreens,
(ii) is shipping its iron oxide to a Fortune 500 cosmetics company for use as a cosmetic colorant, (iii) is shipping titania dispersions to that same customer for use in a product with SPF protection, which was introduced to the market in the fourth quarter of 1997, and (iv) is shipping its nanocrystalline zinc oxide pursuant to a commercial supply contract with Schering-Plough.

Topical Health-Care Applications

The Company recently entered into a four-year requirements contract with Schering-Plough pursuant to which the Company will supply its nanocrystalline zinc oxide to Schering-Plough for certain topical health-care products. For example, the Company's nanocrystalline materials are being supplied for use in new anti-fungal sprays and powders which were introduced to the market in the fourth quarter of 1997. Several skin-care companies are currently evaluating Nanophase's nanocrystalline zinc oxide for use in other topical health-care products. The Company's zinc oxide contains uniformly small particles that contain a large number of surface area atoms. Initial testing by the Company's customers indicates that this attribute provides enhanced anti-fungal activity compared to conventional materials because a lower amount of the Company's zinc oxide is needed to achieve the desired level of activity. In addition, the Company's zinc oxide, because of its weakly agglomerated particles, is better suited than conventional materials for aerosol applicators.

Sunscreens

The market for titania-based sunscreens has rapidly expanded due to (i) increasing consumer awareness of the harmful effects of ultraviolet ("UV") rays and (ii) a desire to replace conventional chemical sun-block ingredients, which can cause irritation, with "chemical-free" ingredients. Because the Company's nanocrystalline titania is comprised of particles that are large enough to block UV rays, but are consistently smaller than the wave length of visible light, it enables "chemical-free" sunscreen products to provide high SPF protection and transparency, which combination is superior to that achieved by conventional titania. Nanophase's total-encapsulation coating, based on its DPE process, also makes Nanophase's titania compatible with certain skin-product ingredients, like self-tanning ingredients, with which competitive titania is not compatible. This compatibility enables cosmetics formulators to develop self-tanning products that offer chemical-free protection from excessive exposure to UV rays.

Cosmetic Colorants

Through its PVS and DPE processes, the Company has engineered nanocrystalline iron oxide for use as a coloring agent in cosmetics. Because of its visible transparency, this iron oxide can intensely color the skin without the caking or streaking effects caused by conventional opaque coloring agents. This is due to the nanometer-sized particles of Nanophase's iron oxide that absorb light without significant visible scattering, thereby providing color without opacity. In addition, the nearly spherical particles of Nanophase's iron oxide

8

enable it to be discretely encapsulated and readily dispersed to create smooth, free-flowing cosmetic foundations which cosmetics formulators can blend to more closely match varying skin tones.

INDUSTRIAL CATALYSTS

Catalysts are materials that help convert, or accelerate the conversion of, one chemical into another. The Company's PVS process allows for the fabrication of two distinct types of solid catalysts: (i) a single pure material, such as iron oxide, which is a widely used chemical-process catalyst for the synthesis of hydrogen, ammonia and other bulk chemicals, and (ii) composite materials in which a nanocrystalline metal, such as palladium, is deposited on a larger substrate. This latter catalyst has a broad range of applications, including polymer synthesis, hydrogen peroxide production and the conversion of petroleum feedstock to higher value chemicals.

The activity of a catalyst (i.e., the amount of desired product that can be produced per unit weight of catalytic material) is an important measure of its efficacy, and is related to a number of physical properties of the catalyst, including surface area, particle size and the reactivity of atoms on the surface of the catalytic material. Nanocrystalline materials offer better performance as catalysts because they have a higher proportion of catalytically active surface atoms than conventional materials. In addition to enhanced reactivity, the Company's materials can potentially reduce costs because less catalyst is needed to achieve a desired level of activity.

Nanophase is developing a process to directly deposit nanocrystalline metals on a substrate for use by DuPont as a catalyst in large-scale chemical production. Early measurements have shown a two to fourfold increase in catalytic activity over the current, chemically produced DuPont catalyst. The Company is working with DuPont to meet specific performance requirements for this catalyst. The Company has also begun an early-stage development program with a Fortune 50 chemical company to produce catalysts comprised of nanocrystalline metal oxides on larger substrates. Based on the Company's discussions with potential customers, additional potential applications for PVS-produced heterogeneous catalysts include wash coats for automotive catalysts and surface-enhanced catalysts for the chemical-process industry.

TECHNOLOGICALLY-SIMILAR APPLICATIONS

Although the Company focuses its efforts on product applications in the above-mentioned markets, the Company believes there is a broad range of technologically similar applications, the performances of which could be substantially improved by utilizing the Company's materials and technologies without extensive additional engineering. Based on the Company's discussions, both internally and with potential customers, these include applications for fibers, textiles, plastics, paper, optical polymers, pigments and other specialty products. These applications are primarily based on the coating or dispersion of nanocrystalline materials produced by the PVS process. The Company only pursues those specialty applications which fit into its business strategy and which receive substantial support from a significant prospective customer.

THE COMPANY'S TECHNOLOGIES

Nanophase has developed and employs several related technologies for the engineering and production of nanocrystalline materials and product applications, including technologies for the synthesis, surface-treatment and dispersion of nanocrystalline materials and the fabrication of structural ceramic components. The Company also is engaged in ongoing research and technology-licensing activities as part of its strategy to maintain a technical and commercial leadership position in the field of nanocrystalline materials.

The PVS Process

The Company uses its patented PVS process to produce nanocrystalline powders. The PVS process is based on the formation of a physical vapor from a selected metallic or ceramic material that is fed through a plasma reactor and heated to a temperature above its melting point. As the temperature rises, the atoms of this material evaporate from its surface into a stream of flowing vapor. These evaporated atoms are then mixed with selected gases that chemically react with the atoms. Additional gases then cool the atoms sufficiently to

9

condense the vapor into solid, nearly spherical clusters of molecules. The flowing gas transports the resulting clusters to a collection vessel. The rapid transport and cooling of the nanometric particles produce a weakly agglomerated powder.

The Company holds two patents relating to its PVS process which expire in 2013; one covers the process itself, while the other covers the apparatus used in the process. The Company's plasma reactor embodies proprietary features that enable the production of high-quality materials at high-volume and competitive cost. Nanophase utilizes its PVS process to exploit the relative advantages of physical versus chemical synthesis of nanocrystalline materials. These advantages include the production of nanocrystalline materials with particles that are nearly spherical, virtually free of chemical residue, uniformly small, not strongly agglomerated, and easily engineered.

The Company believes that the PVS process is a superior commercial process in the degree of control that can be exercised over particle size and particle size distribution. By means of controlled and subtle modifications to the PVS process (e.g., the evaporation rate, the type or pressure of the gas, or how quickly the flow of gas carries the clusters to the collection vessel), the Company can control the size of a material's particles, thereby altering the traits of a substance. The Company is thus able to engineer and produce a wide range of materials and products without substantial process and product re-engineering.

Surface Treatments and Dispersions (The DPE Process)

Many of the applications that the Company is pursuing require further engineering of the particles produced in the PVS process in order to meet specific application requirements. To satisfy these requirements, the Company has developed a variety of surface-treatment technologies to stabilize, alter or enhance the performance of nanocrystalline particles, together with technologies to enable the particles to be dispersed in fluids or polymers. At the core of these surface-treatment and dispersion technologies, many of which are in the early stage of development or are constantly being refined, is Nanophase's proprietary DPE process, which enables Nanophase to completely surround each nanocrystalline particle with a durable coating. The Company has applied for a patent for its DPE process.

The DPE process can coat the surface of each nanometer-sized particle produced by the PVS process with a proprietary polymer that is not removed by subsequent processing. Traditional coating technologies employ strand-like polymers that cannot completely cover the surfaces of nanometric particles. The Company's DPE process uses polymers that are shaped like hands. When the nanometer-sized particles are coated, the fingers of the hand collapse and completely encapsulate each particle with a thin polymeric shell. This shell also can be engineered to contain covalently bound spacer groups of controllable size that function to prevent particles from sticking to each other. The coatings enable the particles to be dispersed in a wide range of media, including water, cosmetic emollients, plastics and polymers, thus enabling these materials to be used in applications ranging from highly transparent sunscreens to dense opaque coatings.

Net-Shaping

Nanophase has developed a proprietary process whereby it net-shapes its nanocrystalline ceramic materials produced by the PVS process to rapidly fabricate precise, high-tolerance industrial ceramic parts without costly machining. This net-shaping technology was developed in collaboration with the Company's subcontractors, Lockheed Missiles & Space Co., Inc. ("LMSC") and Caterpillar, Inc., under an Advanced Technology Program ("ATP") contract funded by the U.S. Department of Commerce.

The Nanophase technologies relevant to net-shaping involve (i) the production of nanocrystalline ceramic materials in commercial quantities, (ii) the consolidation of Nanophase's ceramic materials into dense nanocrystalline preforms without exaggerated particle growth, and (iii) net-shape forming of fully dense, precisely-shaped ceramic parts.

The conventional fabrication of structural ceramics involves machining that uses diamond tools. This process is costly, time consuming and often produces highly stressed ceramic parts and components with structural flaws. Nanophase's process enables fabrication of ceramic parts and components using significantly

10

lower temperatures and pressures than used by conventional fabrication methods (e.g.,1300-1500-C and 2000-4000 psi, as compared to up to 1700-C and 100,000 psi). This technology enables the Company to fabricate dimensionally precise ceramic components in a short period of time without costly machining. This rapid deformation processing is made possible by the consistent ultrafine particle size of the Company's nanocrystalline ceramic materials, the Company's ability to control the consolidation of such particles into preforms of high and uniform density, and the ability of the ultrafine particles to easily slide over one another in the forming process. The Company's net-shaping technology produces ceramic products with a variety of detailed shapes, high tolerances and smooth surface finishes that can be tailored to a customer's needs.

Following the successful completion of the ATP program, the Company entered into a research, development and prototyping agreement with LMSC whereby the Company funds, on a month to month basis, LMSC to perform design, prototyping and research and development tasks related to net-shaping using technology developed during the ATP project. LMSC currently designs, engineers and fabricates prototypes to the Company's specifications for the Company's commercial projects. The Company and LMSC jointly own technology developed during the ATP project. New technology developed under the current arrangement between LMSC and the Company is wholly-owned by the Company and, under the terms of the arrangement, LMSC can use the newly developed technology only for its internal research. The Company has also recently entered into a collaborative relationship with a parts fabricator which has agreed to develop the capability to design, engineer and fabricate net-shaped ceramic parts and components for the Company using the Company's net-shaping technology and nanocrystalline materials.

Other Technologies

The Company constantly seeks to develop new technologies relating to nanocrystalline-based materials through ongoing research and development activities and collaborations with industrial, university and government research programs. For example, the Company is developing a new generation of metallic and ceramic precursors to be processed into nanocrystalline materials. Such activities are intended to enable the Company to develop new product applications and offer more materials with enhanced capabilities.

MARKETING

The members of the Company's marketing department, which the Company intends to expand, have experience in each of the Company's targeted markets and are often teamed with the Company's scientists and researchers to demonstrate the advantages of the Company's materials and product applications to potential customers. The Company's scientists, engineers and marketing personnel attend and speak at advanced materials symposia, publish articles in scientific journals and participate in selected industry trade shows. In addition, the Company uses a web page on the Internet, advertisements in selected industry and trade journals, and specification sheets and corporate brochures.

The Company also seeks to market its materials through distributors in certain application areas where the requirements for ongoing development and technical support by Nanophase are not substantial, or where the distributor has existing customer relationships, marketing or post-processing infrastructure, or companion products or services that may enable Nanophase to enter the market more quickly. For example, as part of its strategy to gain access to foreign markets, Nanophase has entered into a license agreement with CIK, a subsidiary of Itochu, formerly C. Itoh, which enables CIK to use certain of the Company's patented technologies to exclusively manufacture, use and sell Nanophase's nanocrystalline materials in broad-based industrial markets throughout various Asian countries for all applications except cosmetics, skin care and CMP. The fees received from CIK constituted approximately 43% of the Company's revenue in 1997. The agreement will, as of April 1, 1998, supersede an existing distribution agreement between the parties and is intended to enable Nanophase to quickly establish foothold positions in Asian markets by utilizing the technology and market-support capabilities of CIK. The agreement does not target specific materials or applications; however, CIK is pursuing high-volume industrial applications in electronics, industrial ceramics and catalysts. In order to maintain exclusivity under this agreement, CIK is required to (i) achieve 50% of the minimum annual sales obligations set forth in the agreement for 1999 and thereafter, which would

11

approximate $3 million in 1999 and $5 million in each year thereafter; or (ii) pay the Company a minimum royalty of $300,000 for the applicable year. In the event CIK manufactures nanocrystalline materials using certain of the Company's patented technologies, CIK is required to pay the Company a royalty based on the net sales of all such nanocrystalline materials manufactured by CIK. If after 1998 CIK elects to manufacture such nanocrystalline materials in order to achieve the minimum annual sale obligations set forth in the agreement, it must pay a minimum royalty of $300,000 to the Company in any twelve-month period following such election. Any royalties received by the Company from CIK are subject to certain foreign withholding taxes. This agreement expires in 2013 but may be terminated (i) by the Company after 1998 if CIK fails to achieve 20% of the minimum annual sales obligations set forth in the agreement for a given year or (ii) by CIK after March 31, 2000 upon 90 days' prior notice. Upon expiration of the agreement, CIK will have the non-exclusive right to still use the patented technologies licensed by the Company to manufacture, use and sell Nanophase's nanocrystalline materials in various Asian countries as long as CIK pays the Company a royalty based on the net sales of such materials by CIK.

Initially, to gain worldwide access to the cosmetics and skin-care market, the Company had entered into a global distribution agreement with Whittaker, Clark & Daniels, Inc. ("WCD"), a leading distributor of cosmetic and skin-care ingredients. In February 1998, the Company and WCD mutually agreed to end their distribution relationship. The Company may discuss distribution arrangements with other companies having access to the cosmetics and skin-care market or it may elect to sell directly to potential cosmetic and skin-care customers.

Because virtually all of the product applications for the Company's materials are new and innovative, in order for the Company to penetrate its targeted markets, it must participate in a multi-step process that includes initial discussions of the product application which highlight the advantages of the Company's nanocrystalline materials, proof of concept, proof of feasibility within the specific application, and evaluations of cost and manufacturability. Completion of this evaluation process usually takes at least 18 months, and may take several years.

RESEARCH AND DEVELOPMENT

The near-term objective of the Company's research and process-development activities is to develop and consistently produce sufficient commercial quantities of application-specific nanocrystalline materials to meet the Company's near-term requirements. Although the Company has de-emphasized the pursuit of revenue from government research contracts, a key component of the Company's long-term research and development strategy is to identify and develop relationships with leading industrial, university and government research programs across the United States and internationally to leverage the Company's technological and scientific capabilities. The Company believes that these research relationships may provide accelerated introduction of new technologies into its product applications, early indications of new technology developments that could enhance or compete with the Company's nanocrystalline materials, and high-value improvements in its current key technologies. The Company will also continue its efforts to attract and retain top scientists and engineers, which management believes will enable the Company to maintain a long-term leadership position in the nanocrystalline materials field.

The Company's total research and development expenses during the years ended December 31, 1997, 1996 and 1995 were $990,331, $677,284 and $485,059, respectively. The future success of the Company will depend in large part upon its ability to keep pace with evolving advanced materials technologies and industry standards, and there can be no assurance it will be able to do so. See "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations."

INTELLECTUAL PROPERTY AND PROPRIETARY RIGHTS

The objective of Nanophase's intellectual property activities is to implement ongoing strategies that maximize and protect the proprietary rights of the Company. These strategies encompass (i) obtaining patents and trademarks based on Nanophase inventions and products, and (ii) licensing third-party patents to expand the Company's technology base and prevent Nanophase from being blocked should future developments

12

require use of technology covered by those patents. To date, the Company has not been required to license technologies or design around other parties' patents in order to avoid claims of patent infringement.

Nanophase currently owns or licenses an aggregate of 17 United States patents and patent applications: two issued patents owned directly by Nanophase; four pending patent applications owned directly by Nanophase; and eleven patents licensed from third parties.

Two United States patents have been issued to Nanophase: one covering its PVS process for the synthesis of nanocrystalline materials, and the other covering the related apparatus. The patents expire in July 2013. Additional United States patent applications filed by the Company include applications relating to nanocrystalline materials, plasma sensors and the coating of metal oxides. Foreign patent applications owned directly by Nanophase are pending in Australia, Europe and Japan for the PVS process and apparatus. An international patent application owned by the Company for the coating of ceramic powders is also pending under the Patent Cooperation Treaty, with Australia, Canada, Europe and Japan designated for the national phase of the application.

The Company holds the following licenses of United States patents: an exclusive worldwide license of two patents owned by ARCH Development Corporation which embody a laboratory-scale method and apparatus for making nanocrystalline materials; a non-exclusive license from the Japan Science and Technology Corporation (formerly Research Development Corporation of Japan) of four patents which embody early laboratory-scale work in the physical synthesis of nanocrystalline materials; a non-exclusive license of two patents owned by Hitachi, Ltd. which are related to the synthesis of nanocrystalline materials; and a remainder-exclusive license of three patents held by Cornell University relating to a laboratory-scale process for net-shaping of a limited range of materials. Other than the license from the Japan Science and Technology Corporation, which remains in force until May 2006 and is extendable upon further agreement, each of the licenses lasts for the life of their respective patents. Under each of the licenses, the Company is obligated to pay the licensor royalties equal to a percentage of net sales of products, which embody the licensed technology, and related taxes on any such royalty fees paid to foreign licensors.

The Company requires its employees, consultants, outside scientific collaborators and other advisors to execute confidentiality and proprietary rights agreements upon the commencement of employment or consulting relationships with the Company. These agreements generally provide that all confidential information developed or made known to the individual during the course of the individual's relationship with the Company will be kept confidential and will not be disclosed to third parties except in specific circumstances. In the case of research employees, the agreements also provide that all inventions made by the individual shall be the exclusive property of the Company. There can be no assurance, however, that these agreements will provide meaningful protection for the Company's trade secrets, know-how or patent rights or will provide the Company with adequate remedies in the event of unauthorized use or disclosure of such information. In addition, because none of the Company's employees have entered into non-competition agreements with the Company, they may become competitors of the Company upon termination of employment.

COMPETITION

Within each of its targeted markets and product applications, Nanophase faces current and potential competition from numerous chemical companies, as well as the in-house capabilities of several of its current and potential customers. For example, with regard to semiconductor wafer polishing, Cabot Corporation, Rodel Incorporated, Fujimi Corporation (of Japan) and Solution Technology Incorporated, all market polishing slurries for CMP. In addition, Cabot Corporation, Baikowski International Corporation and Norton Company (a unit of Compagnie De Saint-Gobain) all manufacture their own ultrafine alumina. In the cosmetics and skin-care market, various companies manufacture their own sub-micron titania (Tioxide Specialties Limited, Tayca Corporation (of Japan), Ishihara Sangyo Kaisha, Ltd., Kemira Oy, Degussa AG and DuPont), iron oxide (Sun Chemical Corporation, Harcros Pigments Incorporated) and zinc oxide (Zinc Corporation of America) by chemical or other means. In structural ceramics, the Company competes against manufacturers of ceramic composites who machine such composites for specific product applications. In the catalysts market, the Company faces competition from companies that chemically deposit metal oxides onto

13

substrates. Although Nanophase believes that its materials and technologies are superior to the competitive materials and technologies that are utilized by these companies, such companies represent significant competitive risks to Nanophase because they have substantially greater financial and technical resources, larger research and development staffs, and greater manufacturing and marketing capabilities than the Company.

The Company also faces potential competition from Vacuum Metallurgical Co., Ltd. of Japan ("Vacuum Metallurgical"), which manufactures nanocrystalline materials and equipment. Currently, the Company does not compete with Vacuum Metallurgical, but there can be no assurance that Vacuum Metallurgical will not develop products or manufacturing capabilities to compete with the Company in the future. Potential competitive risks are also represented by numerous small development companies engaged in the development of nanocrystalline materials, such as Plasma Quench Technologies, Inc. and Nanopowder Enterprises, Inc. Most of these companies are associated with university or national laboratories and use chemical and physical methods to produce nanocrystalline materials. Nanophase believes that most of such companies are engaged primarily in funded research, and is not aware of any such company with commercial production capability. However, there can be no assurance that such companies will not represent significant competitive risks in the future.

GOVERNMENTAL REGULATIONS

The Company's Chicago facility, which houses its coating operations, is a "small quantity generator" of hazardous materials, including ethanol, under the Federal Resource Conservation and Recovery Act and, as a result, is subject to stringent federal, state and local regulations governing the handling, storage and disposal of such materials. To date, the Company has not been required to make substantial expenditures for preventive or remedial action with respect to the hazardous materials it uses. The manufacture and use of certain of the products that contain the Company's nanocrystalline materials are also subject to governmental regulation. As a result, the Company is required to adhere to the current Good Manufacturing Practices ("cGMP") requirements of the U.S. Food and Drug Administration ("FDA") and similar regulations in other countries which include testing, control and documentation requirements enforced by periodic inspections.

In addition, both of the Company's facilities and all of its operations are subject to the plant and laboratory safety requirements of various occupational safety and health laws. To date, those regulations have not materially restricted or impeded the Company's operations.

EMPLOYEES

On March 15, 1998, the Company had a total of 49 full-time employees, 12 of whom hold advanced degrees. Of the full-time employees, 8 are engaged in research, development and engineering, 22 are engaged in manufacturing, 4 are engaged in quality control, 7 are engaged in marketing and sales, and 8 are engaged in general management, finance and administration. The Company also currently engages two scientists as consultants on a regular basis, one of whom is Dr. Richard W. Siegel, a co-founder and director of the Company. The Company is not subject to any collective bargaining agreements and considers its relations with its employees to be good.

ITEM 2. PROPERTIES

Nanophase operates a 20,000 square-foot production and research facility in Burr Ridge, Illinois, a suburb of Chicago, which also serves as the Company's administrative headquarters. The Company also operates a smaller facility in Chicago, Illinois, for coating nanocrystalline materials using its DPE process and leases offsite warehouse space to store its materials. The Company believes its Burr Ridge facility is the first in the world that is dedicated to the commercial-scale development and production of physically synthesized nanocrystalline materials. The Company's operations in Burr Ridge are registered under ISO 9001 standards, and the Company believes its manufacturing operations are in compliance with the cGMP requirements of the FDA.

14

As of December 31, 1997, 19 PVS plasma reactors were operational and were capable of producing various nanocrystalline materials at the Burr Ridge facility. The throughput of each reactor depends on many factors, including the mix of products produced, the commencement, expiration or termination of development programs, the status of tests and evaluations of samples and prototypes and production yields.

Each PVS plasma reactor is comprised of modular equipment, which is designed and assembled to the Company's proprietary specifications. These modular reactors provide flexibility in the expansion of the Company's manufacturing capability. The Company is currently completing the build-out of its Burr Ridge facility and expects to have 23 PVS reactors available for production in the second quarter of 1998. In addition, the Company expects to increase the throughput per reactor as it increases the efficiency and yields of its PVS process and decreases the amount of downtime for each reactor. The Company believes that additional manufacturing capacity will not be required until 1999. Also operational within the Burr Ridge facility is a quality control laboratory designed for the dual purpose of validating operations to cGMP and ISO standards, and production process control. This laboratory is equipped to handle all routine analytical and in-process techniques that are currently required by the Company. In addition, capability for specialized analytical and physical measurements currently is available at Argonne upon terms, which the Company believes are reasonable and adequate. The Company leases its Burr Ridge facility pursuant to an agreement, which expires in September 1999. The Company has options to extend the lease for up to five additional years.

Based on the Company's current product mix, the Company's coating facility has the capacity to coat those nanocrystalline materials which it desires to coat. The Company believes that its coating capacity is adequate to support the Company's anticipated 1998 production plans. The Company subleases its Chicago facility pursuant to a one-year agreement, which automatically renews unless terminated by either party upon proper notice.

ITEM 3. LEGAL PROCEEDINGS

The Company is not a party to any litigation and is not aware of any pending or threatened litigation against the Company that could have a material adverse effect on the Company's business, results of operations or financial condition.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

During the fourth quarter of 1997, the following matters were submitted to a vote of security holders by written consent dated as of November 7, 1997.

a. The stockholders voted in favor of the Plan and Agreement of Merger by and between the Company and its Illinois predecessor pursuant to which the Company was reincorporated in Delaware. Of the 8,277,467 shares of voting stock then outstanding (on a post-split basis, which split was consummated immediately prior to the Offering), 5,733,058 shares voted for the proposal. The remaining votes were not solicited.

b. The stockholders also voted in favor of the first amendment to the Nanophase Technologies Corporation Amended and Restated 1992 Stock Option Plan. Of the 8,277,467 shares of voting stock then outstanding (on a post-split basis, which split was consummated immediately prior to the Offering) 5,733,058 shares voted for the proposal. The remaining votes were not solicited.

15

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

The Company's Common Stock, $.01 par value per share (the "Common Stock"), is traded on the Nasdaq National Market under the symbol NANX. Such trading began on November 26, 1997 in connection with the Company's initial public offering of Common Stock (the "Offering"). The following table sets forth for the period indicated the range of high and low closing sale prices for the Common Stock on the Nasdaq National Market:

                                                               HIGH      LOW
                                                               ----      ---
Fiscal year ending December 31, 1997:
  Fourth Quarter (beginning November 26, 1997)..............  $14.125   $7.50

On March 27, 1998, the last reported sale price of the Common Stock was $5.5625, and there were approximately 247 holders of record of the Common Stock.

The Company has never declared or paid any cash dividends on its Common Stock and does not anticipate paying any cash dividends or other distributions on its Common Stock in the foreseeable future, but intends instead to retain any future earnings for reinvestment in its business. Any future determination to pay cash dividends will be at the discretion of the Company's Board of Directors and will be dependent upon the Company's financial condition, results of operation, capital requirements and such other factors deemed relevant by the Board of Directors.

In June 1997, the Company privately issued 421,992 shares of Series F Convertible Preferred Stock (the "Series F Preferred") at $5.181 per share to 39 investors, which included various individuals, trusts, partnerships and retirement plans, in exchange for cash in the aggregate amount of $2,186,487. In August 1997, the Company privately issued 183,468 shares of Series F Preferred at $5.181 per share to 10 investors, which included various individuals, trusts, partnerships and retirement plans, in exchange for cash in the aggregate amount of $950,613. In September 1997, the Company privately issued 142,629 shares of Series F Preferred at $5.181 per share to 15 investors, which included employees of Donaldson Lufkin & Jenrette Securities Corporation ("DLJ"), various other individuals and a trust, in exchange for cash in the aggregate amount of $739,008. Each share of Series F Preferred was automatically converted into one share of Common Stock upon consummation of the Offering in December 1997.

The sales of shares of Series F Preferred were made in reliance on the exemption from registration with the Securities and Exchange Commission (the "Commission") pursuant to Section 4(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder as transactions by an issuer not involving any public offering, in that the transactions involved the issuance and sale by the Company of its securities to financially sophisticated institutions or persons who represented that they were aware of the Company's activities as well as its business and financial condition, and who took such securities for investment purposes and understood the ramifications of the same. Each security holder represented that they acquired such securities for investment for their own account and not for distribution. All certificates representing the Series F Preferred, as well as the Common Stock issued upon conversion of the Series F Preferred, issued pursuant to these transactions were legended.

On November 26, 1997, the Company's Registration Statement on Form S-1 (File No. 333-36937) (the "Registration Statement") relating to the Offering was declared effective by the Commission. The Registration Statement registered an amount of Common Stock having an aggregate offering price of $46,000,000. The Offering was consummated on December 2, 1997 and the Company issued 4,000,000 shares of Common Stock at $8.00 per share (for an aggregate offering amount of $32,000,000). The managing underwriters of the Offering were DLJ, Furman Selz LLC and CIBC Oppenheimer Corp. In connection with the Offering, the Company paid underwriting discounts and commissions of $2,240,000 and $922,064 of other expenses. Of such expenses, $100,000 was paid to Cross Technologies, Inc., of which Robert W. Cross is chief executive officer and sole employee, as a consulting bonus in connection with Mr. Cross' efforts in helping the Company consummate the Offering. Mr. Cross is chief executive officer, president and a director of the Company. Otherwise, none of such expenses were paid to directors, officers, 10% stockholders or affiliates of the

16

Company. After deducting such total expenses of $3,162,064, the Company's net proceeds from the Offering were $28,837,936. Pending its use of the net proceeds, the Company has invested the net proceeds in short-term, investment grade, interest-bearing obligations.

ITEM 6. SELECTED FINANCIAL DATA

The following selected financial data is qualified by reference to, and should be read in conjunction with, the financial statements and related notes thereto appearing elsewhere in this Form 10-K and "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations." The selected financial data set forth below as of, and for, each of the years in the five-year period ended December 31, 1997 have been derived from the audited financial statements of the Company.

                                                         YEARS ENDED DECEMBER 31,
                                   ---------------------------------------------------------------------
                                     1993          1994           1995           1996           1997
                                     ----          ----           ----           ----           ----
STATEMENT OF OPERATIONS DATA:
Commercial revenue...............  $  25,265    $    31,144    $    93,591    $   485,036    $ 3,723,492
Government research contracts....         --         64,015         27,995        110,770             --
                                   ---------    -----------    -----------    -----------    -----------
Total revenue....................     25,265         95,159        121,586        595,806      3,723,492
Cost of revenue..................     61,978        164,746        532,124      4,019,484      3,935,766
Research and development
  expense........................    143,362        456,162        485,059        677,284        990,331
Selling, general and
  administrative expense.........    556,616        799,558      1,150,853      1,661,504      2,074,728
                                   ---------    -----------    -----------    -----------    -----------
Total operating expense..........    761,956      1,420,466      2,168,036      6,358,272      7,000,825
                                   ---------    -----------    -----------    -----------    -----------
Operating expense in excess of
  revenue........................   (736,691)    (1,325,307)    (2,046,450)    (5,762,466)    (3,277,333)
Other income, net................      7,022         37,535         86,576        184,778        204,863
                                   ---------    -----------    -----------    -----------    -----------
Net loss.........................  $(729,669)   $(1,287,772)   $(1,959,874)   $(5,577,688)   $(3,072,470)
                                   =========    ===========    ===========    ===========    ===========
Pro forma net loss per
  share(1).......................                                                            $     (0.37)
                                                                                             ===========
Shares used in computing the pro
  forma net loss per share(1)....                                                              8,208,306

                                                        YEARS ENDED DECEMBER 31,
                                  ---------------------------------------------------------------------
                                    1993          1994           1995           1996           1997
                                    ----          ----           ----           ----           ----
BALANCE SHEET DATA:
Cash and cash equivalents.......  $ 225,230    $    18,462    $   261,902    $   617,204    $ 3,988,368
Working capital.................    225,988      2,226,184      2,451,627      3,070,789     32,038,915
Total assets....................    406,238      2,568,691      3,741,128      5,539,634     36,196,569
Total stockholders' equity......    348,434      2,456,516      3,506,050      5,110,450     34,651,334


(1) Does not include as of December 31, 1997 the anti-dilutive effect of (i) 662,287 shares of Common Stock issuable upon the exercise of outstanding warrants at an exercise price of $1.123 per share, (ii) 1,438,989 shares of Common Stock issuable upon the exercise of outstanding options at a weighted average exercise price of $2.471 per share and (iii) 1,275,618 shares of Common Stock reserved for issuance upon the exercise of options that may be granted in the future under the Stock Option Plan.

17

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with "Item 6. Selected Financial Data" and financial statements and related notes thereto appearing elsewhere in this Form 10-K. When used in the following discussions, the words "anticipates," "believes," "estimates," "expects," "plans," "intends" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and contingencies that could cause actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. See "-- Risk Factors."

OVERVIEW

From its inception in November 1989 through December 31, 1996, Nanophase was in the development stage. During that period, the Company primarily focused on the development of its manufacturing processes in order to transition from laboratory-scale to commercial-scale production. As a result, the Company developed an operating capacity to produce significant quantities of its nanocrystalline materials for commercial sale. The Company was also engaged in the development of commercial applications and formulations and the recruiting of marketing, technical and administrative personnel. From inception through December 31, 1997, the Company was primarily capitalized through the private offering of approximately $19,558,069 of equity securities and its initial public offering of $28,837,936 of Common Stock, each net of issuance costs.

Through 1995, the majority of the Company's revenues resulted from government contracts to perform research and development activities. During that period, the Company also entered into cost-sharing agreements with the U.S. government and offset amounts received against the related costs. During 1996, the Company began emerging from the development stage and significantly increased its commercial revenue. Commercial revenue is recorded when the Company ships products, when specific milestones are met regarding development arrangements or when the Company licenses its technology and transfers proprietary information. Cost of revenue generally includes costs associated with commercial production, customer development agreements and licensing arrangements, and net costs of material production and development related to government research contracts. In 1996, the Company also began to scale-up operations in its Burr Ridge manufacturing facility. The Company incurred substantial operating expenses as a result of certain one-time costs associated with the scale-up of operations. In 1997, the Company incurred additional one-time costs as it began the completion of its build-out of the Burr Ridge facility.

Since January 1, 1997, the Company has been engaged in commercial production and sales of its nanocrystalline materials, and the Company no longer considers itself in the development stage.

RESULTS OF OPERATIONS

Years Ended December 31, 1997 and 1996

Total revenue increased to $3,723,492 in 1997, compared to $595,806 in 1996. Commercial revenue increased to $3,723,492 in 1997, compared to $485,036 in 1996. This increase in commercial revenue was due primarily to a one-time technology transfer fee of $1,400,000 from CIK for a license to use certain patented technology to exclusively manufacture, use and sell the Company's nanocrystalline materials in Asia, a product development fee of $775,000 from Moyco, a one-time fee of $160,000 from CIK for training in the operation of a PVS reactor, and increased customer development agreements and product sales. Commercial revenue for the year ended December 31, 1997 was primarily generated from sales of the Company's products to, product development agreements with, and licensing fees paid by, customers in the electronics and structural ceramics and composites markets. In particular, sales to, and fees from, Moyco and fees from CIK constituted approximately 42% and 43%, respectively, of the Company's revenue in 1997. Revenue from governmental research contracts decreased to zero for the year ended December 31, 1997, compared to $110,770 for the same period in 1996, because the Company did not pursue any further U.S. government contracts for the year. See "Item 1. Business -- Customers and Applications -- Electronics -- Semiconductor Polishing" and "-- Marketing."

18

Cost of revenue decreased to $3,935,766 in 1997, compared to $4,019,484 in 1996. This decrease in cost of revenue was generally attributed to increased efficiencies in the manufacture of the Company's products and the reduced cost of product development activities. Cost of revenue as a percentage of total revenue decreased significantly for the year ended December 31, 1997, compared to the same period in 1996 because of the increased efficiencies in the Company's manufacturing processes, minimal costs associated with the one-time technology transfer fee from CIK and the product development fee from Moyco, and increased production volumes.

Research and development expense primarily consists of costs associated with the Company's development or acquisition of new product applications and coating formulations and the cost of enhancing the Company's manufacturing processes. Research and development expense increased to $990,331 in 1997, compared to $677,284 in 1996. The increase in research and development expense is attributable primarily to the acquisition of certain knowledge and technology from Moyco for a one-time fee of $223,000, increased costs of developing new coating formulations and product applications, and ongoing experimentation expenses associated with technological enhancements and product improvements. The Company expects to increase its research and development expense in 1998 in connection with its plans to continue to enhance and expand its product lines and manufacturing processes.

Selling, general and administrative expense increased to $2,074,728 for the year ended December 31, 1997, compared to $1,661,504 for the same period in 1996. This increase is attributable primarily to the expensing of certain one-time costs aggregating $375,103 related to a proposed public offering withdrawn in May 1997 and certain one-time costs associated with the Company's Asian distribution agreement with CIK. These one-time costs were offset by decreases in selling and general expenses. The Company expects its selling, general and administrative expense to increase in 1998 due to the hiring of additional marketing, sales and administrative personnel.

Interest income increased to $204,863 in 1997, compared to $184,778 in 1996. This increase is primarily due to the investment of net proceeds from its sale of equity securities pending use of such proceeds for operations and expansion.

Years Ended December 31, 1996 and 1995

Total revenue increased to $595,806 in 1996, compared to $121,586 in 1995. Commercial revenue increased to $485,036 in 1996, compared to $93,591 in 1995. This increase in commercial revenue was due primarily to increased commercial acceptance and availability of the Company's products. Revenue from government research contracts increased to $110,770 in 1996, compared to $27,995 in 1995, as the Company completed certain development agreements with U.S. governmental agencies.

Cost of revenue increased to $4,019,484 in 1996, compared to $532,124 in 1995. The increase in cost of revenue for 1996 was generally a result of the scale-up of the Company's operations in anticipation of increased commercial sales and development. Specifically, the Company increased expenditures relating to product and process improvement activities. The Company also incurred one-time costs in connection with the establishment of its Chicago coating facility, extensive product development activities, the scale-up of manufacturing operations, and the certification of its Burr Ridge facility under ISO standards.

Research and development expense increased to $677,284 in 1996, compared to $485,059 in 1995. The increase in research and development expense was attributable primarily to the hiring of additional research and development personnel, costs associated with the development and evaluation of new product applications, and increased purchases and use of research supplies.

Selling, general and administrative expense increased to $1,661,504 in 1996, compared to $1,150,853 in 1995. This increase was attributable primarily to the hiring of additional marketing and administrative personnel, an increase in selling expenses, and the increase in costs associated with the establishment of the Company's corporate headquarters.

19

Interest income was $184,778 in 1996, compared to $86,576 in 1995. The increase resulted from the Company's investment of net proceeds from its sales of equity securities pending use of such proceeds for the Company's operations.

LIQUIDITY AND CAPITAL RESOURCES

The Company's cash, cash equivalents and investments were $30,873,220 at December 31, 1997, compared to $2,614,992 at December 31, 1996 and $2,483,303 at December 31, 1995. The Company's net cash used in operating activities was $3,387,367, $5,795,858 and $1,860,353 for the years ended December 31, 1997, 1996 and 1995, respectively. The net cash used in operating activities for the year ended December 31, 1997 was primarily for the further expansion of the production infrastructure to support anticipated growth, the further development of products, the funding of research and development activities, and the funding of trade accounts receivable and inventory levels, which was offset by an increase in accounts payable and accrued liabilities. Net cash used in investing activities, including capital expenditures and purchases and sales of securities in which cash is invested pending its use for the Company's operations, amounted to $25,854,823, $951,806 and $905,615 for the years ended December 31, 1997, 1996 and 1995, respectively. Capital expenditures amounted to $1,063,608, $1,173,437 and $937,956 for the years ended December 31, 1997, 1996 and 1995, respectively, and were primarily for leasehold improvements and equipment purchases. In December 1997, in connection with the Offering, the Company received aggregate proceeds, net of issuance costs, of approximately $28,837,936. In addition, proceeds provided by private placements of equity securities, net of issuance costs, was $3,770,543 during the year ended December 31, 1997, compared to $7,182,088 and $3,009,408 during the years ended December 31, 1996 and 1995, respectively.

The Company believes that funds from operations and cash on hand, together with the net proceeds of its initial public offering consummated in December 1997, will be adequate to fund the Company's current operating plans for the foreseeable future. The Company expects capital expenditures of approximately $20 million over the next two years, which expenditures will be funded in part by the net proceeds from the Offering. The Company's actual future capital requirements will depend, however, on many factors, including continued progress in its research and development and product testing programs, the magnitude of these programs, the costs necessary to increase the Company's manufacturing capabilities and to market any resulting materials and product applications, and customer acceptance of the Company's current and potential materials and product applications. In addition, the Company could potentially be required to fund a rescission of shares of Series F Preferred. Depending on future requirements, the Company may seek additional funding through public or private financing, collaborative relationships, government contracts or licensing agreements. There can be no assurance that such additional financing will be available on acceptable terms or at all, and any such additional financing could be dilutive to the Company's stockholders. See "-- Risk Factors -- Risk of Rescission of Series F Offering."

At December 31, 1997, the Company had a net operating loss carryforward of approximately $13.4 million for income tax purposes. Because the Company may have experienced "ownership changes" within the meaning of the U.S. Internal Revenue Code (the "Internal Revenue Code") related to the issuance of its various equity offerings, future utilization of this carryforward may be subject to certain limitations as defined by the Internal Revenue Code. If not utilized, the carryforward expires at various dates between 2005 and 2012. As a result of the annual limitation, a portion of this carryforward may expire before ultimately becoming available to reduce income tax liabilities. As a result of various agreements with companies located in foreign countries, the Company may have generated foreign tax liabilities for which the Company would be entitled to an offsetting tax credit that could be used to reduce U.S. income taxes.

IMPACT OF YEAR 2000

The Year 2000 Issue is the result of computer programs being written using two digits rather than four to define the applicable year. Computer programs that have time-sensitive software may recognize a date using "00" as the year 1900 rather than the year 2000. This could result in a system failure or miscalculations causing disruptions of operations, including, among other things, a temporary inability to process transactions, send invoices, or engage in similar normal business activities.

20

The Company processes its transactions and applications utilizing personal computers. Based on a recent assessment, the Company determined that no significant modifications or replacements of its software or systems will be required to function properly with respect to dates in the year 2000 and thereafter. As of January 1, 1998, the Company will only acquire software and invest in systems which are compliant with the year 2000 conventions.

To date, the Company does not have any direct interface between its systems and those of any significant supplier or customer. Although the Company recognizes that it is vulnerable to third parties that fail to remediate their own Year 2000 Issues, it does not believe that such failure would significantly affect its operations. However, there can be no guarantee that the systems of other companies on which the Company relies will be timely converted or that their failure to do so would not have an adverse effect on the Company's operations. The Company has determined it has no exposure to contingencies related to the Year 2000 Issue for the products it has previously sold.

QUARTERLY INFORMATION

The following table presents selected unaudited quarterly results of the Company for each quarter of 1997. The financial data is derived from the unaudited quarterly financial statements of the Company which have been prepared by the Company on a basis consistent with the Company's audited financial statements included elsewhere in this Form 10-K and, in the opinion of management, include all adjustments, including normal recurring adjustments, that are necessary for a fair statement of the Company's results of operations for such periods. These operating results are not necessarily indicative of future performance.

                                                                        1997
                                               -------------------------------------------------------
                                                  FIRST         SECOND          THIRD         FOURTH
                                                 QUARTER        QUARTER        QUARTER       QUARTER
                                                 -------        -------        -------       -------
STATEMENT OF OPERATIONS DATA:
Commercial revenue.........................    $   429,464    $   603,003    $ 1,212,948    $1,478,077
Government research contracts..............             --             --             --            --
                                               -----------    -----------    -----------    ----------
Total revenue..............................        429,464        603,003      1,212,948     1,478,077
Cost of revenue............................     (1,102,877)    (1,059,204)    (1,159,207)     (614,478)
Research and development expense...........       (161,198)      (215,334)      (194,678)     (419,121)
Selling, general and administrative
  expense..................................       (425,497)      (765,995)      (523,233)     (360,003)
Interest income............................         21,917          9,830         25,645       147,471
                                               -----------    -----------    -----------    ----------
Net (loss)/income..........................    $(1,238,191)   $(1,427,700)   $  (638,525)   $  231,946
                                               ===========    ===========    ===========    ==========

RISK FACTORS

Limited History of Commercial Sales; Uncertain Market Acceptance of the Company's Nanocrystalline Materials

The Company was founded in November 1989 and through December 31, 1996 was engaged principally in research and development activities. While the Company recently commenced marketing certain nanocrystalline materials, it is in the early stage of commercialization and its potential product applications are in various stages of development or under evaluation. As a result, the Company's nanocrystalline materials have been sold only in limited quantities, generally for testing and evaluation purposes, and there can be no assurance that a significant market will develop for such materials. Because virtually all of the product applications for the Company's materials are new, in order to penetrate its targeted markets, the Company must participate in a multi-step process that includes initial discussions of the product application which highlight the advantages of the Company's nanocrystalline materials, proof of concept, proof of feasibility within the specific application, and evaluations of cost and manufacturability. Completion of this evaluation process usually takes at least 18 months, and may take several years. The Company's current and potential commercial customers establish demanding specifications for performance and reliability. Although the products incorporating the Company's nanocrystalline materials have passed certain product performance and

21

reliability testing by certain current and potential customers, there can be no assurance that the Company's nanocrystalline materials will continue to pass such tests in the future, meet future customer performance standards, or offer sufficient price or performance advantages as required to achieve commercial success. The Company's failure to develop, manufacture and commercialize nanocrystalline materials on a timely and cost-effective basis or successfully complete its customers' multi-step evaluation processes would have a material adverse effect on the Company's business, results of operations and financial condition. Because the Company's materials are used as ingredients in, or components of, other companies' products, the inability of the Company's customers to achieve market acceptance with respect to end-users of their products or successfully to manufacture their products could also have a material adverse effect on the Company's business, results of operations and financial condition. See "Item 1. Business."

Limited Operating History; History of Losses; Uncertainty of Future Profitability

Substantially all of the Company's revenues through December 31, 1996 were derived from government research contracts, commercial development contracts and sales of nanocrystalline products for customer evaluation. The Company has only recently begun shipping significant amounts of its materials for commercial use and there can be no assurance that the Company's nanocrystalline materials will generate significant revenues from commercial applications. Accordingly, the Company has only a limited operating history upon which an evaluation of the Company and its prospects can be based. An investment in the Company must be considered in light of the risks, expenses and difficulties frequently encountered by companies in the early stages of development.

The Company has incurred net losses in each year since its inception, and as of December 31, 1997, had an accumulated deficit of $13,744,671. The Company may continue to incur operating losses and there can be no assurance that the Company will become profitable. Commercial development of the Company's nanocrystalline materials will require the commitment of substantial resources to continuing research and development, establishment of additional commercial-scale manufacturing facilities, and further development of quality control, marketing, sales, service and administrative capabilities. The Company's ability to achieve profitability will depend on many factors, including the Company's ability to enter into collaborative customer relationships and the Company's ability, alone or with its customers, to develop, manufacture, introduce and market commercially acceptable products based on the Company's nanocrystalline materials and proprietary processes. There can be no assurance that significant quantities of the Company's nanocrystalline materials or their product applications will be manufactured, introduced or marketed successfully, or that the Company will ever achieve a profitable level of operations or, if profitability is achieved, that it can be sustained. See "Item 1. Business" and "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations."

Dependence on a Limited Number of Key Customers

A limited number of key customers have initially accounted for a substantial portion of the Company's commercial revenue. For example, sales to, and fees from, Moyco and fees from CIK constituted approximately 42% and 43%, respectively, of the Company's revenue in 1997. The Company's customers are significantly larger than, and are able to exert a high degree of influence over, the Company. The loss of one or more of the Company's customers or failure to attract new customers would have a material adverse effect on the Company's business, results of operations and financial condition. In December 1997, Nanophase entered into a seven-year supply agreement with EKC, a subsidiary of ChemFirst, a manufacturer of semiconductor polishing slurries, pursuant to which the Company will supply certain of its nanocrystalline materials and provide related research and customer and technical support to EKC. This agreement supersedes the Company's five-year requirements contract with Moyco and was entered into after Moyco sold its CMP intellectual property, technologies and certain other intangible assets to EKC in December 1997. Sales to EKC are currently expected to constitute a significant portion of the Company's revenues over the next several years. There can be no assurance, however, that EKC's purchase of the Company's materials will occur as expected or will not be for a lesser dollar amount or on a slower timetable as compared to that which the

22

Company previously expected from Moyco. See "Item 1. Business -- Customers and Applications -- Electronics -- Semiconductor Polishing."

Reliance on Collaborative Development Relationships

The Company has established, and will continue to pursue, collaborative relationships with a variety of corporate customers. Through such relationships, the Company seeks to develop applications for the Company's nanocrystalline materials, share development and manufacturing resources and coordinate the development, manufacturing, commercialization and marketing of nanocrystalline product applications. The Company's future success will depend, in part, on its continued relationships with these customers, its ability to enter into similar collaborative relationships, the commitment of the Company's customers to the potential product applications under development and, eventually, the customers' success in marketing, or willingness to purchase the Company's nanocrystalline materials for, such product applications. There can be no assurance that the Company's customers will not decide to manufacture jointly developed products internally, obtain them from alternative sources or no longer pursue their development. These customers may require the Company to share control of its development, manufacturing and marketing programs, limit its ability to license its technology to others, or restrict its ability to engage in certain product development, manufacturing and marketing activities. These relationships may also be subject to unilateral termination by the Company's customers. If the Company is unable to initiate or sustain such collaborative relationships, there can be no assurance that the Company will be able independently to develop, manufacture, market or sell its current and future nanocrystalline materials or their product applications. The failure of the Company to initiate or sustain such collaborative relationships would have a material adverse effect on the Company's business, results of operations and financial condition. See "Item 1. Business -- Customers and Applications."

Limited Manufacturing Capacity and Experience

The Company's success will depend, in part, on its ability to manufacture its nanocrystalline materials in significant quantities, with consistent quality, at acceptable cost and on a timely basis. The Company has limited experience in high-volume manufacturing, and may incur significant start-up costs and unforeseen expenses in connection with attempts to manufacture substantial quantities of nanocrystalline materials, and will need to increase the efficiency of its manufacturing operations significantly to reach its production goals. In addition, the Company will need to expand its current facilities or obtain additional facilities in the near future in order to manufacture substantial quantities of its products. No assurance can be given that the Company will be able to make the transition to high-volume production successfully. There can also be no assurance that the Company will be able to successfully develop its surface treatment and dispersion technologies so as to be able to coat significant quantities of its nanocrystalline materials with consistent quality, at acceptable cost and on a timely basis. The Company's primary operations, including research, engineering, manufacturing, marketing, distribution and general administration, are housed in a single facility in Burr Ridge, Illinois. Any material disruption in the Company's operations, whether due to fire, natural disaster, power loss or otherwise, could have a material adverse effect on the Company's business, results of operations and financial condition. While the Company maintains property and business interruption insurance, such insurance may not adequately compensate the Company for all losses that it may incur. See "Item 2. Properties."

While most of the Company's product applications involve the Company producing materials which are to be used as ingredients in other companies' products, the Company's net-shaping applications require the Company to produce finished components. The Company currently is not capable of producing ceramic finished components in commercial volume and therefore has recently established an early-stage manufacturing arrangement with a third-party. The Company may also develop an in-house capability to fabricate net-shaped components or establish manufacturing arrangements with additional third parties. There can be no assurance that the Company will be able to successfully collaborate with others for the fabrication of net-shaped components or fabricate its net-shaped components internally, or that it will be able to enter into additional third-party arrangements on satisfactory terms. See "Item 1. Business -- The Company's Technologies -- Net-Shaping."

23

Dependence on Patents and Protection of Proprietary Information

The Company's success will depend, in part, on its ability to obtain patent protection for its nanocrystalline materials and processes, to preserve its trade secrets, and to operate without infringing the patent or other proprietary rights of others and without breaching or otherwise losing rights in the technology licenses upon which any of the Company's products are based. The Company has been granted two United States patents which expire in July 2013, has filed four applications for other United States patents and licenses eleven patents held by others, which licenses generally last the life of their respective patents. No assurance can be given that the patent applications filed by the Company will result in issued patents or that the scope and breadth of any claims allowed in any patents issued to the Company or its licensors will exclude competitors or provide competitive advantages to the Company. In addition, there can be no assurance that any patents issued to the Company or its licensors will be held valid if subsequently challenged or that others will not claim rights in the patents and other proprietary technology owned or licensed by the Company, or that others have not developed or will not develop similar products or technologies without violating any of the Company's proprietary rights. The Company's inability to obtain patent protection, preserve its trade secrets or operate without infringing the proprietary rights of others, as well as the Company's loss of any license to technology that it now has or acquires in the future, would have a material adverse effect on the Company's business, results of operations and financial condition.

Patent applications in the United States are currently maintained in secrecy until patents issue, and patent applications in foreign countries are maintained in secrecy for a period of time after filing. Accordingly, publication of discoveries in the scientific literature or of patents themselves or laying open of patent applications in foreign countries tends to lag behind actual discoveries and filings of related patent applications. Due to this factor and the large number of patents and patent applications related to nanocrystalline materials, comprehensive patent searches and analysis associated with nanocrystalline materials are often impractical or not cost-effective. Therefore, there can be no assurance that the Company's patent and publication searches have been comprehensive, or that materials or processes used by the Company for its planned products do not or will not infringe upon existing technology described in United States patents or will not infringe upon claims of patent applications of others in the future. Because of the volume of patents issued and patent applications filed relating to nanocrystalline materials, there is a significant risk that current and potential competitors and other third parties have filed or will file patent applications for, or have obtained or will obtain patents or other proprietary rights relating to, materials or processes used or proposed to be used by the Company. In any such case, to avoid an infringement, the Company would have to either license such technology or design around any such patents. There can be no assurance that the Company will be able either to successfully design around these third-party patents or obtain licenses to such technology or that, if obtainable, such licenses would be available on terms acceptable to the Company.

Litigation, which could result in substantial cost to, and diversion of effort by, the Company, may be necessary to enforce patents issued or licensed to the Company, to defend the Company against infringement claims made by others, or to determine the ownership, scope or validity of the proprietary rights of the Company and others. An adverse outcome in any such litigation could subject the Company to significant liabilities to third parties, require the Company to seek licenses from third parties, and/or require the Company to cease using certain technology, any of which could have a material adverse effect on the Company's business, results of operations and financial condition. The Company may also become involved in interference proceedings declared by the United States Patent and Trademark Office ("PTO") in connection with one or more of the Company's owned or licensed patents or patent applications to determine priority of invention. Any such proceeding could result in substantial cost to the Company, as well as a possible adverse decision as to priority of invention of the patent or patent application involved. In addition, the Company may become involved in reissue or reexamination proceedings in the PTO in connection with the scope or validity of the Company's owned or licensed patents. Any such proceeding could have a material adverse effect on the Company's business, results of operations and financial condition, and an adverse outcome in such proceeding could result in a reduction of the scope of the claims of any such patents or such patents being declared invalid. In addition, from time to time, to protect its competitive position, the Company may initiate reexamination proceedings in the PTO with respect to patents owned by others. Such proceedings could result

24

in substantial cost to, and diversion of effort by, the Company, and an adverse decision in such proceedings could have a material adverse effect on the Company's business, results of operations and financial condition.

The Company also relies on trade secrets and proprietary know-how in the conduct of its business and uses employee and third-party confidentiality and non-disclosure agreements to protect such trade secrets and know-how. There can be no assurance that the obligation to maintain the confidentiality of such trade secrets or proprietary information will not wrongfully be breached by employees, consultants, advisors or others, that the Company will have adequate remedies for any breach, or that the Company's trade secrets or proprietary know-how will not otherwise become known or be independently developed or discovered by third parties. In addition, because the Company's employees have not entered into noncompetition agreements with the Company, they may become competitors of the Company upon termination of employment. See "Item 1. Business -- Intellectual Property and Proprietary Rights."

Rapid Technological Change

Rapid changes have occurred, and are likely to continue to occur, in the development of advanced materials and processes. The future success of the Company will depend, in large part, upon its ability to keep pace with advanced materials technologies, industry standards and market trends and to develop and introduce new and improved products on a timely basis. The Company will require substantial resources to expand its commercial manufacturing capacity, further develop its technologies and develop and introduce innovative product applications. There can be no assurance that the Company's development efforts will not be rendered obsolete by the research efforts and technological advances of others or that other advanced materials will not prove more advantageous than those produced by the Company.

Limited Marketing Experience; Distribution Agreements

The Company has limited experience marketing and selling its products. To market its nanocrystalline materials directly, the Company will be required to develop a marketing and sales force that can effectively demonstrate the advantages of its nanocrystalline product applications compared to competitive products containing conventional or advanced materials. The Company currently has arrangements for distribution of certain of its nanocrystalline materials and expects to enter into additional distribution or other arrangements with third parties regarding the commercialization or marketing of its materials. The Company's future success will depend in part on its continued relationships with distributors, its ability to enter into additional distribution arrangements, the continuing interest of the Company's distributors in current and potential product applications and, eventually, the distributors' success in marketing, or willingness to purchase, any of the Company's nanocrystalline materials. There can be no assurance that the Company will be successful in its marketing efforts, that it will be able to establish adequate sales and distribution capabilities, that it will be able to enter into or maintain marketing and distribution arrangements with third parties on financially acceptable terms, or that any third parties with whom it enters into such arrangements will be successful in marketing the Company's products. In February 1998, the Company and WCD mutually agreed to end their cosmetics and skin-care ingredients distribution relationship. While the Company expects to either discuss distribution arrangements with other companies having access to the cosmetics and skin-care market or sell directly to potential cosmetic and skin-care customers, there can be no assurance that the Company will be able to maintain significant worldwide access to such market. See "Item 1. Business -- Customers and Applications" and "--Marketing."

International Sales

For the year ended December 31, 1997, 46% of the Company's total revenues were derived from product sales and development agreements with international customers, and the Company expects that it will continue to derive a substantial percentage of revenues from international customers in the future. There can be no assurance that the Company will be able successfully to market, sell and deliver its nanocrystalline materials in international markets. In addition, there are certain risks inherent in conducting international business, including exposure to currency fluctuations, longer payment cycles, greater difficulties in accounts receivable collection, political instability, foreign withholding taxes relating to royalties, difficulties in

25

complying with a variety of foreign laws and unexpected changes in regulatory requirements. There can be no assurance that one or more of such factors will not have a material adverse effect on the Company's business, results of operations and financial condition. In particular, the Company has a license agreement with CIK for the distribution of its materials throughout various Asian countries. There can be no assurance that the recent economic uncertainties in Korea and other Asian markets will not continue and have a material adverse effect on the Company's sale of its materials in such markets. See "Item 1. Business -- Marketing."

Competition

The advanced materials industry is highly competitive. The market for materials having the characteristics and potential uses of the Company's nanocrystalline materials is the subject of intensive research and development efforts by both governmental entities and private enterprises around the world. The Company believes that the level of competition will increase further as more product applications with significant commercial potential are developed. The nanocrystalline product applications being developed by the Company will compete directly with products incorporating conventional and advanced materials and technologies. While the Company is not currently aware of the existence of commercially available competitive products with the same attributes as those offered by the Company, there can be no assurance that such competitive products will not be introduced by third parties, or that competing materials based on different or new technologies may not become commercially available. There can be no assurance that the Company's competitors will not succeed in developing or marketing materials, technologies and products that exhibit superior performance, are more commercially desirable or are more cost effective than those developed or marketed by the Company. In addition, many potential competitors of the Company have substantially greater financial and technical resources, larger research and development staffs, and greater manufacturing and marketing capabilities than the Company. Failure of the Company's current and potential nanocrystalline product applications to improve performance sufficiently at an acceptable price, achieve commercial acceptance or otherwise compete with conventional materials would have a material adverse effect on the Company's business, results of operations and financial condition. See "Item 1. Business -- Competition."

Future Capital Needs

The Company believes that its future capital requirements will depend, on many factors, including continued progress in its research and development and product testing programs, the magnitude of these programs, the costs necessary to increase the Company's manufacturing capabilities and to market any resulting materials and product applications, and customer acceptance of the Company's current and potential materials and product applications. Additional factors that may affect the Company's future capital requirements are the costs involved in preparing, filing, prosecuting, maintaining and enforcing patents and other proprietary rights or in obtaining licenses, the ability of the Company to establish collaborative relationships, and the amount and timing of future revenues. Depending on its requirements, the Company may seek additional funding through public or private financing, collaborative relationships, government contracts or licensing agreements. There can be no assurance that such additional financing will be available on acceptable terms or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, scale-back or eliminate manufacturing and marketing of one or more of its materials or product applications or research and development programs, or to obtain funds through arrangements with customers or others that may require the Company to relinquish rights to certain of its technologies or nanocrystalline materials that the Company would not otherwise relinquish. Inadequate funding also could impair the Company's ability to compete in the marketplace. See "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations."

Dependence on Key Personnel

The Company's success will depend, in large part, upon its ability to attract and retain highly qualified research and development, management, manufacturing and marketing and sales personnel. Due to the specialized nature of the Company's business, it may be difficult to locate and hire qualified personnel, and to retain such personnel once hired. The loss of the services of any of the Company's executive officers or other

26

key personnel, or the failure of the Company to attract and retain other skilled and experienced personnel on acceptable terms, could have a material adverse effect on the Company's business, results of operations and financial condition. The Company does not have "key-man" life insurance policies covering any of its executive officers or other key employees.

Product Liability Risks

The Company may be subject to product liability claims in the event that any of its nanocrystalline product applications are alleged to be defective or cause harmful effects. Because the Company's nanocrystalline materials are used as ingredients in, or components of, other companies' products, to the extent certain of the Company's customers become subject to claims, suits or complaints relating to their products, such as cosmetic and skin-care products, there can be no assurance that such claims will not be asserted against the Company. The Company currently maintains separate insurance coverage in the amount of $1 million for product liability claims. The cost of defending or settling product liability claims may be substantial and there can be no assurance that the Company could do so on acceptable terms or that such claims, if successful or settled, would not have a material adverse effect on the Company's business, results of operations and financial condition.

Possible Volatility of Common Stock Price

The stock market has from time to time experienced significant price and volume fluctuations that may be unrelated to the operating performance of any particular company. In particular, there has been significant volatility in the market price of securities of technology companies, particularly those that, like the Company, are still primarily engaged in product development activities. Factors such as announcements of technology innovations and new product applications by the Company or its competitors, disputes relating to patents and proprietary rights, changes in financial estimates by securities analysts, failure to meet earnings expectations of the market or of analysts, general market conditions and fluctuations in quarterly operating results may have a significant impact on the market price of the Common Stock. In the past, following periods of volatility in the market price of a company's securities, securities class action litigation has often been instituted against such a company. Any such litigation initiated against the Company could result in substantial costs and a diversion of management's attention and resources, which could have a material adverse effect on the Company's business, results of operations and financial condition.

Governmental Regulations

The Company's coating facility, which is located in Chicago, is a "small quantity generator" of hazardous materials, including ethanol, under the Federal Resource Conservation and Recovery Act and, as a result, is subject to stringent federal, state and local regulations governing the handling, storage and disposal of such materials. It is possible that current or future laws and regulations could require the Company to make substantial expenditures for preventive or remedial action, reduction of chemical exposure or waste treatment or disposal. There can be no assurance that the Company's operations, business or assets will not be materially and adversely affected by the interpretation and enforcement of current or future environmental laws and regulations. The Company believes it has complied in all material respects with regard to environmental regulations applicable to it and does not anticipate generating substantially increased amounts of such materials. In addition, although management believes that its safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the Company's coating operations do pose a risk of accidental contamination or injury. To date, the Company has not been required to make substantial expenditures for preventive or remedial action with respect to the hazardous materials it generates. The damages in the event of an accident or the costs of such preventive or remedial actions could exceed the Company's resources or otherwise have a material adverse effect on the Company's business, results of operations and financial condition.

In addition, both of the Company's facilities and all of its operations are subject to the plant and laboratory safety requirements of various occupational safety and health laws. The Company believes it has complied in all material respects with regard to governmental regulations applicable to it. There can be no

27

assurance, however, that the Company will continue to comply with applicable government regulations or that such regulations will not materially restrict or impede the Company's operations in the future.

The manufacture and use of certain products which contain the Company's nanocrystalline materials are subject to governmental regulation. As a result, the Company is required to adhere to the cGMP requirements of the FDA and similar regulations in other countries which include testing, control and documentation requirements enforced by periodic inspections. Such regulations can increase the Company's cost of doing business and/or render certain potential markets prohibitively expensive. See "Item 1. Business -- Governmental Regulations."

Quarterly Fluctuations in Operating Results

The Company has experienced, and expects to continue to experience, quarterly fluctuations in its results of operations as a result of a variety of factors, including the timing and amount of expenses associated with expansion of the Company's operations, the timing of collaborative relationships with, and performance of, customers, the timing of new product application offerings, changes in the Company's revenue mix among its product application offerings, and changes in the mix between pilot production of new nanocrystalline materials and full-scale manufacturing of existing nanocrystalline materials. The Company does not currently have any significant backlog of orders and the timing of revenues will therefore depend upon the amount and timing of new orders received for its nanocrystalline materials.

Anti-Takeover Provisions

The Company's Board of Directors has the authority to issue up to 24,088 shares of undesignated preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without any further vote or action by the Company's stockholders. The rights of the holders of Common Stock will be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire a majority of the outstanding voting stock of the Company. The Company has no present plans to issue such shares of preferred stock. Further, certain provisions of the Company's Certificate of Incorporation and Bylaws and of Delaware law could delay or make more difficult a merger, tender offer or proxy contest involving the Company.

Shares Eligible for Future Sale

The sale of a substantial number of shares of Common Stock, or the perception that such sales could occur, could adversely affect prevailing market prices for the Common Stock. Of the 12,277,467 shares of Common Stock outstanding as of March 27, 1998, 8,277,467 shares of Common Stock are "restricted securities" within the meaning of Rule 144 ("Rule 144") under the Securities Act, (the "Restricted Shares") and all of such Restricted Shares are subject to the lock-up provisions of a registration rights agreement or lock-up agreements pursuant to which the holders of such Restricted Shares have agreed that they will not, directly or indirectly, sell or otherwise dispose of any shares of Common Stock prior to May 26, 1998 without the prior written consent of DLJ. Upon expiration of the lock-up provisions of the registration rights agreement or lock-up agreements (or earlier upon the consent of DLJ), 7,529,365 of the Restricted Shares will be eligible for sale under Rule 144, subject to, in the case of the affiliates, the volume and other limitations of such rule. An additional 662,287 Restricted Shares are issuable upon exercise of currently exercisable warrants issued to certain of the Company's existing stockholders and an additional 1,438,989 Restricted Shares are issuable at various dates upon exercise of options heretofore granted to certain employees, consultants and members of the advisory board of the Company pursuant to stock option agreements. Such optionholders have also agreed not to sell, offer for sale or otherwise dispose of any shares of Common Stock prior to May 26, 1998 without the prior written consent of DLJ.

Subject to the lock-up provisions of the registration rights agreement and lock-up agreements, the holders of all but 95,535 of the outstanding Restricted Shares and all of the Restricted Shares issuable upon exercise

28

of the warrants have been accorded registration rights under the Securities Act. No prediction can be made as to the effect, if any, that future sales of shares, or the availability of shares for future sales, will have on the market price of the Common Stock from time to time or the Company's ability to raise capital through an offering of its equity securities.

Risk of Rescission of Series F Offering

In June, August and September 1997, the Company issued shares of Series F Preferred for an aggregate of $3,876,108 to approximately 60 investors, all of whom are "accredited investors" within the meaning of rules promulgated under the Securities Act. The offering and sale of the Series F Preferred was not registered under the Securities Act, but may not have qualified for an exemption from the registration requirements of the Securities Act. If the sale of the Series F Preferred was not consummated in accordance with a valid exemption under the registration requirements of Section 5 of the Securities Act, purchasers of Series F Preferred may have a right to rescind their purchases of the Series F Preferred (which were converted into approximately 748,000 shares of Common Stock upon consummation of the Offering in December 1997) pursuant to
Section 12(a)(1) of the Securities Act, and there may be a risk of enforcement action by the Commission or state securities regulators. Under Section 13 of the Securities Act, a rescission right, which is the effective equivalent of a put right, can be maintained to enforce liability under Section 12(a)(1) of the Securities Act at any time within one year after the violation on which it is based, but in no event more than three years after the relevant securities were bona fide offered to the public. A rescission right would entitle the holders of the Series F Preferred to receive a return of the consideration paid for their shares of Series F Preferred ($5.18 per share), together with interest from the date of purchase. The Company does not currently intend to offer rescission to the holders of the Series F Preferred. Even if the holders of Series F Preferred are entitled to rescind their purchases, the Company does not believe that any rescission would adversely affect its current financial condition.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The financial statements and financial statement schedules, with the report of independent auditors, listed in Item 14 are included in this Form 10-K.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

29

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

The information in response to this item is incorporated by reference from the "Proposal No. 1 -- Election of Directors," "Executive Officers" and "Section
16(a) Beneficial Ownership Compliance" sections of the Definitive Proxy Statement to be filed with the Commission in connection with the Company's 1998 Annual Meeting of Stockholders (the "1998 Proxy Statement").

ITEM 11. EXECUTIVE COMPENSATION

The information in response to this item is incorporated by reference from the section of the 1998 Proxy Statement captioned "Executive Compensation and Certain Transactions."

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The information in response to this item is incorporated by reference from the section of the 1998 Proxy Statement captioned "Security Ownership of Management and Principal Stockholders."

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

The information in response to this item is incorporated by reference from the section of the 1998 Proxy Statement captioned "Executive Compensation and Certain Transactions."

30

PART IV

ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K

(a) The following documents are filed as part of this Form 10-K:

1. The following financial statements of the Company, with the report of independent auditors, are filed as part of this Form 10-K:

Report of Ernst & Young LLP, Independent Auditors Balance Sheets as of December 31, 1996 and 1997 Statements of Operations for the Years Ended December 31, 1995, 1996 and 1997
Statements of Stockholders' Equity for the Years Ended December 31, 1995, 1996 and 1997
Statements of Cash Flows for the Years Ended December 31, 1995, 1996, and 1997
Notes to Financial Statements

2. The following financial statement schedules of the Company are filed as part of this Form 10-K:

Schedule II -- Valuation and Qualifying Accounts

All other financial schedules are omitted because such schedules are not required or the information required has been presented in the aforementioned financial statements.

3. The following exhibits are filed with this Form 10-K or incorporated by reference as set forth below.

EXHIBIT
NUMBER
-------
 2        Plan and Agreement of Merger dated as of November 25, 1997
          by and between the Company and its Illinois predecessor.
 3.1      Certificate of Incorporation of the Company.
 3.2      Bylaws of the Company.
 4.1      Specimen stock certificate representing Common Stock,
          incorporated by reference to Exhibit 4.1 to the Company's
          Registration Statement on Form S-1 (File No. 333-36937) (the
          "IPO S-1").
 4.2      Form of Warrants, incorporated by reference to Exhibit 4.2
          to the IPO S-1.
10.1      The Nanophase Technologies Corporation Amended and Restated
          1992 Stock Option Plan, as amended, incorporated by
          reference to Exhibit 10.1 to the IPO S-1.
10.2      Form of Indemnification Agreement between the Company and
          each of its directors and executive officers, incorporated
          by reference to Exhibit 10.3 to the IPO S-1.
10.3      Amended and Restated Registration Rights Agreements dated as
          of March 16, 1994, as amended, incorporated by reference to
          Exhibit 10.3 to the IPO S-1.
10.4*     Employment Agreement dated February 3, 1994 between the
          Company and Robert W. Cross, incorporated by reference to
          Exhibit 10.4 to the IPO S-1.
10.5*     Employment Agreement dated as of September 3, 1996 between
          the Company and Dennis J. Nowak, incorporated by reference
          to Exhibit 10.5 to the IPO S-1.
10.6*     Severance Benefits Agreement dated as of November 15, 1994
          between the Company, Steven Lazarus and John C. Parker,
          incorporated by reference to Exhibit 10.6 to the IPO S-1.
10.7      License Agreement dated June 1, 1990 between the Company and
          ARCH Development Corporation, as amended, incorporated by
          reference to Exhibit 10.7 to the IPO S-1.
10.8      License Agreement dated October 12, 1994 between the Company
          and Hitachi, incorporated by reference to Exhibit 10.8 to
          the IPO S-1.

31

EXHIBIT
NUMBER
-------
10.9      License Agreement dated May 31, 1996 between the Company and
          Research Development Corporation of Japan, incorporated by
          reference to Exhibit 10.9 to the IPO S-1.

10.10     License Agreement dated April 1, 1996 between the Company
          and Cornell Research Foundation, incorporated by reference
          to Exhibit 10.1 to the IPO S-1.

10.11*    Consulting and Stock Purchase Agreement between Richard W.
          Siegel and the Company dated as of May 9, 1990, as amended
          February 13, 1991, November 21, 1991 and January 1, 1992,
          incorporated by reference to Exhibit 10.11 to the IPO S-1.

10.12     Lease Agreement between the Village of Burr Ridge and the
          Company, dated September 15, 1994, incorporated by reference
          to Exhibit 10.12 to the IPO S-1.

10.13     Distribution Agreement between the Company and C.I. Kasei,
          Ltd., (a subsidiary of Itochu Corporation) dated as of
          October 30, 1996, incorporated by reference to Exhibit 10.15
          of the IPO S-1.

10.14     Purchase Agreement between the Company and LWT Instruments,
          Inc., dated February 1, 1997, incorporated by reference to
          Exhibit 10.16 to the IPO S-1.

10.15     Letter of Understanding between the Company and LWT
          Services, Inc. dated as of January 13, 1998.

10.16     Supply Agreement between the Company and Schering-Plough
          HealthCare Products, Inc. dated as of March 15, 1997,
          incorporated by reference to Exhibit 10.17 to the IPO S-1.

10.17     License Agreement between the Company and C.I. Kasei Co.,
          Ltd. (a subsidiary of Itochu Corporation) dated as of
          December 30, 1997.

10.18     Supply Agreement by and between the Company and EKC
          Technology, Inc., dated as of December 31, 1997.

11        Statement regarding computation of per share earnings.

27.1      Financial Data Schedule.

27.2      Restated Financial Data Schedule.


* Management contract or compensatory plan or arrangement required to be filed as an exhibit to this Form 10-K.

(b) Reports on Form 8-K:

No reports on Form 8-K were filed by the Company for the quarter ended December 31, 1997.

32

NANOPHASE TECHNOLOGIES CORPORATION
INDEX TO FINANCIAL STATEMENTS

                                                                PAGE
                                                                ----
Report of Ernst & Young LLP, Independent Auditors...........    F-2
Balance Sheets as of December 31, 1996 and 1997.............    F-3
Statements of Operations for the years ended December 31,
  1995, 1996 and 1997.......................................    F-4
Statements of Stockholders' Equity for the years ended
  December 31, 1995, 1996 and 1997..........................    F-5
Statements of Cash Flows for the years ended December 31,
  1995, 1996 and 1997.......................................    F-6
Notes to Financial Statements...............................    F-7

F-1

The Board of Directors and Stockholders
Nanophase Technologies Corporation

We have audited the accompanying balance sheets of Nanophase Technologies Corporation as of December 31, 1996 and 1997, and the related statements of operations, stockholders' equity, and cash flows for each of the three years in the period ended December 31, 1997. Our audits also included the financial statement schedule listed in the Index at Item 14(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Nanophase Technologies Corporation at December 31, 1996 and 1997, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 1997, in conformity with generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, present fairly in all material respects the information set forth therein.

                                          /s/ ERNST & YOUNG LLP
                                          Ernst & Young LLP
Chicago, Illinois
January 23, 1998

F-2

NANOPHASE TECHNOLOGIES CORPORATION

BALANCE SHEETS

                                                                     AS OF DECEMBER 31,
                                                                ----------------------------
                                                                    1996            1997
                                                                    ----            ----
                           ASSETS
CURRENT ASSETS:
  Cash and cash equivalents.................................    $    617,204    $  3,988,368
  Investments...............................................       1,997,788      26,884,852
  Trade accounts receivable, less allowance for doubtful
     accounts of $0 in 1996 and $19,276 in 1997.............         389,501       1,641,489
  Inventories...............................................         445,205         957,303
  Prepaid expenses and other current assets.................          50,275         112,138
                                                                ------------    ------------
     Total current assets...................................       3,499,973      33,584,150
Equipment and leasehold improvements, net...................       1,794,798       2,399,893
Other assets, net...........................................         244,863         212,526
                                                                ------------    ------------
                                                                $  5,539,634    $ 36,196,569
                                                                ============    ============
            LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
  Accounts payable..........................................    $    221,936    $    930,397
  Accrued expenses..........................................         207,248         614,838
                                                                ------------    ------------
     Total current liabilities..............................         429,184       1,545,235
STOCKHOLDERS' EQUITY:
Series A convertible preferred stock, no par value; 292,728
  shares authorized, 169,490 shares issued and outstanding
  at December 31, 1996; no shares authorized, issued, and
  outstanding at December 31, 1997..........................         600,000              --
Series B convertible preferred stock, no par value;
  1,309,722 shares authorized, 758,358 shares issued and
  outstanding at December 31, 1996; no shares authorized,
  issued, and outstanding at December 31, 1997..............         851,351              --
Series C convertible preferred stock, no par value;
  1,143,846 shares authorized, 662,287 shares issued and
  outstanding at December 31, 1996; no shares authorized,
  issued, and outstanding at December 31, 1997..............         743,500              --
Series D convertible preferred stock, no par value;
  6,729,566 shares authorized, 3,896,419 shares issued and
  outstanding at December 31, 1996; no shares authorized,
  issued, and outstanding at December 31, 1997..............       6,429,500              --
Series E convertible preferred stock, no par value;
  3,500,000 shares authorized, 1,921,800 shares issued and
  outstanding at December 31, 1996; no shares authorized,
  issued, and outstanding at December 31, 1997..............       7,157,850              --
Series F convertible preferred stock, no par value; no
  shares authorized, issued, and outstanding at December 31,
  1996 and December 31, 1997................................              --              --
Preferred stock, $.01 par value; no shares authorized,
  issued, and outstanding at December 31, 1996; 24,088
  shares authorized and no shares issued and outstanding at
  December 31, 1997.........................................              --              --
Common stock, no par value at December 31, 1996 and $.01 par
  value at December 31, 1997; 10,316,158 shares authorized
  at December 31, 1996 and 25,000,000 shares authorized at
  December 31, 1997; 77,586 shares issued and outstanding at
  December 31, 1996 and 12,277,467 shares issued and
  outstanding at December 31, 1997..........................             450         122,775
Additional paid-in capital..................................              --      48,273,230
Accumulated deficit.........................................     (10,672,201)    (13,744,671)
                                                                ------------    ------------
  Total stockholders' equity................................       5,110,450      34,651,334
                                                                ------------    ------------
                                                                $  5,539,634    $ 36,196,569
                                                                ============    ============

See Notes to Financial Statements

F-3

NANOPHASE TECHNOLOGIES CORPORATION

STATEMENTS OF OPERATIONS

                                                                  YEARS ENDED DECEMBER 31,
                                                          -----------------------------------------
                                                             1995           1996           1997
                                                             ----           ----           ----
REVENUE:
  Commercial revenue..................................    $    93,591    $   485,036    $ 3,723,492
  Governmental research contracts.....................         27,995        110,770             --
                                                          -----------    -----------    -----------
       Total revenue..................................        121,586        595,806      3,723,492
OPERATING EXPENSE:
  Cost of revenue.....................................        532,124      4,019,484      3,935,766
  Research and development expense....................        485,059        677,284        990,331
  Selling, general and administrative expense.........      1,150,853      1,661,504      2,074,728
                                                          -----------    -----------    -----------
       Total operating expenses.......................      2,168,036      6,358,272      7,000,825
                                                          -----------    -----------    -----------
Operating expenses in excess of revenue...............     (2,046,450)    (5,762,466)    (3,277,333)
Interest income.......................................         86,576        184,778        204,863
                                                          -----------    -----------    -----------
Net loss..............................................    $(1,959,874)   $(5,577,688)   $(3,072,470)
                                                          ===========    ===========    ===========
Pro forma net loss per share..........................    $     (0.48)   $     (0.82)   $     (0.37)
                                                          ===========    ===========    ===========
Pro forma weighted average number of common shares
  outstanding.........................................      4,122,881      6,835,680      8,208,306
                                                          ===========    ===========    ===========

See Notes to Financial Statements

F-4

NANOPHASE TECHNOLOGIES CORPORATION

STATEMENTS OF STOCKHOLDERS' EQUITY

                                       PREFERRED STOCK            COMMON STOCK        ADDITIONAL
                                  -------------------------   ---------------------     PAID-IN     ACCUMULATED
          DESCRIPTION               SHARES        AMOUNT        SHARES      AMOUNT      CAPITAL       DEFICIT         TOTAL
          -----------               ------        ------        ------      ------    ----------    -----------       -----
Balance as of January 1, 1995...   3,730,073   $  5,590,705       77,586   $     --   $       450   $ (3,134,639)  $ 2,456,516
  Issuance of Series D shares...   1,742,447      3,009,408           --         --            --             --     3,009,408
  Net loss for the year ended
    December 31, 1995...........          --             --           --         --            --     (1,959,874)   (1,959,874)
                                  ----------   ------------   ----------   --------   -----------   ------------   -----------
Balance as of December 31,
  1995..........................   5,472,520      8,600,113       77,586         --           450     (5,094,513)    3,506,050
  Issuance of Series D shares...      14,034         24,238           --         --            --             --        24,238
  Issuance of Series E shares
    net of offering costs.......   1,921,800      7,157,850           --         --            --             --     7,157,850
  Net loss for the year ended
    December 31, 1996...........          --             --           --         --            --     (5,577,688)   (5,577,688)
                                  ----------   ------------   ----------   --------   -----------   ------------   -----------
Balance as of December 31,
  1996..........................   7,408,354     15,782,201       77,586         --           450    (10,672,201)    5,110,450
  Issuance of Series F shares
    net of offering costs.......     748,089      3,770,543           --         --            --             --     3,770,543
  Exercise of stock options.....          --             --       43,425        434         4,441             --         4,875
  Conversion of all outstanding
    Preferred shares into Common
    shares and all Common shares
    to $0.01 par value..........  (8,156,443)   (19,552,744)   8,156,456     82,341    19,470,403             --            --
  Issuance of Common shares, net
    of offering costs...........          --             --    4,000,000     40,000    28,797,936             --    28,837,936
  Net loss for the year ended
    December 31, 1997...........          --             --           --         --            --     (3,072,470)   (3,072,470)
                                  ----------   ------------   ----------   --------   -----------   ------------   -----------
Balance as of December 31,
  1997..........................          --   $         --   12,277,467   $122,775   $48,273,230   $(13,744,671)  $34,651,334
                                  ==========   ============   ==========   ========   ===========   ============   ===========

See Notes to Financial Statements

F-5

NANOPHASE TECHNOLOGIES CORPORATION
STATEMENTS OF CASH FLOWS

                                                              YEARS ENDED DECEMBER 31,
                                                     ------------------------------------------
                                                        1995           1996           1997
                                                        ----           ----           ----
OPERATING ACTIVITIES:
Net Loss...........................................  $(1,959,874)  $ (5,577,688)  $  (3,072,470)
  Adjustments to reconcile net loss to net cash
     used in operating activities:
     Depreciation and amortization.................      126,947        309,850         416,414
     Loss on sale of equipment.....................           --             --          29,281
     Write off of patents..........................       19,857             --              --
  Changes in assets and liabilities related to
     operations:
     Trade accounts receivable.....................      (23,573)      (318,656)     (1,251,988)
     Inventories...................................      (65,280)      (379,924)       (512,098)
     Prepaid expense and other assets..............      (50,261)        17,002        (164,365)
     Patent costs..................................      (31,072)       (40,548)        (27,314)
     Accounts payable..............................      168,643          2,525         708,461
     Accrued liabilities...........................      (45,740)       191,581         486,712
                                                     -----------   ------------   -------------
Net cash used in operating activities..............   (1,860,353)    (5,795,858)     (3,387,367)
INVESTING ACTIVITIES:
Acquisition of equipment and leasehold
  improvements.....................................     (937,956)    (1,173,437)     (1,063,608)
Purchases of held-to-maturity investments..........   (8,512,957)   (15,486,131)   (118,684,404)
Maturities of held-to-maturity investments.........    8,547,165     15,709,744      93,797,340
(Increase) decrease in asset held in trust.........       (1,867)        (1,982)         78,849
Proceeds from sale of equipment....................           --             --          17,000
                                                     -----------   ------------   -------------
Net cash used in investing activities..............     (905,615)      (951,806)    (25,854,823)
FINANCING ACTIVITIES:
Proceeds from issuance of stock, net of offering
  costs............................................    3,009,408      7,182,088      32,613,354
Deferred offering costs............................           --        (79,122)             --
                                                     -----------   ------------   -------------
Net cash provided by financing activities..........    3,009,408      7,102,966      32,613,354
                                                     -----------   ------------   -------------
Increase in cash and cash equivalents..............      243,440        355,302       3,371,164
Cash and cash equivalents at beginning of period...       18,462        261,902         617,204
                                                     -----------   ------------   -------------
Cash and cash equivalents at end of period.........  $   261,902   $    617,204   $   3,988,368
                                                     ===========   ============   =============

See Notes To Financial Statements

F-6

NANOPHASE TECHNOLOGIES CORPORATION

NOTES TO FINANCIAL STATEMENTS

(1) DESCRIPTION OF BUSINESS

Nanophase Technologies Corporation (the "Company") was incorporated on November 30, 1989, for the purpose of developing nanocrystalline materials for commercial production and sale in domestic and international markets. The Company was in its development stage for the period from inception through December 31, 1996. The Company began full-scale production in early 1997 at which time it no longer was a development stage company. The Company issued common stock in its initial public offering consummated on December 2, 1997.

In the course of its corporate development, the Company has experienced net losses and negative cash flows from operations. Historically, the Company has funded its operations primarily through the issuance of equity securities.

Export sales approximated $51,400, $256,500, and $1,695,700 for the years ended December 31, 1995, 1996, and 1997, respectively.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cash Equivalents

Cash equivalents primarily consist of money market accounts which have a maturity of three months or less from the date of purchase.

Investments

Investments are classified by the Company at the time of purchase for appropriate designation and such designation is reevaluated as of each balance sheet date. Investments are classified as held-to maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to maturity securities are stated at amortized cost and are adjusted to maturity for the amortization of premiums and accretion of discounts. Such adjustments for amortization and accretion are included in interest income.

Inventory

Inventory is stated at the lower of cost, maintained on a first in, first out basis, or market.

Equipment and Leasehold Improvements

Equipment is stated at cost and is being depreciated over its estimated useful life (5-7 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease.

Patent Costs

Patent costs are included in other assets and are being amortized over the life of the respective patent using the straight-line method.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company to make estimates and assumptions that affect the amounts reported in the Financial statements and accompanying notes. Actual results could differ from those estimates.

F-7

NANOPHASE TECHNOLOGIES CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

Commercial Revenue

Commercial revenue consists of sales of product and revenue from research and development arrangements with non-governmental entities, and fees from the transfer of technology. Sales of product are recorded as shipments are made by the Company. Research and development arrangements include both cost-plus and fixed fee agreements and such revenue is recognized when specific milestones are met under the arrangements. Fees related to the transfer of technology are recognized when the transfer of technology to the acquiring party is completed and the Company has no further significant obligation.

Government Research Contracts

The Company accounts for contracts with governmental entities to complete research and development activities using the percentage of completion method measured by the relationship of costs incurred to total estimated costs. Amounts paid to the Company under its cooperative cost-sharing agreement with the U.S. government are accounted for as offsets against cost of revenues. See Note 8.

All payments to the Company for work performed on contracts and agreements with agencies of the U.S. government are subject to adjustment upon audit by agencies of the U.S. government. The Company believes that such audits, if any, will not have significant effect on the financial position or results of operation of the Company.

Research and Development Expense

Expenditures for research and development activities are charged to operations as incurred by the Company. During 1997, the Company acquired certain research and development from a customer for $223,000 and charged this acquisition to research and development expense.

Income Taxes

The Company accounts for income taxes using the liability method. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur.

Employee Stock Options

The Company accounts for stock options granted to employees in accordance with APB Opinion No. 25, "Accounting for Stock Issued to Employees" (APB No. 25). The exercise price of the options granted equals the estimated fair value of the underlying stock on the date of grant. As such, no compensation expense has been recognized by the Company for these options. In October 1995, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation" (FASB No. 123). FASB No. 123, which was adopted by the Company in 1996, establishes an alternative method of accounting for stock-based compensation plans. In 1996, the Company adopted the disclosure alternative for stock-based compensation (Note 12) which provides for the use of APB No. 25 for financial statement purposes with pro forma disclosure of the impact of FASB No. 123.

Fair Value of Financial Instruments

The Company's financial instruments include investments, accounts receivable, accounts payable and accrued liabilities. The fair values of all financial instruments were not materially different from their carrying values.

F-8

NANOPHASE TECHNOLOGIES CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

Net Loss and Pro Forma Net Loss Per Share

In 1997, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 128, "Earnings Per Share" (FASB No. 128). FASB No. 128 replaced the calculation of primary and fully diluted earnings per share with basic and diluted earnings per share. Unlike primary earnings per share, basic earnings per share excludes any dilutive effects of options, warrants and convertible securities. Diluted earnings per share is generally consistent with the previously reported fully diluted earnings per share. All earnings per share amounts for all periods have been presented and, where appropriate, restated to conform to the FASB No. 128 requirements.

Pro forma net loss per share and historical net loss per common share are computed based upon the weighted average number of common shares outstanding. Common equivalent shares are not included in the pro forma and historical per share calculations since the effect of their inclusion would be anti-dilutive. In addition, for the pro forma calculation, all convertible preferred stock is treated as if converted into common shares for all periods shown.

Net loss per common share computed on a historical basis is as follows:
$25.26, $71.89 and $2.39 for the years ended December 31, 1995, 1996 and 1997, respectively. The weighted average number of common shares outstanding used to calculate these net loss per common share amounts are 77,586, for 1995 and 1996, and 1,283,359 for 1997.

(3) INVESTMENTS

Investments consist of U.S. Treasury bills, government bonds, and commercial paper with an estimated fair value of $1,998,000 and $26,885,000 at December 31, 1996 and 1997, respectively. All investments have been classified as held-to-maturity and mature in the subsequent year.

(4) INVENTORIES

Inventories consist of the following:

                                                              AS OF DECEMBER 31,
                                                             --------------------
                                                               1996        1997
                                                               ----        ----
Raw Materials............................................    $332,167    $379,505
Finished Goods...........................................     113,038     577,798
                                                             --------    --------
                                                             $445,205    $957,303
                                                             ========    ========

(5) EQUIPMENT AND LEASEHOLD IMPROVEMENTS

Equipment and leasehold improvements consist of the following:

                                                             AS OF DECEMBER 31,
                                                          ------------------------
                                                             1996          1997
                                                             ----          ----
Machinery and equipment...............................    $1,662,721    $1,835,964
Office equipment......................................       113,959       116,307
Office furniture......................................        49,864        49,864
Leasehold improvements................................       447,465       610,932
                                                          ----------    ----------
                                                           2,274,009     2,613,067
Less: Accumulated depreciation and amortization.......      (479,211)     (881,323)
                                                          ----------    ----------
                                                           1,794,798     1,731,744
Construction in progress..............................            --       668,149
                                                          ----------    ----------
                                                          $1,794,798    $2,399,893
                                                          ==========    ==========

F-9

NANOPHASE TECHNOLOGIES CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

(6) LEASE COMMITMENTS

The Company leases manufacturing and office space under an agreement that will expire in September 1999. Monthly minimum lease payments amount to $8,100 for this facility. The Company also leases a smaller pilot manufacturing space as well as offsite warehouse space, both under renewable annual agreements. Monthly minimum lease payments amount to $5,000 and $2,100, respectively, for these facilities.

Net rent expense under these leases amounted to $122,422, $175,538, and $168,781, for the years ended December 31, 1995, 1996, and 1997, respectively.

(7) ACCRUED EXPENSES

Accrued expenses consist of the following:

                                                              AS OF DECEMBER 31,
                                                             --------------------
                                                               1996        1997
                                                               ----        ----
Accrued subcontract costs................................    $ 40,000    $161,791
Accrued payroll and related expenses.....................      87,124     138,798
Accrued costs for goods received but not invoiced........      24,332      98,802
Other....................................................      55,792     215,447
                                                             --------    --------
                                                             $207,248    $614,838
                                                             ========    ========

(8) RESEARCH AND DEVELOPMENT AGREEMENTS

In July 1992, the Company entered into a cooperative cost-sharing agreement with the U.S. Government under the Department of Commerce Advanced Technology Program. The three-year agreement ended in 1995. Under the terms of the agreement, the U.S. Government agreed to share costs of the Company's research efforts up to an aggregate of $944,259, including subcontractor costs. The net costs associated with the total effort amounted to $2,992,130. The difference between these amounts represented indirect costs of $2,047,871 which were absorbed as operating expenses by the Company. For the year ended December 31, 1995, the Company offset $154,710 received from the U.S. government against cost of revenues in the statement of operations.

The Company is party to a number of other research and development arrangements with both governmental and commercial entities. These arrangements are generally short-term in nature and provided $54,680, $236,019, and $1,445,705 of revenues for the years ended December 31, 1995, 1996, and 1997, respectively.

(9) LICENSE AGREEMENTS

In 1991, the Company was granted an exclusive license by a third party to make, have made, use and sell products of the type claimed in a U.S. patent. In consideration for this license, the Company agreed to pay royalties of 1/2% of net sales of licensed products, as defined. As of December 31, 1997, no royalty payments were due under this agreement.

In 1994, the Company was granted a non-exclusive license by a third party to make, use, and sell products of the type claimed in two U.S. patents. In consideration for this license, the Company agreed to pay royalties of 1% of net sales, as defined, and made an advance royalty payment of $17,500. As of December 31, 1997, royalties under this agreement amounting to $10,688 have been offset against the royalty advance.

In 1996, the Company was granted a non-exclusive license by a third party to produce and sell ultrafine powders of metal and ceramics claimed in four U.S. patents. In consideration for this license, the Company agreed to pay $14,000 as an initial payment, and pay royalties of 3% of net proceeds of sales of the product, as

F-10

NANOPHASE TECHNOLOGIES CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

defined. As of December 31, 1997, royalties under this agreement approximated $13,000. The Company was also granted a remainder-exclusive license by a third party to make, have made, use, import, sell or have sold products of the type claimed in three U.S. patents. In consideration for this license, the Company agreed to pay $5,000 as an initial payment, $5,000 upon reaching the earlier of either defined profitability or the second anniversary of the agreement, and royalties at the rate of 4% of the defined net sales of the related products. As of December 31, 1997, no royalty payments were due to this party under this agreement.

In December 1997, the Company entered into a license agreement whereby the Company granted a royalty-bearing exclusive right and license, as defined, to purchase, make, use and sell nanocrystalline materials to a third party. As consideration for the right and license thereby granted, the Company recognized a non-refundable technology transfer fee of $1,400,000, which was earned upon execution of the agreement. As defined, the Company also will earn royalties on net sales of manufactured products containing nanocrystalline materials. The agreement also provides for minimum sales targets and minimum royalty payments to maintain exclusivity. The agreement expires on March 31, 2013 unless earlier terminated as provided therein. As of December 31, 1997, no royalty payments were earned by the Company under this agreement.

(10) INCOME TAXES

The Company has net operating loss carryforwards for tax purposes of approximately $13,400,000 at December 31, 1997, which expire between 2005 and 2012. The Company has not paid income taxes since inception.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred income taxes consist of the following:

                                                         AS OF DECEMBER 31,
                                                      -------------------------
                                                         1996          1997
                                                         ----          ----
DEFERRED TAX ASSETS:
  Net operating loss carryforward...................  $ 4,212,000   $ 5,226,000
  Start-up cost capitalized for income tax
     purposes.......................................      162,000       122,000
  Other accrued costs...............................       29,000        74,000
                                                      -----------   -----------
     Total deferred tax assets......................    4,403,000     5,422,000
DEFERRED TAX LIABILITY:
  Accelerated tax depreciation......................      (53,000)      (62,000)
                                                      -----------   -----------
Net deferred tax asset..............................    4,350,000     5,360,000
  Less: Valuation allowance.........................   (4,350,000)   (5,360,000)
                                                      -----------   -----------
Deferred income taxes...............................  $        --   $        --
                                                      ===========   ===========

The valuation allowance increased $1,010,000 for the year ended December 31, 1997 due principally to the increase in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and the Company's initial public offering of common stock, may subject the Company to annual limitations on the utilization of its net operating loss carryforward.

As a result of certain transactions with third parties operating in foreign countries, the Company may be subject to the withholding and payment of foreign income taxes as transactions are completed. Under the Internal Revenue Code, foreign tax payments may be used to offset federal income tax liabilities when

F-11

NANOPHASE TECHNOLOGIES CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

incurred, subject to certain limitations. At December 31, 1997, the Company had not recognized any foreign tax liability or foreign tax credit regarding these transactions.

(11) CAPITAL STOCK

In November 1997, the Company's Board of Directors approved a migratory merger of the Company from Illinois to Delaware, authorized a reverse stock split and restated the par value of the Company's common stock. All share and per share amounts in the financial statements and notes to financial statements have been restated to reflect a .579-for-1 reverse stock split and restatement of the par value to $0.01 for all common stock.

In 1997, a total of 748,089 shares of Series F convertible preferred stock was issued for cash amounting to $3,770,543, which is net of financing costs of $105,565.

In November 1997, a total of 4,000,000 shares of common stock was issued in conjunction with the Company's initial public offering at an offering price of $8 per share. The Company received proceeds of $28,837,936, which is net of offering costs of $3,162,064. Pursuant to the Company's prior Illinois articles of incorporation, all Series A,B,C,D,E and F convertible preferred stock was automatically converted to common stock in conjunction with the initial public offering.

At December 31, 1997, authorized but unissued shares of common stock have been reserved for future issuance as follows:

Warrants....................................................      662,287
Options.....................................................    2,714,607
                                                                ---------
                                                                3,376,894
                                                                =========

(12) STOCK OPTIONS AND WARRANTS

The Company has entered into stock option agreements with certain officers, employees, directors (one of whom is also a service provider) and three Advisory Board members. At December 31, 1997, the Company had granted options to purchase 1,438,989 shares of common stock. The stock options generally expire ten years from the date of grant. Of the total number of options granted, 673,377 of the outstanding options vest on the eighth anniversary following their grant date, subject to an earlier five-year vesting period if specified performance targets are met. Of the remaining 765,612 outstanding options, 748,242 vest over a five-year period and 17,370 vest over a three-year period from their respective grant dates.

F-12

NANOPHASE TECHNOLOGIES CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

Exercise prices are determined by the Board of Directors and equal the estimated fair values of the Company's common stock at the grant date. The table below summarizes all option activity through December 31, 1997:

                                                                                            WEIGHTED
                                                            NUMBER        EXERCISE      AVERAGE EXERCISE
                                                          OF OPTIONS       PRICE             PRICE
                                                          ----------      --------      ----------------
Outstanding at December 31, 1994......................      255,339     $       .112         $ .112
Options granted during 1995...........................      186,728             .432           .432
Options canceled during 1995..........................       (6,948)       .112-.432           .180
                                                          ---------
Outstanding at December 31, 1995......................      435,119        .112-.432           .249
Options granted during 1996...........................    1,192,508      1.727-3.886          3.309
Options canceled during 1996..........................      (12,101)      .112-1.727          1.549
                                                          ---------
Outstanding at December 31, 1996......................    1,615,526       .112-3.886          2.499
Options granted during 1997...........................       17,370            5.181          5.181
Options exercised during 1997.........................      (43,425)            .112           .112
Options canceled during 1997..........................     (150,482)      .112-3.886          3.760
                                                          ---------
Outstanding at December 31, 1997......................    1,438,989       .112-5.181          2.471
                                                          =========

At December 31, 1997, options for 180,378, 75,270, 62,903 and 17,833 shares of common stock were exercisable at $.112, $.432, $1.727 and $3.886 per share, respectively. To date, 43,425 options have been exercised and none have expired. The weighted average remaining contractual life of the outstanding options at December 31, 1997 was eight years.

In connection with the issuance of Series C convertible preferred stock, the Company issued common stock purchase warrants for 662,287 shares at no additional cost to the Series C convertible preferred stockholders. These warrants have an exercise price of $1.123 per share and expire upon the tenth anniversary of issuance. All warrants were outstanding at December 31, 1997.

The Company has elected to follow APB No. 25 and related interpretations in accounting for its employee stock options because, as discussed below, the alternative fair value accounting provided for under FASB No. 123 requires use of option valuation models that were not developed for the use in valuing employee stock options. Pro forma information regarding net income is required by FASB No. 123, which also requires that the information be determined as if the Company had accounted for the employee stock options granted subsequent to December 31, 1994 under the fair value method of that Statement. The fair value for these options was estimated at the date of grant using a Black-Scholes option pricing model with the following assumptions for the years ended December 31, 1995, 1996, and 1997: U.S. government zero coupon 7-year bond interest rates ranging from 6.0% to 7.2%, depending upon the specific grant date of the options; a dividend yield of zero percent; and a weighted-average expected life of the option of 7 years. The volatility factor was assumed to be zero as the Company was privately held and no market existed for its stock in 1995, 1996, or during the period during which options were granted in 1997. The weighted average fair value of the net options granted during 1995, 1996 and 1997 was $.170, $1.124 and $1.753 per share, respectively.

The Black-Scholes option valuation model was developed for the use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.

F-13

NANOPHASE TECHNOLOGIES CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)

For purposes of the pro forma disclosures, the estimated fair value of the options is amortized to expense over the vesting period of the respective option. Because FASB No. 123 is applicable only to options granted subsequent to December 31, 1994, its pro forma impact will not be fully reflected until 2002. The Company's pro forma net loss would be $1,965,649, $5,621,482, $3,275,177 and the pro forma net loss per share would be $0.48, $0.82, and $0.40 for the years ended December 31, 1995, 1996, and 1997, respectively.

(13) 401(K) PROFIT-SHARING PLAN

The Company has a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. The plan provides for deferred salary contributions by the plan participants and a Company contribution. Company contributions, if any, are at the discretion of the Board of Directors and are not to exceed the amount deductible under applicable income tax laws. No Company contributions have been made since inception of the plan.

(14) RELATED PARTY TRANSACTIONS

The Company has an ongoing consulting agreement with a director/stockholder. The agreement is on a month-to-month basis. Payments under this agreement amount to $2,500 per month.

(15) SIGNIFICANT CUSTOMERS

Revenue from two customers was approximately 43% and 42%, respectively, of total revenue for the year ended December 31, 1997. The amount due from one of these companies comprised 85% of the Company's trade accounts receivable at December 31, 1997.

F-14

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS

                                                                    ADDITIONS
                                      ----------------------------------------------------------------------
                                      BALANCE BEGINNING   COSTS AND     OTHER                   BALANCE AT
            DESCRIPTION                   OF PERIOD        EXPENSES    ACCOUNTS   DEDUCTIONS   END OF PERIOD
            -----------               -----------------   ---------    --------   ----------   -------------
Year ended December 31, 1995:
Deferred tax asset valuation
  account...........................     $1,254,000       $1,015,000     $ --      $    --      $2,269,000
                                         ==========       ==========     ====      =======      ==========
Year ended December 31, 1996:
Deferred tax asset valuation
  account...........................     $2,269,000       $2,081,000     $ --      $    --      $4,350,000
                                         ==========       ==========     ====      =======      ==========
Year ended December 31, 1997:
Allowance for doubtful accounts.....     $       --       $   46,976     $ --      $27,700      $   19,276
                                         ==========       ==========     ====      =======      ==========
Deferred tax asset valuation
  account...........................     $4,350,000       $1,010,000     $ --      $    --      $5,360,000
                                         ==========       ==========     ====      =======      ==========

S-1

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned; thereunto duly authorized, on the 30th day of March, 1998.
NANOPHASE TECHNOLOGIES CORPORATION

By:      /s/ ROBERT W. CROSS

  ------------------------------------
            Robert W. Cross
     President and Chief Executive
                 Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on the 30th day of March, 1998.

                   SIGNATURE                                               TITLE
                   ---------                                               -----

              /s/ ROBERT W. CROSS                   President, Chief Executive Officer (Principal
------------------------------------------------    Executive Officer) and a Director
                Robert W. Cross

              /s/ DENNIS J. NOWAK                   Vice President -- Finance and Administration, Chief
------------------------------------------------    Financial Officer, Treasurer and Secretary
                Dennis J. Nowak                     (Principal Financial and Accounting Officer)

            /s/ LEONARD A. BATTERSON                Chairman of the Board and Director
------------------------------------------------
              Leonard A. Batterson

               /s/ STEVEN LAZARUS                   Director
------------------------------------------------
                 Steven Lazarus

               /s/ DONALD PERKINS                   Director
------------------------------------------------
                 Donald Perkins

             /s/ RICHARD W. SIEGEL                  Director
------------------------------------------------
               Richard W. Siegel

            /s/ ROBERT W. SHAW, JR.                 Director
------------------------------------------------
              Robert W. Shaw, Jr.


EXHIBIT INDEX

EXHIBIT
NUMBER
-------
 2        Plan and Agreement of Merger dated as of November 25, 1997
          by and between the Company and its Illinois predecessor.

 3.1      Certificate of Incorporation of the Company.

 3.2      Bylaws of the Company.

10.15     Letter of Understanding between the Company and LWT
          Services, Inc. dated as of January 13, 1998.

10.17     License Agreement between the Company and C.I. Kasei Co.,
          Ltd. (a subsidiary of Itochu Corporation) dated as of
          December 30, 1997.

10.18     Supply Agreement by and between the Company and EKC
          Technology, Inc., dated as of December 31, 1997.

11        Statement regarding computation of per share earnings.

27.1      Financial Data Schedule.

27.2      Restated Financial Data Schedule.





EXHIBIT 2

PLAN AND AGREEMENT OF MERGER
OF
NANOPHASE TECHNOLOGIES CORPORATION
AN ILLINOIS CORPORATION

WITH AND INTO

NANOPHASE TECHNOLOGIES CORPORATION OF DELAWARE
A DELAWARE CORPORATION

SECTION 1. AGREEMENT TO MERGE. Nanophase Technologies Corporation, an Illinois corporation ("NTC-ILLINOIS"), shall be merged into Nanophase Technologies Corporation of Delaware, a Delaware corporation ("NTC-DELAWARE"), in accordance with applicable provisions of the laws of Illinois and Delaware. NTC-Delaware shall be the surviving corporation.

SECTION 2. TERMS AND CONDITIONS.

2.1 The terms and conditions of the merger and the mode of carrying the merger into effect are as follows.

2.2 NTC-Illinois and NTC-Delaware shall become a single corporation which shall be NTC-Delaware, the surviving corporation. The separate existence of NTC-Illinois shall cease but the existence of NTC-Delaware shall continue.

2.3 NTC-Delaware shall possess all the rights, privileges, immunities, and franchises, of a public as well as of a private nature, of NTC-Delaware and of NTC-Illinois. All property, real, personal and mixed, and all debts due on whatever account, including subscriptions to shares, and all other choses in action, and all and every other interest, of or belonging to or due to NTC-Illinois shall be taken and deemed to be transferred to and vested in NTC-Delaware without further act. The title to any real estate, or any interest therein, vested in NTC-Illinois shall be taken and deemed to be transferred to NTC-Delaware and shall not revert or be in any way impaired by reason of the merger contemplated by this Plan and Agreement of Merger (the "MERGER").

2.4 NTC-Delaware shall be responsible and liable for all the liabilities and obligations of NTC-Illinois.

2.5 The aggregate amount of the net assets of NTC-Delaware and NTC-Illinois available for the payment of dividends or the purchase of treasury shares immediately prior to the Merger, to the extent that the value thereof is not transferred to paid-in capital by the issuance of shares of NTC-Delaware or otherwise, shall continue to be available for the payment of dividends or the purchase of treasury shares by NTC-Delaware.


SECTION 3. CONVERSION OF SHARES.

3.1 The manner and basis of converting the shares of NTC-Delaware and NTC-Illinois into shares or other securities or obligations of NTC-Delaware are as follows.

3.2 The number of shares which NTC-Illinois has authority to issue is:

(a) 21,817,198 shares of Common Stock, no par value, of which 134,000 shares are issued; and

(b) 24,849,324 shares of Preferred Stock, no par value, of which 292,728 are designated Series A Convertible Preferred Stock, 1,309,772 are designated Series B Convertible Preferred Stock, 1,143,846 are designated Series C Convertible Preferred Stock, 1,143,846 are designated Series C-1 Convertible Preferred Stock, 6,729,566 are designated Series D Convertible Preferred Stock, 6,729,566 are designated Series D-1 Convertible Preferred Stock, 3,500,000 are designated Series E Convertible Preferred Stock, and 4,000,000 are designated Series F Convertible Preferred Stock.

(c) Of the shares designated Series A Convertible Preferred Stock, 292,728 shares are issued. Of the shares designated Series B Convertible Preferred Stock, 1,309,772 shares are issued. Of the shares designated Series C Convertible Preferred Stock, 1,143,846 shares are issued. Of the shares designated Series C-1 Convertible Preferred Stock, no shares are issued. Of the shares designated Series D Convertible Preferred Stock, 6,729,566 shares are issued. Of the shares designated Series D-1 Convertible Preferred Stock, no shares are issued. Of the shares designated Series E Convertible Preferred Stock, 3,319,171 shares are issued. Of the shares designated Series F Convertible Preferred Stock, 1,292,036 are issued.

3.3 The number of shares which NTC-Delaware has authority to issue is:

(a) 25,000,000 shares of Common Stock, $0.01 par value, of which one share is issued; and

(b) 17,000,000 shares of Preferred Stock, $0.01 par value, of which 292,728 are designated Series A Convertible Preferred Stock, 1,309,772 are designated Series B Convertible Preferred Stock, 1,143,846 are designated Series C Convertible Preferred Stock, 1,143,846 are designated Series C-1 Convertible Preferred Stock, 6,729,566 are designated Series D Convertible Preferred Stock, 6,729,566 are designated Series D-1 Convertible Preferred Stock, 3,500,000 are designated Series E Convertible Preferred Stock, and 4,000,000 are designated Series F Convertible Preferred Stock.

(c) None of the shares of Preferred Stock of NTC-Delaware is issued.

-2-

3.4 Upon the issuance of a Certificate of Merger:

(a) Each share of Common Stock of NTC-Illinois which is issued and outstanding on the effective date of the Merger shall be converted, by and upon the Merger and without any action on the part of the holder of such share, into 0.579 shares or portion of a share of fully paid and non-assessable Common Stock of NTC-Delaware, as described below. The rate at which such shares shall be converted is hereby designated as the "Conversion Rate". Prior to the effective date of the Merger, the Boards of Directors of NTC-Illinois and NTC-Delaware, or authorized committees thereof, shall, upon the advice of their investment bankers, fix the Conversion Rate such that the shares of Common Stock of the surviving corporation to be sold in the surviving corporation's initial public offering (the "OFFERING") may be issued in a price range necessary or appropriate to effect the Offering.

(b) Each share of Series A Convertible Preferred Stock of NTC-Illinois which is issued and outstanding on the effective date of the Merger shall be converted, by and upon the Merger and without any action on the part of the holder of such share, into such number of shares or portion of a share of fully paid and non-assessable Series A Convertible Preferred Stock of NTC-Delaware as shall be determined by multiplying such share by the Conversion Rate.

(c) Each share of Series B Convertible Preferred Stock of NTC-Illinois which is issued and outstanding on the effective date of the Merger shall be converted, by and upon the Merger and without any action on the part of the holder of such share, into such number of shares or portion of a share of fully paid and non-assessable Series B Convertible Preferred Stock of NTC-Delaware as shall be determined by multiplying such share by the Conversion Rate.

(d) Each share of Series C Convertible Preferred Stock of NTC-Illinois which is issued and outstanding on the effective date of the Merger shall be converted, by and upon the Merger and without any action on the part of the holder of such share, into such number of shares or portion of a share of fully paid and non-assessable Series C Convertible Preferred Stock of NTC-Delaware as shall be determined by multiplying such share by the Conversion Rate.

(e) Each share of Series D Convertible Preferred Stock of NTC-Illinois which is issued and outstanding on the effective date of the Merger shall be converted, by and upon the Merger and without any action on the part of the holder of such share, into such number of shares or portion of a share of fully paid and non-assessable Series D Convertible Preferred Stock of NTC-Delaware as shall be determined by multiplying such share by the Conversion Rate.

(f) Each share of Series E Convertible Preferred Stock of NTC-Illinois which is issued and outstanding on the effective date of the Merger shall be converted, by and upon the Merger and without any action on the part of the holder of such share, into such number of shares or portion of a share of fully paid and non-assessable Series E Convertible Preferred Stock of NTC-Delaware as shall be determined by multiplying such share by the Conversion Rate.

(g) Each share of Series F Convertible Preferred Stock of NTC-Illinois which is issued and outstanding on the effective date of the Merger shall be converted, by and upon the Merger and without any action on the part of the holder of such share, into such number of shares or

-3-

portion of a share of fully paid and non-assessable Series F Convertible Preferred Stock of NTC-Delaware as shall be determined by multiplying such share by the Conversion Rate.

(h) The paid-in capital of NTC-Illinois shall be transferred to the paid-in capital of NTC-Delaware.

(i) Certificates for the shares of Common Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D Convertible Preferred Stock, Series E Convertible Preferred Stock and Series F Convertible Preferred Stock of NTC-Delaware shall be issued to the holders of all of the outstanding Common Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D Convertible Preferred Stock, Series E Convertible Preferred Stock and Series F Convertible Preferred Stock, respectively, as of the Merger date, in place and upon the surrender of previously issued stock certificates, on the aforesaid basis. Stock certificates of NTC-Illinois shall be surrendered to NTC-Delaware at its office located at 453 Commerce Street, Burr Ridge, Illinois 60521. However, upon the Merger becoming effective, the holders of the shares of NTC-Illinois outstanding immediately prior to the Merger shall thereupon cease to be holders of said shares and shall be and become holders of shares of NTC-Delaware upon the basis hereinabove specified, whether or not stock certificates representing the previously outstanding shares of NTC-Illinois are surrendered or stock certificates representing shares of NTC-Delaware are issued and delivered. Upon the effective time of the Merger, the shares of NTC-Delaware outstanding immediately prior to the Merger shall be automatically cancelled and retired and shall cease to exist and no new shares shall be issued in lieu thereof.

SECTION 4. CERTIFICATE OF INCORPORATION.

4.1 The Certificate of Incorporation of the surviving corporation shall be amended by the Merger by the deletion of Article 1 in its entirety and the insertion in lieu thereof of the following Article 1:

"ARTICLE 1. NAME

The name of the Corporation is NANOPHASE TECHNOLOGIES CORPORATION

(the "CORPORATION")."

4.2 As of the effective time of the Merger, the Certificate of Incorporation of NTC-Delaware, amended in accordance with Section 4.1 above, and the By-Laws of NTC-Delaware shall be the Certificate of Incorporation and the By-Laws of the surviving corporation.

SECTION 5. TERMINATION. At any time prior to the filing of the Articles of Merger with respect to the Merger, the Merger may be terminated or abandoned by the Board of Directors of either NTC-Delaware or NTC-Illinois notwithstanding approval of the Merger by the shareholders of NTC-Illinois or the stockholders of NTC-Delaware, subject to the provisions of applicable law.

-4-

SECTION 6. AMENDMENTS. The Board of Directors of either NTC-Illinois or NTC-Delaware may amend this Plan and Agreement of Merger at any time prior to the filing of the Articles of Merger with respect to the Merger, provided that an amendment made subsequent to the adoption of this Plan and Agreement of Merger by the shareholders of NTC- Illinois and the stockholders of NTC-Delaware shall not, without the consent of such shareholders and stockholders, as appropriate, effect any change which could not be effected under applicable law without their consent.

SECTION 7. ADOPTION. This Plan and Agreement of Merger has been approved, adopted, certified, executed and acknowledged by NTC-Illinois and NTC-Delaware in accordance with the laws under which each is, respectively, organized.

***END OF TEXT***


NANOPHASE TECHNOLOGIES CORPORATION Dated November 25, 1997
(AN ILLINOIS CORPORATION)

By       /S/ ROBERT CROSS                Attested by:   /S/ DENNIS NOWAK
         -------------------                            -------------------
         Robert Cross                                   Dennis Nowak
         President                                      Secretary

NANOPHASE TECHNOLOGIES CORPORATION OF DELAWARE Dated November 25, 1997
(A DELAWARE CORPORATION)

By       /S/ ROBERT CROSS                Attested by:   /S/ DENNIS NOWAK
         -------------------                            -------------------
         Robert Cross                                   Dennis Nowak
         President                                      Secretary

-6-

EXHIBIT 3.1

CERTIFICATE OF INCORPORATION
OF
NANOPHASE TECHNOLOGIES CORPORATION

ARTICLE I

The name of the corporation is Nanophase Technologies Corporation.

ARTICLE II

The address of the Corporation's registered office in the State of Delaware is Corporation Service Company, 1013 Centre Road, Wilmington, Delaware 19805. The name of its registered agent at such address is Corporation Service Company.

ARTICLE III

The nature of the business to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the DGCL.

ARTICLE IV

A. The Corporation shall have authority to issue the following classes of stock, in the number of shares and at the par value as indicated opposite the name of the class:

                                               NUMBER OF
                                                SHARES         PAR VALUE
                CLASS                          AUTHORIZED      PER SHARE
------------------------------------------   --------------   -----------
  Common Stock (the"Common Stock")             25,000,000         $.01

  Preferred Stock (the "Preferred Stock")      17,000,000         $.01

B. The designations and the powers, preferences and relative, participating, optional or other rights of the Common Stock and the Preferred Stock, in general, and the qualifications, limitations or restrictions thereof are as follows:

1. Common Stock.

a. Voting Rights: Except as otherwise required by law or expressly provided herein, the holders of shares of Common Stock shall be entitled to one vote per share on each matter submitted to a vote of the stockholders of the


Corporation, and the holders of shares of Common Stock and "Old Preferred" (as defined below) shall vote together and not as separate classes.

b. Dividends: Subject to the rights of the holders, if any, of Preferred Stock, the holders of Common Stock shall be entitled to receive cash dividends as, when and if declared, and at such times and in such amounts as may be determined, by the Board of Directors of the Corporation, but only out of funds legally available therefor.

c. Liquidation Rights: In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, after payment or provision for payment of the debts and other liabilities of the Corporation and the preferential amounts to which the holders of any outstanding shares of Preferred Stock or Old Preferred shall be entitled upon dissolution, liquidation or winding up, the holders of the Common Stock shall be entitled to share ratably in the remaining assets of the Corporation with the holders of any outstanding shares of Old Preferred (with each share of Old Preferred being treated for such purpose as equal to the number of shares of Common Stock into which each such share of Old Preferred is convertible on the date of such distribution), or, if no shares of Old Preferred are outstanding, such assets available for distribution to stockholders shall be distributed ratably among the holders of the shares of Common Stock.

2. Preferred Stock.

Preferred Stock may be issued from time to time in one or more series. One series consists of 292,728 shares and is designated Series A Convertible Preferred Stock, $.01 par value (herein designated "Series A Preferred"). A second series consists of 1,309,772 shares and is designated Series B Convertible Preferred Stock, $.01 par value (herein called "Series B Preferred"). A third series consists of 1,143,846 shares designated as Series C Convertible Preferred Stock, $.01 par value (herein called "Series C Preferred"), and 1,143,846 shares designated as Series C-1 Convertible Preferred Stock, $.01 par value (herein called "Series C-1 Preferred"). A fourth series consists of 6,729,566 shares designated as Series D Convertible Preferred Stock, $.01 par value (herein called "Series D Preferred"), and 6,729,566 shares designated as Series D-1 Convertible Preferred Stock, $.01 par value (herein called "Series D-1 Preferred"). A fifth series consists of 3,500,000 shares and is designated as Series E Convertible Preferred Stock, $.01 par value (herein called "Series E Preferred"). A fifth series consists of 4,000,000 shares designated as Series F Convertible Preferred Stock, $.01 par value (herein called "Series F Preferred"). Subject to the other provisions of this Certificate of Incorporation, the Board of Directors is authorized, subject to any limitations prescribed by law, to provide for the issuance of and to issue shares of the Preferred Stock in one or more series, and by filing a certificate pursuant to the laws of the State of Delaware, to establish from time to time the number of shares to be included

-2-

in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and any qualifications, limitations or restrictions thereof. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the Common Stock, without a vote of the holders of any Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the certificate or certificates establishing such series of Preferred Stock.

C. The designations and the powers, preferences and relative, participating, optional or other rights of the Series A Preferred, Series B Preferred, Series C Preferred, Series C-1 Preferred, Series D Preferred, Series D-1 Preferred, Series E Preferred and Series F Preferred (hereinafter referred to collectively and individually as the "Old Preferred") and the qualifications, limitations or restrictions thereof are as follows:

1. Voting Rights. Except as otherwise required by law, each share of outstanding Old Preferred shall entitle the holder thereof to vote on each matter submitted to a vote of the stockholders of the Corporation and to have the number of votes equal to the number (including any fraction) of shares of Common Stock into which such share of Old Preferred is then convertible pursuant to the provisions hereof at the record date for the determination of stockholders entitled to vote on such matters or, if no such record date is established, at the date such vote is taken or any written consent of stockholders becomes effective. Except as otherwise required by law, the holders of shares of Common Stock and Old Preferred shall vote together and not as separate classes, and the holders of Series A Preferred, Series B Preferred, Series C Preferred, Series C-1 Preferred, Series D Preferred, Series D-1 Preferred, Series E Preferred and Series F Preferred shall vote together as a single class of Preferred Stock and not as separate series.

2. Dividends.

(a) The holders of the Series B Preferred shall be entitled to receive, out of funds legally available therefor, and without declaration by the Board of Directors, cumulative cash dividends in the amount of $0.052 per share per annum (such amount to be adjusted proportionally in the event the shares of Series B Preferred are subdivided into a greater number or combined into a lesser number of shares). Dividends on the Series B Preferred shall accrue and be cumulative commencing on the date of issuance of the first shares of Series B Preferred and will be payable to Series B Preferred stockholders of record only upon the liquidation of the Corporation, and then only upon the prior satisfaction by the Corporation of the liquidation preference attaching to any share of Preferred Stock senior in liquidation preference to the Series B Preferred pursuant to this Certificate of Incorporation. The amount of dividends paid on shares of Series B Preferred shall be calculated on the basis of a 360 day year consisting of 12 thirty day months. Dividends paid on shares of Series B Preferred in an amount less than the total amount of such dividends at the time accumulated and payable shall be allocated ratably among all shares of Series B Preferred then outstanding.

-3-

(b) The holders of Old Preferred shall be entitled to receive, as, when and if declared by the Board of Directors, but only out of funds legally available therefor, cash dividends in such amounts as the Board of Directors may determine.

(c) Other than with respect to dividends paid on the Series B Preferred which represent payment of accumulated but unpaid dividends thereon payable pursuant to and at the time stated in Section C.2(a) above, no dividends shall be declared or paid on the shares of any series of Old Preferred for any dividend period unless at the same time such dividend shall be declared or paid on all shares of Old Preferred equally.

(d) If any dividend or other distribution payable in cash, securities or other property (other than securities of the Corporation the issuance of which gives rise to adjustment of the Conversion Price pursuant to Section C.4(c) of this Article IV) is declared on the Common Stock, each holder of shares of Old Preferred on the record date for such dividend or distribution shall be entitled to receive on the date of payment or distribution of such dividend or other distribution the same cash, securities or other property which such holder would have received on such record date if such holder was the holder of record of the number (including any fraction) of shares of Common Stock into which the shares of Old Preferred then held by such holder are then convertible. No dividend which has been previously declared but unpaid shall be paid prior to the voluntary or involuntary liquidation, dissolution or winding up of the Corporation pursuant to Section C.3 of this Article IV.

3. Liquidation Rights. If the Corporation shall be voluntarily or involuntarily liquidated, dissolved or wound up:

(a) The holder of each then outstanding share of Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred shall be entitled to receive out of the assets of the Corporation available for distribution to stockholders, and before any payment or declaration and setting apart for payment of any amount or dividend with respect to the Series B Preferred, Series A Preferred, Common Stock or any other equity security, the amount of $3.00 per share (with respect to the Series F Preferred), the amount of $2.25 per share (with respect to the Series E Preferred), the amount of $.80 per share (with respect to the Series D Preferred and Series D-1 Preferred purchased prior to October 1, 1994), $1.00 per share (with respect to the Series D Preferred and Series D-1 Preferred purchased on or after October 1, 1994) and $0.65 per share (with respect to the Series C Preferred and Series C-1 Preferred) (such amounts to be adjusted proportionally in the event the shares of Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred or Series C-1 Preferred are subdivided into a greater number or combined into a lesser number of shares), plus all declared but unpaid dividends on such share for each share of Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred then held by them. The Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred shall rank on a parity with each other as to the receipt of the respective preferential amounts for

-4-

each such series upon the occurrence of such event. If the Corporation shall have insufficient assets and funds to pay such amounts in full to the holders of the Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred, then all assets and funds of the Corporation legally available for distribution shall be distributed ratably among the holders of the Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred in proportion to the preferential amount each such holder is otherwise entitled to receive pursuant to this subsection (a).

(b) Subject to the liquidation rights of the holders of the Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred set forth in Section C.3(a) above, the holder of each then outstanding share of Series C Preferred and Series C-1 Preferred shall be entitled to receive out of the assets of the Corporation available for distribution to stockholders, and before any payment or declaration and setting apart for payment of any amount or dividend with respect to the Series B Preferred, Series A Preferred, Common Stock or any other equity security, an amount equal to $1.30 per share (such amount to be adjusted proportionally in the event the shares of Series C Preferred and Series C-1 Preferred are subdivided into a greater number or combined into a lesser number of shares), plus all declared but unpaid dividends thereon. If the Corporation shall have insufficient assets and funds to pay such amounts in full to the holders of the Series C Preferred and Series C-1 Preferred, then all assets and funds of the Corporation legally available for distribution shall be distributed ratably among the holders of the Series C Preferred and Series C-1 Preferred in accordance with the number of shares of Series C Preferred and Series C-1 Preferred held by each such holder.

(c) Subject to the liquidation rights of the holders of the Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred set forth in Sections C.3(a) and
(b) above, the holder of each then outstanding share of Series B Preferred shall be entitled to receive out of the assets of the Corporation available for distribution to stockholders, and before any payment or declaration and setting apart for payment of any amount or dividend with respect to the Series A Preferred, Common Stock or any other equity security, an amount equal to $.65 per share (such amount to be adjusted proportionally in the event the shares of Series B Preferred are subdivided into a greater number or combined into a lesser number of shares), plus all accrued or declared but unpaid dividends thereon. If the Corporation shall have insufficient assets and funds to pay such amounts in full to the holders of the Series B Preferred, then all assets and funds of the Corporation legally available for distribution shall be distributed ratably among the holders of the Series B Preferred in accordance with the number of shares of Series B Preferred held by each such holder.

(d) Subject to the liquidation rights of the holders of the Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred, Series C-1 Preferred and Series B Preferred set forth in Sections C.3(a), (b) and (c) above, the holder of each then outstanding share of Series A Preferred shall be entitled to receive out of the assets of the Corporation available for distribution to stockholders, and before any payment or declaration and

-5-

setting apart for payment of any amount or dividend with respect to the Common Stock or any other equity security, an amount equal to $2.05 per share (such amount to be adjusted proportionally in the event the shares of Series A Preferred are subdivided into a greater number or combined into a lesser number of shares), plus all declared but unpaid dividends thereon. If the Corporation shall have insufficient assets and funds to pay such amounts in full to the holders of the Series A Preferred, then all assets and funds of the Corporation legally available for distribution shall be distributed ratably among the holders of the Series A Preferred in accordance with the number of shares of Series A Preferred held by each such holder.

(e) After payment in full of the amounts payable pursuant to Sections C.3(a), (b), (c) and (d) above to the holders of Old Preferred, the holder of each then outstanding share of Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred shall be entitled to share ratably in the remaining assets of the Corporation with the holders of Common Stock (with each share of Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred being treated, for such purpose, as equal to the number of shares of Common Stock into which such share of Series F Preferred, Series E Preferred, Series D Preferred, Series D-1 Preferred, Series C Preferred and Series C-1 Preferred is convertible on the date of such distribution).

(f) For purposes of this Section C.3, (i) any acquisition of the Corporation by means of a merger or other form of corporate reorganization in which outstanding shares of the Corporation are exchanged for securities or other consideration issued, or caused to be issued, by the acquiring corporation or its subsidiary (other than a mere reincorporation transaction), or (ii) a sale of all or substantially all of the assets of the Corporation, shall (for purposes of the distribution of such securities or other consideration to the holders of Common Stock and Old Preferred) be treated as a liquidation, dissolution or winding up of the Corporation and shall entitle the holders of Common Stock and Old Preferred to receive at closing in cash, securities or other property (valued as provided in Section C.3(g) below) amounts as specified and otherwise in the order of preference as set forth in Sections C.3(a), (b), (c), (d) and (e) above.

(g) Whenever the distribution provided in this Section C.3 shall be payable in securities or property other than cash, the value of such distribution shall be the fair market value of such securities or other property as determined in good faith by the Board of Directors.

4. Conversion.

(a) Terms of Conversion.

(i) Optional Conversion. The holder of each share of Old Preferred shall have the right (the "Conversion Right"), at such holder's option, to convert such share at any time, without cost and otherwise on the terms of this Section C.4, into the number of fully paid and non-assessable shares of Common Stock that results from dividing the Conversion Price of the applicable series of Old Preferred that is in effect at the time of conversion (the "Conversion

-6-

Price") into the Original Issue Price for such series of Old Preferred. The initial Conversion Price for the Series F Preferred is $3.00 per share, for the Series E Preferred $2.25 per share, for the Series D Preferred $.80 per share (for shares of Series D Preferred issued prior to October 1, 1994) and $1.00 per share (for shares of Series D Preferred issued on or after October 1, 1994), for the Series C Preferred $.65 per share, for the Series B Preferred $.65 per share, and for the Series A Preferred $2.05 per share. The initial conversion price for each share of the Series D-1 Preferred shall equal the Conversion Price of the Series D Preferred from which such share of Series D-1 Preferred is converted at the time of such conversion. The initial conversion price for each share of the Series C-1 Preferred shall equal the Conversion Price of the Series C Preferred from which such share of Series C-1 Preferred is converted at the time of such conversion. The "Original Issue Price" for each of the Series F Preferred, Series E Preferred, Series D Preferred (for shares of Series D Preferred issued prior to October 1, 1994), Series D-1 Preferred (issued with respect to shares of Series D Preferred issued prior to October 1, 1994), Series D Preferred (for shares of Series D Preferred issued on or after October 1, 1994), Series D-1 Preferred (issued with respect to shares of Series D Preferred issued on or after October 1, 1994), Series C, Series C-1, Series B and Series A Preferred are, respectively, $3.00, $2.25, $1.00, $1.00, $.80, $.80, $.65, $.65, $.65 and $2.05. The Conversion Price of each share of each series of Old Preferred shall be subject to adjustment from time to time as provided in this Section C.4 entitled "Conversion".

(ii) Mandatory Conversion. Upon the occurrence of a Qualified Initial Public Offering (as hereinafter defined), each share of Old Preferred shall be automatically converted, without cost and on the terms of this Section C.4 entitled "Conversion", into the number of shares of Common Stock into which such share of Old Preferred would be convertible under clause B.4(a)(i) above immediately prior to such Qualified Initial Public Offering.

(b) Mechanics of Conversion.

(i) Optional Conversion. A holder of any share of Old Preferred may exercise the Conversion Right of such share by surrendering the certificate therefor, duly endorsed, at the office of the Corporation or of any transfer agent for the Old Preferred, together with a written notice to the Corporation which shall state:

(A) that such holder elects to convert the same, and;

(B) the number of shares of Old Preferred being converted.

Thereupon the Corporation shall promptly issue and deliver to the holder of such shares a certificate or certificates for the number of shares of Common Stock to which such holder shall be entitled. If the certificate evidencing the Old Preferred being converted shall also evidence shares of Old Preferred not being converted, then the Corporation shall also deliver to the holder of such certificate a new stock certificate evidencing the Old Preferred not converted. The conversion of any shares of Old Preferred shall be deemed to have been made immediately prior

-7-

to the close of business on the date that the shares of Old Preferred to be converted are surrendered to the Corporation, and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common Stock on such date. Any dividends or distributions declared but unpaid at the time of conversion with respect to the Old Preferred so converted shall be paid to the Holder of such Common Stock. The Corporation shall give written notice to each holder of a share of Old Preferred promptly upon the liquidation, dissolution or winding up of the Corporation, and not more than forty (40) nor less than twenty (20) days before the anticipated date of consummation of any acquisition of the Corporation or any sale of all or substantially all of the assets of the Corporation referred to in Section C.3(g) and no such acquisition of the Corporation or sale of assets shall be effective until such notice shall have been given.

(ii) Mandatory Conversion. The Corporation shall give written notice to each holder of a share of Old Preferred not more than forty
(40) nor less than ten (10) days before the anticipated effective date of the registration statement with respect to any Qualified Initial Public Offering, and shall also give written notice to each such holder upon the actual occurrence of any Qualified Initial Public Offering. Following the conversion of such shares, each holder of shares so converted may surrender the certificate therefor at the office of the Corporation or any transfer agent for the Old Preferred. Upon such surrender, the Corporation shall issue and deliver to each holder a certificate or certificates for the number of shares of Common Stock to which such holder is entitled.

The conversion of shares of Old Preferred shall take place upon the occurrence of the Qualified Initial Public Offering, whether or not the certificates representing such shares of Old Preferred shall have been surrendered or new certificates representing the shares of Common Stock into which such shares have been converted shall have been issued.

(c) Adjustment of Conversion Price. The Conversion Price for each share of Old Preferred and the kind of securities issuable upon the conversion of any share of Old Preferred shall be adjusted from time to time as follows:

(i) Subdivision or Combination of Shares. If the Corporation at any time effects a subdivision or combination of the outstanding Common Stock, each Conversion Price shall be decreased, in the case of a subdivision, or increased, in the case of a combination, in the same proportions as the Common Stock is subdivided or combined, in each case effective automatically upon, and simultaneously with, the effectiveness of the subdivision or combination which gives rise to the adjustment.

(ii) Stock Dividends. If the Corporation at any time pays a dividend, or makes any other distribution, to holders of Common Stock payable in shares of Common Stock, or fixes a record date for the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in shares of Common Stock, each Conversion Price shall be decreased by multiplying it by a fraction:

-8-

(A) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and

(B) the denominator of which shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution (plus, if the Corporation paid cash instead of fractional shares otherwise issuable in such dividend or distribution, the number of additional shares which would have been outstanding had the Corporation issued fractional shares instead of cash),

in each case effective automatically as of the date the Corporation shall take a record of the holders of its Common Stock for the purpose of receiving such dividend or distribution (or if no such record is taken, as of the effectiveness of such dividend or distribution).

(iii) Reclassification, Consolidation or Merger. If at any time, as a result of:

(A) a capital reorganization or reclassification (other than a subdivision, combination or dividend which gives rise to an adjustment of each Conversion Price pursuant to clauses (i) or (ii) of this Section C.4(c) entitled "Adjustment of Conversion Price"); or

(B) a merger or consolidation of the Corporation with another corporation (whether or not the Corporation is the surviving corporation),

the Common Stock issuable upon the conversion of the Old Preferred shall be changed into or exchanged for the same or a different number of shares of any class or classes of stock of the Corporation or any other corporation, or other securities convertible into such shares, then, as a part of such reorganization, reclassification, merger or consolidation, appropriate adjustments shall be made in the terms of the Old Preferred (or of any securities into which the Old Preferred is changed or for which the Old Preferred is exchanged), so that:

(Y) the holders of Old Preferred or of such substitute securities shall thereafter be entitled to receive, upon conversion of the Old Preferred or of such substitute securities, the kind and amount of shares of stock, other securities, money and property which such holders would have received at the time of such capital reorganization, reclassification, merger, or consolidation, if such holders had converted their Old Preferred immediately prior to such capital reorganization, reclassification, merger, or consolidation, and

(Z) the Old Preferred or such substitute securities shall thereafter be adjusted on terms as nearly equivalent as may be practicable to the adjustments theretofore provided in this Section C.4(c) entitled "Adjustment of Conversion Price".

-9-

No consolidation or merger in which the Corporation is not the surviving corporation shall be consummated unless the surviving corporation shall agree, in writing, to the provisions of this Section C.4(c)(iii). The provisions of this Section C.4(c)(iii) shall similarly apply to successive capital reorganizations, reclassifications, mergers, and consolidations.

(iv) Ratchet. (A) For purposes of this Section C.4(c)(iv) entitled "Ratchet", "Additional Shares of Common Stock" means all shares of Common Stock sold by the Corporation after the date on which Series F Preferred has been last issued and sold, whether or not subsequently reacquired or retired by the Corporation, other than:

(1) shares of Common Stock issued in transactions giving rise to adjustments under Sections C.4(c)(i), (ii), or
(iii) above;

(2) shares of Common Stock issued upon conversion of shares of Old Preferred; and

(3) up to 4,763,440 shares of Common Stock which may be issued in the discretion of the Board of Directors to employees or directors of, or consultants or advisors to, the Corporation or any wholly-owned subsidiary of the Corporation, and options for the purchase of such shares.

(B) Except as otherwise provided in Section C.4(c)(v) below entitled "Convertible Securities", if at any time the Corporation issues or is deemed to issue Additional Shares of Common Stock for a consideration per share less than the Conversion Price in effect with respect to any shares of the Series F Preferred, Series E Preferred, Series D Preferred or the Series C Preferred, respectively, at such issuance or deemed issuance,

(1) the Conversion Price with respect to such shares of the Series F Preferred or Series E Preferred, as applicable, shall be reduced to a price per share equal to a price determined by dividing:

(y) the sum of (1) the product derived by multiplying the Conversion Price with respect to the Series F Preferred or the Series E Preferred, as applicable, in effect immediately prior to such issue times the number of shares of Common Stock (including shares of Common Stock deemed to have been issued upon conversion of the outstanding Old Preferred) outstanding immediately prior to such issue, plus (2) the consideration, if any, received by or deemed to have been received by the Corporation upon such issue,

by:

(z) the sum of (3) the number of shares of Common Stock (including shares of Common Stock deemed to have been issued upon

-10-

conversion of the outstanding Old Preferred) outstanding immediately prior to such issue, plus (4) the number of shares of Common Stock issued or deemed to have been issued in such issue, and

(2) the Conversion Price with respect to such shares of the Series D Preferred or the Series C Preferred, as applicable, shall be reduced to a price per share equal to the consideration per share, if any, for which such Additional Shares of Common Stock are issued or deemed to be issued.

(v) Convertible Securities.

(A) "Convertible Securities" means all rights or options for the purchase of, or stock or other securities convertible into, Additional Shares of Common Stock or other Convertible Securities, whenever and each time issued.

(B) The "Effective Price" with respect to any Convertible Securities means the result of dividing:

(1) the sum of (a) the total consideration, if any, received by the Corporation for the issuance of such Convertible Securities, plus (b) the minimum consideration, if any, payable to the Corporation upon exercise or conversion of such Convertible Securities, plus (c) the minimum consideration, if any, payable to the Corporation upon exercise or conversion of any Convertible Securities issuable upon exercise or conversion of such Convertible Securities,

by:

(2) the maximum number of Additional Shares of Common Stock issuable upon exercise or conversion of such Convertible Securities or of any Convertible Securities issuable upon exercise or conversion of such Convertible Securities.

(C) If at any time the Corporation issues or is deemed to issue a Convertible Security with respect to which the Effective Price is less than the Conversion Price in effect with respect to any shares of the Series F Preferred, Series E Preferred, Series D Preferred or the Series C Preferred, respectively, at such issuance or deemed issuance,

(1) the Conversion Price with respect to such shares of the Series F Preferred or the Series E Preferred, as applicable, shall be reduced to a price per share determined by dividing:

(y) the sum of (1) the product derived by multiplying the Conversion Price with respect to the Series F Preferred or the Series E Preferred, as applicable, in effect immediately prior to such issue times the number of shares of Common Stock (including shares of Common

-11-

Stock deemed to have been issued upon conversion of the outstanding Old Preferred) outstanding immediately prior to such issue, plus (2) the consideration, if any, received by or deemed to have been received by the Corporation upon such issue,

by:

(z) the sum of (3) the number of shares of Common Stock (including shares of Common Stock deemed to have been issued upon conversion of the outstanding Old Preferred) outstanding immediately prior to such issue, plus (4) the number of shares of Common Stock issued or deemed to have been issued in such issue, and

(2) the Conversion Price with respect to such shares of the Series D Preferred or the Series C Preferred, as applicable, shall be reduced to a price per share equal to the Effective Price with respect to such Convertible Security, effective automatically as of the effectiveness of the issuance of such Convertible Security.

(D) If an adjustment has been made under this Section C.4(c)(v) entitled "Convertible Securities" as a consequence of any issuance of a Convertible Security, then no further adjustment shall be made under Section C.4(c)(iv) entitled "Ratchet" upon the actual issuance of Additional Shares of Common Stock upon the exercise or conversion of such Convertible Securities, or upon the issuance of Convertible Securities issuable upon exercise or conversion of the original Convertible Security.

(E) If an adjustment has been made under this Section C.4(c)(v) entitled "Convertible Securities" as a consequence of any issuance of any Convertible Security and the conversion rights, options or privileges represented by such Convertible Security (or by any Convertible Security issued upon exercise or conversion of the original Convertible Security) shall expire without having been exercised, the Conversion Price with respect to the previously affected shares of the Series F Preferred, Series E Preferred, Series D Preferred or the Series C Preferred shall be re-adjusted as applicable, effective upon such expiration, to eliminate the effect of the adjustments previously made as a result of the issuance of the conversion rights, options or privileges which shall have expired (without affecting shares of Common Stock already issued upon the conversion of any shares of Series F Preferred, Series E Preferred, Series D Preferred or Series C Preferred already converted, and without affecting any other adjustments made under this Section C.4(c)).

(vi) Valuation of Consideration. For purposes of the operation of Sections C.4(c)(iv) and (v) entitled "Ratchet" and "Convertible Securities", respectively, the consideration received by the Corporation for any issue or sale of securities shall:

-12-

(A) to the extent it consists of cash, be computed as the aggregate amount of cash received by the Corporation;

(B) to the extent it consists of property other than cash, be computed at the fair value of that property as determined in good faith by the Board of Directors; and

(C) to the extent Additional Shares of Common Stock or Convertible Securities are issued or sold together with other stock or securities or other assets of the Corporation for a consideration that covers both, be such portion of the consideration so received that may be reasonably determined in good faith by the Board of Directors to be allocable to such Additional Shares of Common Stock or Convertible Securities.

(vii) Special Mandatory Conversion.

(A) If (1) a holder of shares of Series D Preferred or Series C Preferred (for purposes of this Section C.4(c)(vii) only being treated as separate series, regardless of whether a holder holds shares of one or both of the Series D Preferred and the Series C Preferred) is entitled to exercise the "Right Of First Refusal" set forth in Section 6 of the Amended and Restated Shareholders' Agreement dated as of March 16, 1994, as subsequently amended, with respect to the issuance of "New Securities" (as defined in said Agreement) by the Corporation at a price per share which is less than the Conversion Price then in effect for all or any portion of such holder's Series D Preferred and/or Series C Preferred as applicable (the "Equity Financing"), (2) the Corporation has complied with its obligations under the Right of First Refusal with respect to such Equity Financing (each such Equity Financing being referred to in this Section C.4(c)(vii) as a "Mandatory Offering"), and (c) such holder (a "Non-Participating Holder") does not exercise such holder's Right of First Refusal to acquire at least his "Pro Rata Share" (as defined in said Shareholders' Agreement) offered in such Mandatory Offering, then each of such Non-Participating Holder's shares of Series D Preferred and/or Series C Preferred as to which the Conversion Price is greater than the price per share paid in such Equity Financing shall automatically and without further action on the part of such holder be converted into a share of Series D-1 Preferred or Series C-1 Preferred respectively (a "Special Mandatory Conversion") effective upon, subject to and concurrently with the consummation of the Mandatory Offering (the "Mandatory Offering Date"); provided, however, that if pursuant to the request of the Corporation the holders of Series D Preferred and Series C Preferred are requested to purchase on a pro rata basis less than their Pro Rata Share in connection with a particular Equity Financing, the Pro Rata Share of each holder of Series D Preferred and Series C Preferred shall for purposes of the application of this subsection (A) be deemed reduced to such lesser number as the Corporation shall have requested. Upon conversion pursuant to this subsection (A), the shares of Series D Preferred and Series C Preferred so converted shall be canceled and not subject to reissuance.

(B) The holder of any shares of Series D Preferred or Series C Preferred converted pursuant to this Section C.4(c)(vii) shall deliver to the Corporation during regular business hours at the office of the Corporation or of any transfer agent for the Series D

-13-

Preferred and Series C Preferred a certificate or certificates for the shares of Series D Preferred and Series C Preferred so converted, duly endorsed or assigned in blank to the Company. Thereafter, the Corporation shall promptly deliver to such holder a certificate or certificates for the number of shares of Series D-1 Preferred and Series C-1 Preferred to be issued as appropriate, and such holder shall be deemed to have become a stockholder of record on the Mandatory Offering Date, or on the next succeeding date on which the transfer books are open.

(C) If any shares of Series D-1 Preferred or Series C-1 Preferred are issued, the Corporation shall use its best efforts to take all action with respect to such shares as may be required, including amending its Articles of Incorporation, (1) to cancel all authorized shares of Series D-1 Preferred or Series C-1 Preferred, as appropriate, that remain after such issuance, (2) to create and reserve for issuance upon a subsequent Special Mandatory Conversion of the Series D Preferred or Series C Preferred a new series of Preferred equal in number to the number of shares of Series D-1 or Series C-1 Preferred so canceled and designated Series D-2 Preferred or Series C-2 Preferred, with the powers, preferences and rights and the qualifications, limitations and restrictions identical respectively to those then applicable to the Series D-1 or Series C-1 Preferred, except that the Conversion Price for such shares of Series D-1 Preferred or Series C-1 Preferred once initially issued shall respectively be the Conversion Price with respect to the Series D Preferred and Series C Preferred in effect immediately prior to such issuance, and (3) to amend the provisions of this Section C.4(c)(vii) to provide that any subsequent Special Mandatory Conversion will be into shares of Series D- 2 Preferred or Series C-2 Preferred, as appropriate. The Corporation shall take the same actions with respect to the Series D-2 Preferred and Series C-2 Preferred and each subsequently authorized series of Preferred upon initial issuance of shares of the last such series to be authorized.

(viii) Other Action Affecting Common Stock. If at any time the Corporation takes any action affecting its Common Stock which, in the opinion of the Board of Directors of Directors of the Corporation, would have an adverse effect upon the Conversion Rights of the Old Preferred, the Conversion Price and the kind of Securities issuable upon the conversion of Old Preferred shall be adjusted in such manner and at such time as the Board of Directors of the Corporation may in good faith determine to be equitable in the circumstances.

(ix) Notice of Adjustment Events. Whenever the Corporation contemplates the occurrence of an event which would give rise to adjustments under Sections C.4(c)(i) - (v) or (viii) above, the Corporation shall mail to each holder of Old Preferred, at least 30 days prior to the record date with respect to such event or, if no record date shall be established, at least 30 days prior to such event, a notice specifying (A) the nature of the contemplated event, (B) the date on which any such record is to be taken for the purpose of such event, (C) the date on which such event is expected to become effective, and (D) the time, if any is to be fixed, when the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other securities) for securities or other property deliverable in connection with such event.

-14-

(x) Notice of Adjustments. Whenever the Conversion Price or the kind of securities issuable upon the conversion of any one of or all of the Old Preferred shall be adjusted pursuant to Section C.4(c)(i) - (v), (vii) or
(viii) above, the Corporation shall make a certificate signed by its President or a Vice President and by its Chief Financial Officer, Secretary or Assistant Secretary, setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated (including a description of the basis on which the Board of Directors made any determination hereunder), and the Conversion Price and the kind of securities issuable upon the conversion of any one of or all of the Series A Preferred, Series B Preferred, Series C Preferred or Series C-1 Preferred after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (by first class mail postage prepaid) to each holder of Preferred promptly after each adjustment.

(d) Reservation of Shares. The Corporation will take such corporate action as may be necessary from time to time so that at all times it will have authorized, and reserved out of its authorized but unissued Common Stock for the sole purpose of issuance upon conversion of shares of Old Preferred, a sufficient number of shares of Common Stock to permit the conversion in full of all outstanding shares of Old Preferred.

(e) Full Consideration. All shares of Common Stock which shall be issued upon the conversion of any Old Preferred (which is itself fully paid and non-assessable) will, upon issuance, be fully paid and non-assessable. The Corporation will pay such amounts and will take such other action as may be necessary from time to time so that all shares of Common Stock which shall be issued upon the conversion of any Old Preferred will, upon issuance and without cost to the recipient, be free from all pre-emptive rights, taxes, liens and charges with respect to the issue thereof.

(f) Definitions. For the purpose of this Article IV, the following term shall have the meaning ascribed below:

"Qualified Initial Public Offering" means the consummation of the first issuance and sale to the public of Common Stock pursuant to an effective registration statement under the Securities Act of 1933 in connection with which (a) the price per share to the public of such securities immediately before such sale is not less than $3.00, as adjusted for stock splits, stock dividends and other similar events,
(b) the price to the public of such securities is not less than the minimum share price necessary to obtain a National Market Systems listing from The Nasdaq Stock Market, Inc., and (c) the aggregate price to the public of the securities actually sold to the public in such first sale, before brokers' commissions and expense allowances paid by the Corporation in connection with the original sale of such securities, is not less than $10,000,000.

5. Residual Rights. All rights accruing to the outstanding shares of the Corporation not otherwise expressly provided for herein shall be vested in the Common Stock.

-15-

ARTICLE V

The name and mailing address of the incorporator is:

Bruce A. Zivian 20 N. Wacker, Suite 3220 Chicago, Illinois 60606

ARTICLE VI

The business and affairs of the Corporation shall be managed by or under the direction of a board of directors consisting of not less than five
(5) nor more than nine (9) directors. The number of directors shall be determined from time to time by resolution adopted by the affirmative vote of a majority of the directors in office at the time of adoption of such resolution. Initially, the number of directors shall be five (5) and shall consist of the following persons: Leonard A. Batterson, Robert W. Cross, Steven Lazarus, Robert W. Shaw, Jr. and Richard W. Siegel.

Such directors shall be divided into three classes, Class I, Class II and Class III; with Class I having two members, Class II having two members and Class III having one member. Class I shall initially consist of the following directors: Robert W. Cross and Robert W. Shaw, Jr. Class II shall initially consist of the following directors: Steven Lazarus and Richard W. Siegel. Class III shall initially consist of Leonard A. Batterson. The initial term of office of the Class I, Class II and Class III directors shall expire at the annual meeting of stockholders in 1998, 1999 and 2000, respectively. Beginning in 1998, at each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting shall be elected for a three-year term. If the number of directors is changed, any increase or decrease shall be apportioned among the classes by the Board of Directors so as to maintain the number of directors in each class as nearly equal as is reasonably possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class shall hold office for a term that shall coincide with the remaining term of that class. In no case will a decrease in the number of directors shorten the term of any incumbent director even though such decrease may result in an inequality of the classes until the expiration of such term. A director shall hold office until the annual meeting of stockholders in the year in which such director's term expires and until such director's successor shall be elected and shall qualify, subject, however, to such director's prior death, resignation, retirement or removal from office. Directors may only be removed for cause, except as otherwise provided by law, by the holders of at least sixty-six and two-thirds percent (66 2/3%) of the shares entitled to vote at an election of directors. Except as required by law or the provisions of this Certificate of Incorporation, all vacancies on the Board of Directors and newly-created directorships shall be filled by the Board of Directors. Any director elected to fill a vacancy not resulting from an increase in the number of directors shall have the same remaining term as that of his or her predecessor.

-16-

Notwithstanding the foregoing, whenever the holders of any one or more classes or series of Preferred Stock issued by the Corporation shall have the right, voting separately by class or series, to elect directors at an annual or special meeting of stockholders, the election, term of office, filling of vacancies and other features of such directorships shall be governed by the terms of this Certificate of Incorporation and any resolutions of the Board of Directors applicable thereto, and such directors so elected shall not be divided into classes pursuant to this Article VI. Notwithstanding anything to the contrary contained in this Certificate of Incorporation, the affirmative vote of the holders of at least eighty percent (80%) of the voting power of the shares entitled to vote generally in the election of directors shall be required to amend, alter or repeal, or to adopt any provision inconsistent with, this Article VI.

ARTICLE VII

The Board of Directors of the Corporation may adopt a resolution proposing to amend, alter or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this reservation.

ARTICLE VIII

A. Indemnification of Officers and Directors: The Corporation shall:

1. indemnify, to the fullest extent permitted by the DGCL, any director and any officer, employee or agent of the Corporation selected by the Board of Directors for indemnification, such selection to be evidenced by an indemnification agreement, who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that such person is or was a director, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, or if such person has previously been designated for indemnification by a resolution of the Board of Directors, an officer, employee or agent of the Corporation, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person's conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any

-17-

criminal action or proceeding, had reasonable cause to believe that such person's conduct was unlawful; and

2. indemnify any director and any officer, employee or agent of the Corporation selected by the Board of Directors for indemnification, such selection to be evidenced by an indemnification agreement, who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that such person is or was a director, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, or if such person has previously been designated for indemnification by a resolution of the Board of Directors, an officer, employee or agent of the Corporation, against expenses (including attorneys' fees) actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper; and

3. indemnify any director, officer, employee or agent against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection therewith, to the extent that such director, officer, employee or agent of the Corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Article VIII.A.1. and 2., or in defense of any claim, issue or matter therein; and

4. make any indemnification under Article VIII.A.1. and
2. (unless ordered by a court) only as authorized in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances because such director, officer, employee or agent has met the applicable standard of conduct set forth in Article VIII.A.1. and 2. Such determination shall be made (1) by the Board of Directors by a majority vote of a quorum consisting of directors who were not parties to such action, suit or proceeding, or (2) if such a quorum is not obtainable, or, even if obtainable a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, or (3) by the stockholders of the Corporation; and

5. pay expenses incurred by a director or officer in defending a civil or criminal action, suit or proceeding in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer

-18-

to repay such amount if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the Corporation as authorized in this Article VIII.

Notwithstanding anything to the contrary in this Article
VIII.A, (i) the Corporation shall not be obligated to indemnify a director, officer or employee or pay expenses incurred by a director, officer or employee with respect to any threatened, pending, or completed claim, suit or action, whether civil, criminal, administrative, investigative or otherwise ("Proceedings") initiated or brought voluntarily by a director, officer or employee and not by way of defense (other than Proceedings brought to establish or enforce a right to indemnification under the provisions of this Article VIII unless a court of competent jurisdiction determines that each of the material assertions made by the director, officer or employee in such Proceedings were not made in good faith or were frivolous) and (ii) the Corporation shall not be obligated to indemnify a director, officer or employee for any amount paid in settlement of a Proceeding covered hereby without the prior written consent of the Corporation to such settlement; and

6. not deem the indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this Article VIII as exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any By-law, agreement, or vote of stockholders or disinterested directors or otherwise, both as to action in such director's or officer's official capacity and as to action in another capacity while holding such office; and

7. have the right, authority and power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the Corporation would have the power to indemnify such person against such liability under the provisions of this Article VIII; and

8. deem the provisions of this Article VIII to be a contract between the Corporation and each director, or appropriately designated officer, employee or agent who serves in such capacity at any time while this Article VIII is in effect and any repeal or modification of this Article VIII shall not affect any rights or obligations then existing with respect to any state of facts then or theretofore existing or any action, suit or proceeding theretofore or thereafter brought or threatened based in whole or in part upon such state of facts. The provisions of this Article VIII shall not be deemed to be a contract between the Corporation and any directors, officers, employees or agents of any other corporation (the "Second Corporation") which shall merge into or consolidate with this Corporation when this Corporation shall be the surviving or resulting Corporation, and any such directors, officers, employees or agents of the Second Corporation shall be

-19-

indemnified to the extent required under the DGCL only at the discretion of the board of directors of this Corporation; and

9. continue the indemnification and advancement of expenses provided by, or granted pursuant to, this Article VIII, unless otherwise provided when authorized or ratified, as to a person who has ceased to be a director, officer, employee or agent of the Corporation and shall inure to the benefit of the heirs, executors and administrators of such a person.

B. Elimination of Certain Liability of Directors: No director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided, however, that this provision shall not eliminate or limit the liability of a director (i) for any breach of the director's duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law,
(iii) under Section 174 of the DGCL, as the same exists or may hereafter be amended, or (iv) for any transaction from which the director derived an improper personal benefit. If the DGCL is amended to authorize the further elimination or limitation of liability of directors, then the liability of a director of the Corporation existing at the time of such elimination or limitation, in addition to the limitation on personal liability provided herein, shall be limited to the fullest extent permitted by the amended DGCL. Any repeal or modification of this Article VIII by the stockholders of the Corporation shall be prospective only, and shall not adversely affect any limitation on the personal property of a director of the Corporation existing at the time of such repeal or modification.

ARTICLE IX

A director of the Corporation shall not, in the absence of fraud, be disqualified by his office from dealing or contracting with the Corporation either as a vendor, purchaser or otherwise, nor in the absence of fraud shall a director of the Corporation be liable to account to the Corporation for any profit realized by him from or through any transaction or contract of the Corporation by reason of the fact that such director, or any firm of which such director is a member or any corporation of which such director is an officer, director or stockholder, was interested in such transaction or contract if such transaction or contract has been authorized, approved or ratified in a manner provided in the DGCL for authorization, approval or ratification of transactions or contracts between the Corporation and one or more of its directors or officers or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are directors or officers or have a financial interest.

-20-

ARTICLE X

A. Written Consent. At any time after the closing of a public offering of the Corporation's Common Stock, any action required or permitted to be taken by the stockholders of the Corporation shall be effected at a duly called annual or special meeting of stockholders of the Corporation and shall not be effected by any consent in writing by such stockholders pursuant to
Section 228 of the DGCL or any other provision of the DGCL.

B. Special Meetings. Special meetings of stockholders of the Corporation may be called upon not less than ten (10) nor more than sixty (60) days' written notice only by the Board of Directors pursuant to a resolution approved by a majority of the Board of Directors.

C. Amendment. Notwithstanding anything contained in this Certificate of Incorporation to the contrary, the affirmative vote of the holders of at least eighty percent (80%) of the shares entitled to vote generally in the election of directors shall be required to amend, alter or repeal, or to adopt any provision inconsistent with, this Article X.

ARTICLE XI

Meetings of stockholders may be held within or without the State of Delaware as the By-laws of the Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors of the Corporation or in the By-laws of the Corporation. Election of directors need not be by written ballot unless the By-laws of the Corporation so provide.

ARTICLE XII

Whenever a compromise or arrangement is proposed between the Corporation and its creditors or any class of them and/or between the Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of the Corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for the Corporation under the provisions of Section 291 of the DGCL or on the application of trustees in dissolution or of any receiver or receivers appointed for the Corporation under the provisions of Section 279 of the DGCL, order a meeting of the creditors or class of creditors and/or the stockholders or class of stock of the Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing two-thirds of the value of the creditors or class of creditors and/or the stockholders or class of stockholders of the Corporation, as the case may be, agree to any compromise or arrangement or to any reorganization of the Corporation as a consequence of such compromise or arrangement, said compromise or arrangement of said reorganization shall, if sanctioned by the Court to which said application has been made, be binding on all the

-21-

creditors or class of creditors and/or on all the stockholders or class of stockholders, of the Corporation, as the case may be, and also on the Corporation.

ARTICLE XIII

In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, alter amend or repeal the By-laws of the Corporation. The By-laws of the Corporation may be altered, amended, or repealed or new By-laws may be adopted, by the Board of Directors in accordance with the preceding sentence or by the vote of the holders of at least sixty-six and two-thirds percent (66 2/3%) of the voting power of the shares of the Corporation entitled to vote generally in the election of directors at an annual or special meeting of stockholders, provided that if such alteration, amendment, repeal or adoption of new By-laws is effected at a duly called special meeting, notice of such alteration, amendment, repeal or adoption of new By-laws is contained in the notice of such special meeting.

-22-

EXHIBIT 3.2

BY-LAWS

OF

NANOPHASE TECHNOLOGIES CORPORATION OF DELAWARE

ARTICLE I

OFFICES

Section 1.1. Registered Office. The registered office of Nanophase Technologies Corporation of Delaware (the "Corporation") shall be in the City of Wilmington, County of New Castle, State of Delaware.

Section 1.2. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation may require.

ARTICLE II

MEETINGS OF STOCKHOLDERS

Section 2.1. Place of Meeting. All meetings of the stockholders for the election of directors shall be held at such place either within or without the State of Delaware as shall be designated from time to time by the Board of Directors and stated in the notice of the meeting. Meetings of stockholders for any other purpose may be held at such time and place, within or without the State of Delaware, as shall be stated by the Board of Directors in its notice of the meeting or in a duly executed waiver of notice thereof.

Section 2.2. Time of Annual Meeting. Annual meetings of stockholders shall be held on the third Thursday in June, if not a legal holiday, and if a legal holiday, then on the next secular day following, at 10:00 A.M., or at such other date and time as shall be designated from time to time by the Board of Directors and stated in the notice of the meeting, at which stockholders shall elect directors to hold office for the term provided in Section 3.2 of these By-laws and conduct such other business as shall be considered.

Section 2.3. Notice of Annual Meetings. Except as otherwise required by law, written notice of the annual meeting stating the place, date and hour of the meeting shall be given to each stockholder entitled to vote at such meeting not fewer than ten (10) nor more than sixty (60) days before the date of the meeting.


Section 2.4. Director Nominations. Only persons who are nominated in accordance with the following procedures shall be eligible to serve as directors. Nominations of persons for election to the Board of Directors of the Corporation at a meeting of stockholders may be made (i) by or at the direction of the Board of Directors, or (ii) by any stockholder of the Corporation entitled to vote in the election of directors at the meeting who complies with the notice procedures set forth in this Article II, Section 2.4. Such nominations, other than those made by or at the direction of the Board of Directors, shall be made pursuant to timely notice in writing to the Secretary of the Corporation. To be timely, a stockholder's notice must be delivered to, or mailed and received by, the Secretary of the Corporation at the principal executive offices of the Corporation not less than sixty (60) nor more than ninety (90) days prior to the meeting; provided, however, that if the Corporation has not "publicly disclosed" (in the manner provided in the last sentence of this Article II, Section 2.4) the date of the meeting at least seventy (70) days prior to the meeting date, notice may be timely made by a stockholder under this Section if received by the Secretary of the Corporation not later than the close of business on the tenth day following the day on which the Corporation publicly disclosed the meeting date. Such stockholder's notice shall set forth (i) as to each person whom the stockholder proposes to nominate for election or re-election as a director, all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (including such person's written consent to being named in the proxy statement as a nominee and to serving as director if elected); and (ii) as to the stockholder giving notice (A) the name and address, as they appear on the Corporation's books, of such stockholder and (B) the class and number of shares of the Corporation which are beneficially owned by such stockholder. At the request of the Board of Directors, any person nominated by the Board of Directors for election as a director shall furnish to the Secretary of the Corporation that information required to be set forth in a stockholder's notice of nomination which pertains to the nominee. No person shall be eligible to serve as a director of the Corporation unless nominated in accordance with the procedures set forth herein. The presiding officer shall, if the facts so warrant, determine and declare to the meeting that a nomination was not made in accordance with the procedures prescribed by the By-laws, and if such officer should so determine, such officer shall so declare to the meeting and the defective nomination shall be disregarded. For purposes of these By-laws, "publicly disclosed" or "public disclosure" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission.

Section 2.5. Annual Meeting Agenda Items. At an annual meeting of the stockholders, only such business shall be conducted as shall have been brought before the meeting (i) by or at the direction of the Board of Directors, or (ii) by any stockholder of the Corporation who complies with the notice procedures set forth in this Article II, Section 2.5, in the time herein provided. For business to be properly brought before an annual meeting by a stockholder, the stockholder must deliver written notice to, or mail such written notice so that it is received by, the Secretary of the Corporation, at the principal executive offices of the Corporation, not less than one hundred twenty (120) days prior to the first anniversary of the date of the Corporation's proxy statement released to stockholders in connection with the previous year's annual meeting of stockholders, except that if no annual meeting of stockholders was held in the previous year or if the date of the annual meeting has been changed by more than thirty (30) days from the

-2-

previous year's meeting, a proposal shall be received by the Corporation within ten (10) days after the Corporation has "publicly disclosed" the date of the meeting in the manner provided in Article II, Section 2.4 above. The stockholder's notice to the Secretary shall set forth as to each matter the stockholder proposes to bring before the annual meeting (A) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (B) the name and address, as they appear on the Corporation's books, of the stockholder proposing such business, (C) the class and number of shares of the Corporation which are beneficially owned by the stockholder and (D) any material interest of the stockholder in such business. At an annual meeting, the presiding officer shall, if the facts warrant, determine and declare to the meeting that business was not properly brought before the meeting in accordance with the provisions of this Article, Section 2.5, and if such officer should so determine, such officer shall so declare to the meeting, and any such business not properly brought before the meeting shall not be transacted. Whether or not the foregoing procedures are followed, no matter which is not a proper matter for stockholder consideration shall be brought before the meeting.

Section 2.6. Special Meetings of the Stockholders. Special meetings of the stockholders of the Corporation may be called only by the Board of Directors pursuant to a resolution approved by a majority of the Board of Directors. The business transacted at any special meeting of the stockholders shall be limited to the purposes stated in the notice for the meeting transmitted to stockholders.

Section 2.7. Notice of Special Meetings. Written notice of a special meeting stating the place, date and hour of the meeting and the purpose or purposes for which the meeting is called, shall be given by the Secretary of the Corporation not fewer than ten (10) nor more than sixty (60) days before the date of the meeting, to each stockholder entitled to vote at such meeting.

Section 2.8. Fixing of Record Date. In order that the Corporation may determine the stockholders entitled to vote at any meeting of stockholders or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted, and which shall be (i) not more than sixty (60) nor less than ten (10) days before the date of a meeting, and (ii) not more than sixty (60) days prior to any other action. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for any adjourned meeting.

Section 2.9. Voting Lists. The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where

-3-

the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.

Section 2.10. Quorum and Adjournments. The holders of a majority of the voting power of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business, except as otherwise provided by statute or by the Corporation's Certificate of Incorporation. If, however, such quorum shall not be present or represented at any such meeting of the stockholders, the stockholders entitled to vote thereat, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present or represented; provided that if the adjournment is for more than thirty (30) days, or if after the adjournment a new record date is fixed by the directors for the adjourned meeting, a new notice shall be transmitted to the stockholders of record entitled to vote at the adjourned meeting. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally notified.

Section 2.11. Vote Required. When a quorum is present at any meeting of all stockholders, the affirmative vote of the holders of a majority of the voting power of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall decide any question brought before such meeting, unless the question is one upon which by express provision of statute or of the Corporation's Certificate of Incorporation, a different vote is required in which case such express provision shall govern and control the decision of such question; provided, however, all elections of directors shall be determined by a plurality of the votes cast.

Section 2.12. Voting Rights. Unless otherwise provided in the Corporation's Certificate of Incorporation, each stockholder having voting power shall at every meeting of the stockholders be entitled to one (1) vote in person or by proxy for each share of the capital stock having voting power held by such stockholder, but no proxy shall be voted on after three (3) years from its date, unless the proxy provides for a longer period. At any meeting of the stockholders, every stockholder entitled to vote may vote in person or by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to this paragraph may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used; provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission. All voting, including on the election of directors may (except where otherwise required by law) be by a voice vote; provided, however, that upon demand therefor by a stockholder entitled to vote or by his or her proxy, a stock vote shall be taken. Every stock vote shall be taken by ballots, each of which shall state the name of the stockholder or proxy voting and such other information as may be required under the procedure established for the meeting. The Corporation may, and to the extent required by law shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of

-4-

stockholders, the person presiding at the meeting may, and to the extent required by law shall, appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath to faithfully execute the duties of inspector with strict impartiality and according to the best of his or her ability. Every vote taken by ballots shall be counted by an inspector or inspectors appointed by the chairman of the meeting.

Section 2.13. Presiding Over Meetings. The Chairman of the Board of Directors shall preside at all meetings of the stockholders. In the absence or inability to act of the Chairman, the Vice Chairman, the President or a Vice President (in that order) shall preside, and in their absence or inability to act another person designated by one of them shall preside. The Secretary of the Corporation shall act as Secretary of each meeting of the stockholders. In the event of his or her absence or inability to act, the chairman of the meeting shall appoint a person who need not be a stockholder to act as Secretary of the meeting.

Section 2.14. Conducting Meetings. Meetings of the stockholders shall be conducted in a fair manner but need not be governed by any prescribed rules of order. The presiding officer of the meeting shall establish an agenda for the meeting. The presiding officer's rulings on procedural matters shall be final. The presiding officer is authorized to impose reasonable time limits on the remarks of individual stockholders and may take such steps as such officer may deem necessary or appropriate to assure that the business of the meeting is conducted in a fair and orderly manner.

ARTICLE III

DIRECTORS

Section 3.1. General Powers. The business and affairs of the Corporation shall be under the direction of and managed by, a board comprised of directors, which may exercise all such powers of the Corporation and do all such lawful acts and things as are not required by statute, by the Corporation's Certificate of Incorporation or by these By-laws to be done by the stockholders. Directors need not be residents of the State of Delaware or stockholders of the Corporation. The number of directors shall be determined in the manner provided in the Corporation's Certificate of Incorporation.

Section 3.2. Election. Directors shall be elected by class for three
(3) year or other terms as specified in the Corporation's Certificate of Incorporation, and each director elected shall hold office during the term for which he or she is elected and until his or her successor is elected and qualified, subject, however, to his or her prior death, resignation, retirement or removal from office.

Section 3.3. Removal. Directors may only be removed for cause, except as otherwise provided by law, by the holders of at least 66-2/3% of the voting power of the shares entitled to vote at an election of directors.

-5-

Section 3.4. Vacancies. Any vacancies occurring in the Board of Directors and newly created directorships shall be filled in the manner provided in the Corporation's Certificate of Incorporation.

Section 3.5. Place of Meetings. The Board of Directors of the Corporation may hold meetings, both regular and special, either within or without the State of Delaware. The first meeting of each newly elected Board of Directors shall be held immediately following the adjournment of the annual meeting of the stockholders at the same place as such annual meeting and no notice of such meeting shall be necessary to the newly elected directors in order to legally constitute the meeting, provided a quorum shall be present. In the event such meeting is not held at such time and place, the meeting may be held at such time and place as shall be specified in a notice given as hereinafter provided for special meetings of the Board of Directors, or as shall be specified in a written waiver signed by all of the directors.

Section 3.6 Participation by Conference Telephone. Unless otherwise restricted by the Corporation's Certificate of Incorporation or these By-laws, members of the Board of Directors, or any committee designated by the Board of Directors, may participate in a meeting of the Board of Directors, or committee, by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation by such means shall constitute presence in person at such meeting.

Section 3.7. Regular Meetings. Regular meetings of the Board of Directors may be held without notice at such time and at such place as shall from time to time be determined by the Board of Directors.

Section 3.8. Special Meetings. Special meetings of the Board of Directors may be called by the Chairman of the Board, the Chief Executive Officer or the President on at least one day's notice to each director, either personally, or by courier, telephone, telefax, mail or telegram. Special meetings shall be called by the Chairman of the Board, the Chief Executive Officer or the President in like manner and on like notice at the written request of one- half or more of the directors comprising the Board of Directors stating the purpose or purposes for which such meeting is requested. Notice of any meeting of the Board of Directors for which a notice is required may be waived in writing signed by the person or persons entitled to such notice, whether before or after the time of such meeting, and such waiver shall be equivalent to the giving of such notice. Attendance of a director at any such meeting shall constitute a waiver of notice thereof, except where a director attends a meeting for the express purpose of objecting to the transaction of any business because such meeting is not lawfully convened. Neither the business to be transacted at nor the purpose of any meeting of the Board of Directors for which a notice is required need be specified in the notice, or waiver of notice, of such meeting. The Chairman of the Board shall preside at all meetings of the Board of Directors. In the absence or inability to act of the Chairman of the Board, the Vice Chairman of the Board, the Chief Executive Officer, the President or the Chief Financial Officer (in that order) shall preside, and in their absence or inability to act another director designated by one of them shall preside.

-6-

Section 3.9. Quorum; No Action on Certain Matters. At all meetings of the Board of Directors, a majority of the then duly elected directors shall constitute a quorum for the transaction of business and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board of Directors, except as may be otherwise specifically provided by statute or by the Certificate of Incorporation. If a quorum shall not be present at any meeting of the Board of Directors, the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present.

Section 3.10. Resignations. Any director of the Corporation may resign at any time by giving written notice to the Board of Directors, the Chairman of the Board or the President. Such resignation shall take effect at the time specified therein and, unless tendered to take effect upon acceptance thereof, the acceptance of such resignation shall not be necessary to make it effective.

Section 3.11. Informal Action. Unless otherwise restricted by the Corporation's Certificate of Incorporation or these By-laws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board of Directors or committee.

Section 3.12. Presumption of Assent. A director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be conclusively presumed to have assented to the action taken unless his or her dissent shall be entered in the minutes of the meeting or unless he or she shall file his or her written dissent to such action with the person acting as the Secretary of the meeting before the adjournment thereof or shall forward such dissent by registered mail to the secretary of the Corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a director who voted in favor of such action.

Section 3.13. Compensation of Directors. In the discretion of the Board of Directors, the directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors or a committee thereof, may be paid a fixed sum for attendance at each meeting of the Board of Directors or a committee thereof, and may be awarded other compensation for their services as directors. No such payment or award shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members of special or standing committees may be allowed like compensation for attending committee meetings.

ARTICLE IV

COMMITTEES OF DIRECTORS

Section 4.1. Appointment and Powers. The Board of Directors may, by resolution passed by a majority of the whole Board of Directors, designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or

-7-

disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to amending the Certificate of Incorporation (except that a committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of stock adopted by the Board of Directors as provided in subsection (a) of Section 151 of the Delaware General Corporation Law, fix the designations and any of the preferences or rights of such shares relating to dividends, redemption, dissolution, any distribution of assets of the Corporation or the conversion into, or the exchange of such shares for, shares of any other class or classes or any other series of the same or any other class or classes of stock of the Corporation or fix the number of shares of any series of stock or authorize the increase or decrease of the number of shares of any series), and if the resolution which designates the committee or a supplemental resolution of the Board of Directors shall so provide, such other items or tasks as may be determined from time to time by resolution adopted by the Board of Directors.

Section 4.2. Committee Minutes. Each committee shall keep regular minutes of its meetings and shall file such minutes and all written consents executed by its members with the Secretary of the Corporation. Each committee may determine the procedural rules for meeting and conducting its business and shall act in accordance therewith, except as otherwise provided herein or required by law. Adequate provision shall be made for notice to members of all meetings; one-third of the members shall constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all matters shall be determined by a majority vote of the members present. Action may be taken by any committee without a meeting if all members thereof consent thereto in writing, and the writing or writings are filed with the minutes of the proceedings of such committee.

ARTICLE V

NOTICES

Section 5.1. Manner of Notice. Whenever, under applicable law or the Corporation's Certificate of Incorporation or these By-laws, notice is required to be given to any director or stockholder, unless otherwise provided in the Corporation's Certificate of Incorporation or these By-laws, such notice may be given in writing, by courier or mail, addressed to such director or stockholder, at such director's or stockholder's address as it appears on the records of the Corporation, with freight or postage thereon prepaid, and such notice shall be deemed to be given at the time when the same shall have been deposited with such courier or in the United States mail. Notice may be given orally if such notice is confirmed in writing in a manner provided therein. Notice to directors may also be given by telegram, mailgram, telex or telecopier.

-8-

Section 5.2. Waiver. Whenever any notice is required to be given under applicable law or the provisions of the Corporation's Certificate of Incorporation or these By-laws, a waiver thereof in writing, signed by the person or persons entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent thereto.

ARTICLE VI

OFFICERS

Section 6.1. Number and Qualifications. The officers of the Corporation shall be chosen by the Board of Directors and shall be a Chairman of the Board, a Chief Executive Officer, a President, a Chief Financial Officer, one or more Vice Presidents, a Secretary and a Treasurer. The Board of Directors may also choose a Vice Chairman of the Board (or Vice Chairmen), one or more Assistant Secretaries and Assistant Treasurers and such additional officers as the Board of Directors may deem necessary or appropriate from time to time. Membership on the Board of Directors shall not be a prerequisite to the holding of any other office. Any number of offices may be held by the same person, unless the Corporation's Certificate of Incorporation or these By-laws otherwise provide.

Section 6.2. Election. The Board of Directors at its first meeting after each annual meeting of stockholders shall elect a Chairman of the Board, a Chief Executive Officer, a President, a Chief Financial Officer, one or more Vice-Presidents, a Secretary and a Treasurer, and may choose a Vice Chairman of the Board, one or more Assistant Secretaries and Assistant Treasurers and such other officers as the Board of Directors shall deem desirable.

Section 6.3. Other Officers and Agents. The Board of Directors may choose such other officers and agents as it shall deem necessary who shall hold their offices for such terms and shall exercise such powers and perform such duties as shall be determined from time to time by the Board of Directors.

Section 6.4. Salaries. The salaries or other compensation of the officers and agents of the Corporation shall be fixed from time to time by the Board of Directors, and no officer shall be prevented from receiving such salary or other compensation by reason of the fact that such officer is also a director of the Corporation.

Section 6.5. Term of Office. The officers of the Corporation shall hold office until their successors are chosen and qualify or until their earlier resignation or removal. Any officer elected or appointed by the Board of Directors may be removed at any time, either with or without cause, by the affirmative vote of a majority of the directors then in office at any meeting of the Board of Directors. If a vacancy shall exist in the office of the Corporation, the Board of Directors may elect any person to fill such vacancy, such person to hold office as provided in Section 6.1 of this Article VI.

Section 6.6. The Chairman of the Board. The Chairman of the Board shall preside at all meetings of the stockholders and of the Board of Directors and shall see that orders and

-9-

resolutions of the Board of Directors are carried into effect. The Chairman of the Board shall perform such duties as may be assigned to him by the Board of Directors.

Section 6.7. The Chief Executive Officer. The Chief Executive Officer shall be the principal executive officer of the Corporation and shall, in general, supervise and control all of the business and affairs of the Corporation, unless otherwise provided by the Board of Directors. In the absence of the Chairman of the Board, the Chief Executive Officer shall preside at all meetings of the stockholders and of the Board of Directors and shall see that orders and resolutions of the Board of Directors are carried into effect. The Chief Executive Officer may sign bonds, mortgages, certificates for shares and all other contracts and documents whether or not under the seal of the Corporation except in cases where the signing and execution thereof shall be expressly delegated by law, by the Board of Directors or by these By-laws to some other officer or agent of the Corporation. The Chief Executive Officer shall have general powers of supervision and shall be the final arbiter of all differences between officers of the Corporation and the Chief Executive Officer's decision as to any matter affecting the Corporation shall be final and binding as between the officers of the Corporation subject only to its Board of Directors.

Section 6.8. The President. Unless another party has been designated as Chief Operating Officer, the President shall be the Chief Operating Officer of the Corporation responsible for the day-to-day active management of the business of the Corporation, under the general supervision of the Chief Executive Officer. In the absence of the Chief Executive Officer, the President shall perform the duties of the Chief Executive Officer, and when so acting, shall have all the powers of and be subject to all the restrictions upon the Chief Executive Officer. The President shall have concurrent power with the Chief Executive Officer to sign bonds, mortgages, certificates for shares and other contracts and documents, whether or not under the seal of the Corporation except in cases where the signing and execution thereof shall be expressly delegated by law, by the Board of Directors, or by these By-laws to some other officer or agent of the Corporation. In general, the President shall perform all duties incident to the office of the President and such other duties as the Chief Executive Officer or the Board of Directors may from time to time prescribe.

Section 6.9. The Chief Financial Officer. The Chief Financial Officer shall be the principal financial and accounting officer of the Corporation. The Chief Financial Officer shall: (a) have charge of and be responsible for the maintenance of adequate books of account for the Corporation; (b) have charge and custody of all funds and securities of the Corporation, and be responsible therefor and for the receipt and disbursement thereof; and (c) perform all the duties incident to the office of the Chief Financial Officer and such other duties as from time to time may be assigned to him by the President or by the Board of Directors. If required by the Board of Directors, the Chief Financial Officer shall give a bond for the faithful discharge of the Chief Financial Officer's duties in such sum and with such surety or sureties as the Board of Directors may determine.

Section 6.10. The Vice-Presidents. In the absence of the President or in the event of the President's inability or refusal to act, the Vice-Presidents (in the order designated, or in the absence of any designation, then in the order of their election) shall perform the duties of the President, and when so acting, shall have all the powers of and be subject to all the restrictions

-10-

upon the President. The Vice-Presidents shall perform such other duties and have such other powers as the Chief Executive Officer or the Board of Directors may from time to time prescribe.

Section 6.11. The Secretary. The Secretary shall attend all meetings of the Board of Directors and all meetings of the stockholders and record all the proceedings of the meetings of the Corporation and of the Board of Directors in a book to be kept for that purpose and shall perform like duties for the standing committees when required. The Secretary shall give, or cause to be given, or cause to be given notice of all meetings of the stockholders and special meetings of the Board of Directors, and shall perform such other duties as may be prescribed by the Board of Directors or the Chief Executive Officer, under whose supervision the Secretary shall be. The Secretary shall have custody of the corporate seal of the Corporation and the Secretary or an Assistant Secretary, shall have authority to affix the same to any instrument requiring it and when so affixed, it may be attested by the Secretary's signature or by the signature of such Assistant Secretary. The Board of Directors may give general authority to any other officer to affix the seal of the Corporation and to attest the affixing by such officer's signature.

Section 6.12. The Treasurer. In the absence of the Chief Financial Officer or in the event of the Chief Financial Officer's inability or refusal to act, the Treasurer shall perform the duties of the Chief Financial Officer, and when so acting, shall have all the powers of and be subject to all the restrictions upon the Chief Financial Officer. The Treasurer shall perform such other duties and have such other powers as the Chief Executive Officer or the Board of Directors may from time to time prescribe.

Section 6.13. The Assistant Secretary. The Assistant Secretary, or if there be more than one, the Assistant Secretaries in the order determined by the Board of Directors (or if there be no such determination, then in the order of their election), shall, in the absence of the Secretary or in the event of the Secretary's inability or refusal to act, perform the duties and exercise the powers of the Secretary and shall perform such other duties and have such other powers as the Chief Executive Officer or the Board of Directors may from time to time prescribe.

Section 6.14. The Assistant Treasurer. The Assistant Treasurer, or if there shall be more than one, the Assistant Treasurers in the order determined by the Board of Directors (or if there be no such determination, then in the order of their election), shall, in the absence of the Treasurer or in the event of the Treasurer's inability or refusal to act, perform the duties and exercise the powers of the Treasurer and shall perform such other duties and have such other powers as the Chief Executive Officer or the Board of Directors may from time to time prescribe.

-11-

ARTICLE VII

CERTIFICATES OF STOCK, TRANSFERS AND RECORD DATES

Section 7.1. Form of Certificates. Every holder of stock in the Corporation shall be entitled to have a certificate, signed by, or in the name of the Corporation by (a) the Chairman of the Board, the President or the Chief Executive Officer, and (b) the Chief Financial Officer, Treasurer, Secretary, an Assistant Secretary or an Assistant Treasurer of the Corporation; certifying the number of shares owned by such holder in the Corporation. If the Corporation shall be authorized to issue more than one class of stock or more than one series of any class, the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate which the Corporation shall issue to represent such class or series of stock; provided that, except as otherwise provided in
Section 202 of the General Corporation Law of Delaware, in lieu of the foregoing requirements, there may be set forth on the face or back of the certificate which the Corporation shall issue to represent such class or series of stock, a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Subject to the foregoing, certificates of stock of the Corporation shall be in such form as the Board of Directors may from time to time prescribe.

Section 7.2. Facsimile Signatures. Where a certificate is countersigned
(1) by a transfer agent other than the Corporation or its employee, or (2) by a registrar other than the Corporation or its employee, any other signatures on the certificate may be facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.

Section 7.3. Lost Certificates. The Board of Directors may direct a new certificate or certificates to be issued in place of any certificate or certificates theretofore issued by the Corporation alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed. When authorizing such issue of a new certificate or certificates, the Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificate or certificates, or such owner's legal representative, to advertise the same in such manner as the Corporation shall require and/or give the Corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the Corporation or its transfer agent or registrar with respect to the certificate alleged to have been lost, stolen or destroyed.

Section 7.4. Transfers of Stock. Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignment or authority to transfer, it shall be the duty of the

-12-

Corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books.

Section 7.5. Registered Stockholders. The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner and to hold liable for calls and assessments a person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not the Corporation shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.

ARTICLE VIII

CONFLICT OF INTERESTS

Section 8.1. Contract or Relationship Not Void. No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association, or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because such director or officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract or transaction, or solely because such director's or officer's vote is counted for such purpose, if:

(i) The material facts as to such director's or officer's relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the board or committee in good faith authorizes the contract or transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or

(ii) The material facts as to such director's or officer's relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or

(iii) The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee thereof, or the stockholders.

Section 8.2. Quorum. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction.

-13-

ARTICLE IX

GENERAL PROVISIONS

Section 9.1. Dividends. Dividends upon the capital stock of the Corporation, subject to the provisions of the Certificate of Incorporation, if any, may be declared by the Board of Directors at any regular or special meeting, pursuant to law. Dividends may be paid in cash, in property, or in shares of the capital stock or rights to acquire same, subject to the provisions of the Corporation's Certificate of Incorporation. Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purpose as the directors shall think conducive to the interest of the Corporation, and the directors may modify or abolish any such reserve in the manner in which it was created.

Section 9.2. Checks. All checks or demands for money and notes of the Corporation shall be signed by such officer or officers or such other person or persons as the Board of Directors may from time to time designate.

Section 9.3. Fiscal Year. The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors.

Section 9.4. Seal. The corporate seal shall have inscribed thereon the name of the Corporation and the words "Corporate Seal, Delaware." The seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.

Section 9.5. Stock in Other Corporations. Shares of any other corporation which may from time to time be held by this Corporation may be represented and voted at any meeting of stockholders of such corporation by the Chairman of the Board, the Chief Executive Officer, the President, the Chief Financial Officer or a Vice President of the Corporation, or by any proxy appointed in writing by the Chairman of the Board, the Chief Executive Officer, the President, the Chief Financial Officer or a Vice President of the Corporation, or by any other person or persons thereunto authorized by the Board of Directors. Shares represented by certificates standing in the name of the Corporation may be endorsed for sale or transfer in the name of the Corporation by the Chairman of the Board, the Chief Executive Officer, the President, the Chief Financial Officer or any Vice President of the Corporation or by any other officer of officers thereunto authorized by the Board of Directors. Shares belonging to the Corporation need not stand in the name of the Corporation, but may be held for the benefit of the Corporation in the individual name of the Chief Financial Officer or of any other nominee designated for the purpose of the Board of Directors.

-14-

ARTICLE X

AMENDMENTS

These By-laws may be altered, amended, or repealed or new by-laws may be adopted only in the manner provided in the Corporation's Certificate of Incorporation.

-15-

EXHIBIT 10.15

LETTER OF UNDERSTANDING

1. Payment of NTC invoices 3199 and 3271 relating to $1200.00 per gallon x 25 gallons, plus shipping, taxes, etc., for a total of $30,163.97(USD) shall be made immediately, based on shipment made July 23, 1997.

2. Payment of NTC invoice 3021 relating to scale-up development work completed on March 31, 1997, shall be made on February 1, 1998. Amount of Payment shall be $32,000.00(USD)

3. LWT and NTC agree to revise the existing Purchase Agreement dated February 3, 1997, when adequate information regarding production timing and volumes are established.

4. NTC agrees to a discount of $70.0(USD) per gallon for the first Five Hundred (500) gallons of product purchased under the revised Purchase agreement.

5. LWT and NTC shall mutually agree upon the Product Specifications at the conclusion of LWT's field trials. NTC shall provide a product which meets these agreed upon specifications. If NTC cannot provide such a product, payment of $17,500.00(USD) shall be made to LWT. Payment shall not be required as long as NTC is diligently pursuing perfection of the product to the agreement specifications.

ACKNOWLEDGED AND AGREED to this 13th day of January, 1998.

LWT Services, Inc.                        Nanophase Technologies Corporation


Per: /s/ Jeffrey West                         Per: /s/ Don Freed
    -------------------------                 -------------------------------
    Jeffrey West, President                   Don Freed, Vice President


EXHIBIT 10.17

LICENSE AGREEMENT

Nanophase Technologies Corporation of Burr Ridge, Illinois (NTC) and C.I.Kasei Co., Ltd., of Tokyo, Japan (CIK), effective December 30th, 1997 ("Effective Date") agree as follows:

WHEREAS, NTC owns Information, as hereinafter defined, relating to nanocrystalline materials; and

WHEREAS, CIK desires to have a royalty-bearing exclusive right and license to purchase, make, use and sell NTC Product using such Information upon the terms and conditions set forth in this Agreement; and

WHEREAS, for such consideration and upon such terms as hereinafter set forth, NTC is willing to grant such royalty-bearing exclusive right and license to CIK;

THEREFORE, NTC and CIK hereby agree as follows:

1. DEFINITIONS

1.1 The "Territory" is China, India, Indonesia, Japan, Korea, Malaysia, the Philippines, Singapore, Kingdom of Thailand and Taiwan.

1.2 "NTC Product" shall be any nanocrystalline materials made using the Information.

1.3 "Applications" are all applications except cosmetics, skin care and chemical/mechanical planarization of metal layers on semiconductor wafers.

1.4 "Information" shall mean US patent Nos. 5,460,701 and 5,514,349 and any foreign counterpart applications (hereinafter collectively called "Patents"), and "Confidential Information" as hereafter defined.

1.5 (a) "Confidential Information" shall mean all information of confidential or proprietary nature disclosed by NTC to CIK during the period commencing August 18, 1996 and ending on the termination of this Agreement, including, but not limited to, all NTC drawings, specifications, know-how and other information, whether such information is in tangible or intangible form, provided that all information that is in written form or other tangible medium shall prior to delivery be marked as "Confidential" or "Proprietary", and all information disclosed orally or otherwise shall be identified as being "Confidential" or "Proprietary" by a memorandum delivered to CIK within thirty days after the date of disclosure.
(b) Notwithstanding the foregoing, this Agreement shall not apply to Confidential Information which is:
a) in the public domain at the time it is disclosed under this Agreement;
b) subsequently published or publicly disclosed by persons other than CIK;
c) acquired by CIK from a third party having no obligation of confidentiality;

1

d) known to CIK at the time of disclosure, provided that CIK shall have the burden of establishing such prior knowledge by competent written proof;
e) developed independently by or on behalf of CIK, without reliance on or use of any Confidential Information of NTC, or
f) compelled by law to be disclosed, provided that CIK shall use its best efforts to give NTC ten days prior written notice of compelled disclosure.

1.6 "Net Sales" shall be determined as follows:
(a) for NTC Product sold directly in normal commercial transactions, Net Sales are the total sales of NTC Product based on the actual gross sales price less ordinary discounts, allowances, rebates, returns, sales taxes, insurance, packing costs and transportation expenses (therein included freight and postage), (b) for NTC Product incorporated in another product which is not itself an NTC Product, Net Sales shall be determined by the selling price or fair market value of the incorporated NTC Product which would be billed if it were sold independently and separately from such another product.

1.7 "Term" shall be from Effective Date to March 31, 2013 unless earlier terminated as provided herein.

2. LICENSE

2.1 NTC hereby grants to CIK the exclusive right and license, with no right to sublicense, to use the Information to manufacture subject to the additional terms and conditions in this Paragraph 2.1, and to use and sell NTC Product subject to the other terms in this Agreement, in the Territory for use in the Applications, provided, however, that in case of the application for transparent conductive coatings the licensed territory shall be limited to Japan. The right and license granted herein by NTC to CIK shall (a) oblige CIK to purchase NTC Product worth 30 million yen from NTC for the period of 1998, and thereafter no less than 60% of actual gross sales amount by CIK, and (b) allow CIK to manufacture the balance of each such annual obligation (Sales target) as set forth in Paragraph 2.3.

2.2 As consideration for the right and license granted herein by NTC to CIK, CIK agrees to pay NTC,

a) technology transfer fee of US$ 1.4 million, payable by CIK to NTC within 60 days of the Effective Date, which shall be fully earned and non-refundable on said date, and
b) running royalties on Net Sales of CIK-manufactured NTC Product as follows:

Year            Royalty
----            -------
1998:           5.0% of Net Sales
1999:           4.5% of Net Sales
2000:
  |             4.0% of Net Sales

2013(March 31)

  |             2.0% of Net Sales (non-exclusive) * see Par. 5.4

2.3 As further consideration for the right and license granted herein, and subject to Paragraph 2.5 and 5.2, CIK agrees to the following annual obligations;

2

Sales target (minimum)
------------
1998:         100 million yen (Yen 100,000,000) sales of NTC Product
1999:         300 million yen (Yen 300,000,000) sales of NTC Product
2000:         500 million yen (Yen 500,000,000) sales of NTC Product

2013 (March 31)

* For the purpose of this Paragraph, "sales of NTC Product" shall be calculated in accordance with actual gross sales price by CIK.

There shall be no penalty if CIK fails to meet 100% of the annual obligation in 1998 and thereafter. In 1999 and thereafter, however, NTC may terminate the exclusive nature of this Agreement if CIK fails to meet at least 50% of the sales target for each year, and may terminate the entire Agreement if CIK fails to meet at least 20% of the sales target for each year. In either of such cases, however, the exclusive nature shall remain if CIK pays to NTC minimum royalty of three hundred thousands U.S. dollars (US$300,000).

2.4 Royalty reports and payments shall be made within 30 days of each semi-annual period ending on September 30 and March 31 during the Term of this Agreement. CIK shall furnish to NTC a statement of royalty specifying Net Sales and the total amount of royalties accrued under Paragraph 2.2. At the same time, CIK shall make the payment to NTC by telegraphic transfer. CIK shall keep complete and accurate records with respect to NTC Product for which royalties are due and payable and such records shall be available at all reasonable times for a period of two years after each semi-annual period for inspection by NTC. The first royalty period shall begin on April 1, 1998. Thereafter, for the purpose of payments for royalty, purchase or any other payments required under this Agreement, each annual period begins on April 1 of each year and ends on March 31 of the following year. CIK is allowed to start the installation of PVS Reactor Systems from the Effective Date.

2.5 At any time after December 31, 1998, CIK may elect to manufacture its total annual obligation for NTC Product. In such event, CIK agrees to a minimum royalty payment to NTC in any twelve-month period following such election of three hundred thousands U.S. dollars (US$300,000.). Should CIK elect to manufacture its total obligation, there shall be no requirement or obligation under Paragraph 2.3 hereof, including requirement to purchase NTC Product from NTC.

2.6 For as long as this Agreement remains in effect, unless the parties otherwise agree in writing, and subject to the provisions of Paragraph 2.3, NTC will not directly or indirectly grant the right or license to manufacture, use or sell NTC Product to anyone other than CIK in the Territory, except that NTC shall retain its right to manufacture, license or sell any of the Product in the Territory for use in cosmetics, skin care or chemical/mechanical planarization of metal layers on semiconductor wafers.

2.7 All payments which are.
a) required by this Agreement,

3

b) subject to a tax by the Government of Japan on payments by CIK, and
c) subject to a requirement by said Government that CIK withhold said tax from said payments and submit the withheld amount to the Government on behalf of NTC, shall have said tax withheld by CIK, and the payments made shall be net after deduction of said tax. CIK shall supply NTC with certificates of payment of said withholding tax.

2.8 In case NTC assigns or transfers its rights and obligations under this Agreement to other person or entity by way of merger or otherwise, such assignee shall succeed and undertake all obligations and rights specified herein.

3. IMPROVEMENTS AND WARRANTY

3.1 NTC agrees to supply to CIK improvements including, but not limited to, inventions, system modifications and precursor modifications without any additional payments by CIK, however, such improvements are the sole property of NTC.

3.2 CIK agrees that any improvements relating to or arising from CIK's manufacture, sale or use of NTC Product including, but not limited to, inventions, patents and patent applications, system modifications and precursor modifications which arise during the term of this Agreement shall be transmitted promptly to NTC and CIK further agrees that NTC shall have a royalty-free, worldwide excluding Territory hereof, non-exclusive right and license, including the right to use such improvements, with no right to sublicense.

3.3 NTC provides no performance warranty and no implied warranty of merchantability or fitness for a particular purpose. NTC is not responsible for consequential damages, and assumes no risk or liability involved in the manufacture or use of NTC Product, including without limitation liability with regard to third-party patent claims. NTC represents, however, that to the best of its knowledge as of this date there exists no valid patent which covers NTC Product.

4. CONFIDENTIALITY

CIK shall, during the term of this Agreement, keep confidential and shall cause its employees to keep confidential Confidential Information disclosed and supplied to CIK by NTC under this Agreement, and CIK shall prevent and shall cause its employees to prevent disclosure thereof to other parties except as may be required for the proper performance of CIK's obligation under this Agreement. NTC shall undertake the same confidentiality obligation with regard to any confidential information transmitted by CIK to NTC pursuant to Paragraph 3.2 hereof.

5. TERMINATION

5.1 In the event of any material breach of this Agreement, the non-defaulting party may terminate this Agreement if the breach is not cured within 60 days following notice of breach. In the event of termination by reason of the breach or default

4

by either party hereunder, other party shall be entitled to recover all losses and damages calculated on the profits such other party would have received but for the breach or default on the part of either party. This Agreement shall be governed by and construed in accordance with the laws of State of Illinois.

5.2 CIK may terminate this Agreement effective at the beginning of any 12-month period after March 31, 2000 provided that notice of such cancellation shall be given at least 90 days prior to such effective date. NTC may not terminate this Agreement unless otherwise provided herein.

5.3 Upon expiration or earlier termination of this Agreement as provided herein, all rights and obligations provided in this Agreement shall forthwith terminate except (1) the obligation concerning any amount payable to NTC by CIK which would have accrued under this Agreement on or prior to such termination and (2) the confidentiality obligation set forth in Paragraph 4 hereof for five years after the termination or expiration of this Agreement.

5.4 Notwithstanding Paragraph 5.3, after the expiration of this Agreement CIK shall have a non-exclusive rights and license to use the Information and to manufacture, sell and use NTC Product in the Territory if CIK pays to NTC running royalty of 2% of Net Sales of NTC Product. NTC agrees to have a meeting with CIK, upon request by CIK, to discuss appropriate reduction of royalty, if appropriate, in view of decrease of Confidential Information.

6. GENERAL

6.1 All notices required or desired to be given hereunder shall be given by hand delivery, or by registered or certified mail, return receipt requested, to the addresses stated below, and shall be effective upon receipt.

6.2 NTC and CIK agree that any prior agreements between NTC and CIK relating to the distribution, use or manufacture of NTC Product, including Confidentiality and Non-Use Agreement dated August 13, 1996, shall be superseded by this Agreement excepting that the License Agreement of April 15, 1997 and Distribution Agreement of October 30, 1996 between NTC and CIK shall be effective until April 1, 1998, when the first royalty period under this Agreement begins, to the extent and solely for the purpose of enabling CIK to continue its manufacture and distribution of NTC Product until April 1, 1998.

6.3 Each party is an independent contractor. Neither party is the agent of the other, and neither shall have authority to bind the other.

AGREED:

Nanophase Technologies Corporation         C.I.Kasei Co., Ltd.
453 Commerce Street                        18-1, 1-Chome, Kyobashi, Chuo-ku
Burr Ridge, Illinois 60521                 Tokyo, Japan

By: /s/ Donald J. Freed                    By: /s/ Shigeo Sano
   ---------------------------------          ----------------------------------
   Donald J. Freed, Vice President         Shigeo Sano, Senior Managing Director

5

EXHIBIT 10.18

SUPPLY AGREEMENT

This SUPPLY AGREEMENT (the "Agreement") is made and entered into as of December 31, 1997 by and among EKC TECHNOLOGY, INC., a California corporation ("EKC") and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation ("Nanophase") with reference to the following recitals:

RECITALS

A. Effective on the date hereof, Moyco Technologies, Inc. ("Moyco") and certain of its affiliates and EKC have entered into that certain Asset Purchase Agreement (the "Asset Purchase Agreement") and agreed to sell to EKC all of its CMP Assets (as defined in the Asset Purchase Agreement).

B. Effective on the date hereof, Moyco and EKC have entered into that certain Interim Manufacturing Agreement whereby Moyco has agreed to manufacture for EKC certain CMP Products (as defined in the Asset Purchase Agreement) for an interim period.

C. In connection with the Asset Purchase Agreement and with the express written consent of Nanophase, Moyco has assigned, or will assign, to EKC the supply contract by and between Moyco and Nanophase (the "Existing Supply Agreement") relating to Nanophase Particles (as defined below).

D. It is understood that EKC has substantial experience in developing products for the semiconductor industry and obtaining the necessary qualifications therefor, and that the process of qualifying CMP Products (defined below) with semiconductor companies is a lengthy and expensive process that EKC would be unwilling to undertake without the assurances granted hereby.


E. It is further understood that Nanophase has limited experience in developing a market application for CMP Products or obtaining the necessary qualifications from semiconductor companies with respect thereto.

F. Accordingly, subject to the terms of this Agreement, Nanophase believes that it is in the best interest of fostering competition in the market for CMP Products for the right to use of Nanophase Particles in CMP Products to be granted to a single company in the business of marketing CMP Products.

G. EKC and Nanophase believe it is in their respective best interests to amend and restate the Existing Supply Agreement as provided herein.

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1. AGREEMENT TO SUPPLY. Subject to the terms and conditions hereof, Nanophase agrees to sell and deliver to EKC such Nanophase Particles (as defined below) that EKC shall order for its use in the production and sale or use of products, chemicals, slurries, compounds or other materials which are in any way used or useful in chemical mechanical polishing ("CMP Activities"). Nanophase Particles shall mean those products described in EXHIBIT A hereto together with any improvements thereto and any new particles developed by or for Nanophase which are used or useful in chemical mechanical polishing.

2. EXCLUSIVITY.

(a) Subject to the terms and conditions of this Agreement, Nanophase agrees that without the express written consent of EKC, it shall not sell or deliver to any party other than EKC any Nanophase Particles which it has reason to believe, after investigation or advised by EKC, shall be used in any of the CMP Activities.

2

(b) The parties hereto understand and agree that EKC shall not be precluded from obtaining, by purchase or otherwise, particles or abrasives for use in chemical mechanical polishing from suppliers other than Nanophase; except, however, before obtaining plasma produced particles for use in chemical mechanical polishing from other suppliers, EKC shall give Nanophase the first right of refusal to supply such plasma produced particles on no less favorable terms and conditions as the other supplier.

3. TERM. This Agreement shall commence on January 1, 1998 and shall extend through and until December 31 2004, unless earlier terminated as provided in
Section 4 hereof.

4. TERMINATION. Nanophase may terminate this Agreement upon thirty (30) days written notice to EKC following EKC's failure to meet the applicable Minimum Annual Purchase Threshold (set forth below); however, EKC shall have the right to cure such deficiency and avoid termination of this Agreement by submitting to Nanophase a prepaid order for the deficiency in the applicable Minimum Annual Purchase Threshold prior to the expiration of the 30-day notice period.

For each year during the term hereof, the Minimum Annual Purchase Threshold shall be as follows:

             Minimum Annual
Year         Purchase Threshold
----         ------------------
              (000's omitted)
1998                $   50
1999                $  100
2000                $  250
2001                $  600
2002                $1,000
2003                $1,500
2004                $1,500

3

5. TERMINATION OF EXCLUSIVITY. If EKC fails to purchase from Nanophase an amount of Nanophase Particles required to meet the applicable Minimum Annual Exclusivity Threshold (set forth below), then Nanophase may terminate its exclusivity obligation only as set forth in Section 2(a) hereof, upon thirty
(30) days written notice to EKC; however, EKC shall have the right to cure such deficiency and avoid the termination of Nanophase's exclusivity obligation by submitting to Nanophase a prepaid order in the amount of such deficiency prior to the expiration of the 30-day notice period. In the event the exclusivity obligation of Nanophase is so terminated, the remaining rights and obligations of this Agreement shall nevertheless remain in full force and effect unless terminated in accordance with Section 4 hereof.

For each year during the term hereof, the Minimum Annual Exclusivity Threshold shall be as follows:

                             Minimum Annual
                          Exclusivity Threshold
                          ---------------------
Year                         (000's omitted)
----
1998                         $   500 (1)
1999                         $ 1,000
2000                         $ 2,500
2001                         $ 6,000
2002                         $10,000
2003                         $15,000
2004                         $15,000

6. TERMINATION OF SUPPLY MAINTENANCE OBLIGATION. If EKC fails to purchase from Nanophase an amount of Nanophase Particles required to meet the applicable supply maintenance obligation (set forth below), Nanophase may terminate its obligation to supply Nanophase Particles to EKC hereunder, except, however, Nanophase shall thereafter continue to be obligated to supply EKC with quantities of Nanophase Particles sufficient for EKC to satisfy all orders for CMP Products that EKC receives from its customer base existing at the time of such termination (the "Supply Maintenance Obligation"). Nanophase may terminate its


(1) For purposes of the 1998 Minimum Exclusivity Threshold, Nanophase shall give credit to EKC for EKC's purchase, pursuant to the Asset Purchase Agreement, of $250,000 of Nanophase Particles from Moyco.

4

obligation to supply Nanophase Particles other than to EKC's existing customers base upon thirty (30) days written notice to EKC following EKC's failure to meet the applicable Minimum Supply Maintenance Threshold (set forth below); however, EKC shall have the right to cure such deficiency and avoid such termination by submitting to Nanophase a prepaid order for the deficiency in the applicable Minimum Supply Maintenance Threshold prior to the expiration of the 30-day notice period.

For each of the years during the term hereof, the Minimum Supply Maintenance Threshold shall be as follows:

                             Minimum Annual
                          Maintenance Threshold
                          ---------------------
Year                         (000's omitted)
----
1998                            $  250 (2)
1999                            $  500
2000                            $1,250
2001                            $3,000
2002                            $5,000
2003                            $7,500
2004                            $7,500

7. TECHNICAL SERVICE. Nanophase shall provide EKC with customer and technical support and related research, with respect to Nanophase Particles and CMP products containing Nanophase Particles. The scope and level of such technical support and related research shall be established by mutual agreement of the parties prior to the beginning of each year that this Agreement is in effect. The parties shall also mutually agree prior to each year this Agreement is in effect the extent to which, if any, EKC shall fund such technical support and related research, except, however, EKC and Nanophase agree that EKC shall pay to Nanophase $100,000 for technical support and related research in calendar year 1998, such amount to be payable in quarterly installments of $25,000 each. Such technical support and related research shall include, but be not limited to (i) customer technical presentations, (ii) customer technical support


(2) For purposes of meeting the 1998 Minimum Supply Maintenance Threshold, Nanophase shall give credit to EKC for EKC's purchase of $250,000 of Nanophase Particles from Moyco.

5

activities, (iii) hosting visits by EKC customers and prospective customers at Nanophase's facilities, and (iv) provide such other reasonable support requested by EKC. Nanophase agrees to provide competent, qualified personnel, facilities and material to perform the technical support and related research required by this Section 7.

8. ORDERS. On or before the 15th day of each month during the term hereof, EKC shall submit to Nanophase a schedule of its anticipated requirements of Nanophase Particles for the succeeding four (4) months (each a "Monthly Schedule"). It is agreed that EKC's anticipated requirements of Nanophase Particles as set forth on the Monthly Schedule for the first and second succeeding months shall be deemed an irrevocable purchase order and the anticipated requirements for the third and fourth succeeding months shall be deemed non-binding estimates. Notwithstanding the foregoing, EKC shall not be required to submit a Monthly Schedule to Nanophase before June 15, 1998.

9. PRICE. The initial prices for Nanophase Particles to be supplied to EKC under this Agreement are set forth on Exhibit "A" attached hereto. Nanophase agrees not to increase such prices prior to January 1, 2000 and that any proposed price changes thereafter shall not be effective for any quarter unless Nanophase has given EKC ninety (90) days prior written notice of proposed price changes prior to the first day of such quarter. For example, in order for a proposed price change to be effective on January 1, 2000, written notice thereof shall have to be given to EKC no later than October 2, 1999.

10. PAYMENT. Payment for Nanophase Particles shall be due within thirty
(30) days of delivery of such Nanophase Particles to a suitable common carrier F.O.B. Nanophase's domestic Plant.

11. Specifications, Warranty, etc. Nanophase agrees that all Nanophase Particles supplied to EKC pursuant hereto shall meet the specifications set forth on Exhibit "A" hereto.

6

12. SHIPMENT. The Nanophase Particles shall be shipped F.O.B. Nanophase's domestic Plant via a common carrier reasonably suitable to EKC and title and risk of loss with respect thereto shall pass to EKC at the FOB point.

13. NON-EXCLUSIVE LICENSE. If Nanophase fails to perform any of its material obligations hereunder and such failure has not been cured within sixty (60) days following written notice from EKC, in addition to any other rights and remedies EKC may have, then Nanophase shall grant to EKC, at commercially reasonable royalty rates, a non-exclusive license to manufacture Nanophase Particles for use in CMP Products. In that event Nanophase shall promptly supply to EKC any and all trade secrets, know-how, manufacturing information, documents, software, databases or other information used or which may be used in the manufacture of Nanophase Particles. EKC reserves the right to offset against such royalties otherwise due and payable to Nanophase any claims, damages, expenses or losses it suffered as a result of Nanophase's failure to perform its obligation hereunder.

14. NOTICES. All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party's address set forth below or to such other address as a party may designate by written notice hereunder, and shall be either (i) delivered by hand, (ii) made by telex or facsimile transmission, (iii) sent by recognized overnight courier, or (iv) sent by registered or certified mail, return receipt requested, postage prepaid:

If to Nanophase:           Nanophase Technology Corporation
                           453 Commerce Street
                           Burr Ridge,IL 60521
                           ATTN: Vice President, Marketing
                           Phone: (630) 323-1200
                           Fax: (630) 323-1221
With copy to:


If to EKC:                 EKC Technology, Inc.
                           2520 Barrington Court
                           Hayward, California 94545
                           ATTN: President

7

                           Phone: (510) 784-9105
                           Fax: (510) 784-9182


With a copy to:            ChemFirst Inc.
                           700 North Street
                           Jackson, MS 39202
                           ATTN: General Counsel
                           Phone: (601)948-7550
                           Fax: (601) 949-0292

All notices, requests, consents and other communication hereunder shall be deemed effective (i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by telex, or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic confirmation or otherwise, (iii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the fifth business day following the day such mailing is made.

15. ENTIRE AGREEMENT. This Agreement together with the Exhibits hereto (the "Documents") embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in the Documents shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.

16. MODIFICATIONS AND AMENDMENTS. No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power of remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or

8

demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

17. ASSIGNMENT. Neither this Agreement, nor any right or obligation hereunder, may be assigned by any of the parties hereto without the prior written consent of the other party, which consent shall not be unreasonably withheld.

18. PARTIES IN INTEREST. This Agreement shall be binding upon and inure solely to the benefit of each party hereto and their permitted assigns, and nothing in this Agreement, express or implied, is intended to confer upon any other person any rights or remedies of any nature whatsoever under or by reason of this Agreement. Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this Agreement.

19. GOVERNING LAW. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the internal laws of the State of Illinois, without giving effect to the conflict of law principles thereof.

20. SEVERABILITY. In the event that any court of competent jurisdiction shall finally determine that any provision, or any portion thereof, contained in this Agreement shall be void or unenforceable in any respect, then such provision shall be deemed limited to the extent that such court determines it enforceable, and as so limited shall remain in full force and effect. In the

9

event that such court shall determine any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect.

21. HEADINGS AND CAPTIONS. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify, or affect, or be considered in construing or interpreting the meaning or construction of any of the terms or provisions hereof.

22. EXPENSES. Each of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others engaged by such party) in connection with this Agreement and the transactions contemplated hereby whether or not the transactions contemplated hereby are consummated.

23. COUNTERPARTS. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

24. ALTERNATE DISPUTE RESOLUTION. If a dispute arises concerning or related to this Agreement, it is the express intent of the parties hereto that they commit to enter into good faith efforts to resolve the dispute at a meeting or meetings in which a senior official or officials with decision making power shall participate. The purposes of such negotiations will be an honest effort to allow the parties an opportunity to determine if the dispute is resolvable prior to expensive and lengthy litigation. The parties shall have complete discretion as to what procedure shall be used and what agenda shall be discussed.

Any such negotiation or series of negotiations shall be held as confidential by all parties and the parties hereto do commit themselves that they shall not disclose either the existence of such proceedings or the content thereof. Any participation in or initiation of such discussions shall not be deemed to be an admission of liability and no statement made or provided in or

10

related to such negotiations shall be construed as a statement against interest or otherwise disclosed or used in any proceeding involving the parties.

The parties commit to commence these negotiations prior to litigation being filed (except for injunctive proceedings); but in no event shall they commence later than four (4) months after litigation is filed. If a party declines to participate, the other party may request the Court to grant a stay of the litigation (except for injunctive relief) while the parties attempt to settle the litigation through this negotiation method, and the party declining to participate agrees not to oppose such a stay.

25. TERMINATION OF EXISTING SUPPLY AGREEMENT. The parties hereby terminate, without further liability to either party, that certain Purchase and Distribution Agreement effective February 27, 1997 as amended and that certain Marketing Agreement dated August 29, 1996 by and between Moyco Technologies, Inc. and Nanophase, which agreements were assigned by Moyco to EKC as of December 31, 1997, and the rights and obligations of Nanophase and EKC with respect to the supply of Products shall be solely governed by this Supply Agreement.

IN WITNESS WHEREOF, Buyer and Seller have executed this Agreement as of the day and year first above written.

EKC TECHNOLOGY, INC.

By: /s/ SIGNATURE
   -------------------------------

Title:
      ----------------------------

NANOPHASE TECHNOLOGIES CORPORATION

By: /s/ Donald J. Freed
   -------------------------------

Title: VP, Marketing
      ----------------------------

11

EXHIBIT "A"

PART A: PRICE SCHEDULE

Price per kilogram, FOB NTC Plant

NanoTek(R) Aluminum Oxide per specification A(1) $50.00

NanoTek(R) Cerium Oxide per specification A(2) $70.00

PART B: PARTICLE SPECIFICATIONS

Al. NanoTek Aluminum Oxide:

Free flowing, white powder manufactured by Physical Vapor Synthesis under one or more of U.S. Patents 5,128,081, 5,320,800, 5,460,701, 5,514,349, 4,482,134, 4,642,207, 4,689,075, 4,889,665, 4,610,718 and 4,732,369, and having the

following attributes:

Crystal Phase                   Gamma
                                    2    +     2

Surface Area (BET) 45 m /gm - 15 m /gm Chemical Purity (assay) >99.6%

A2. NanoTek Cerium Oxide:

Free flowing, pale yellow powder manufactured by Physical Vapor Synthesis under one or more of U.S. Patents 5,128,081, 5,320,800, 5,460,701, 5,514,349, 4,482,134, 4,642,207, 4,689,075, 4,889,665, 4,610,718 and 4,732,369, and having the following attributes:

Crystal Phase                   Gamma
                                    2   +      2
Surface Area (BET)              80 m gm - 10 m /gm
Chemical Purity (assay)         >99.6%

12

EXHIBIT 11

STATEMENT REGARDING COMPUTATION OF LOSS PER SHARE

                                        YEAR ENDED DECEMBER 31,

                                    1995          1996          1997


HISTORICAL:
Weighted average common shares
outstanding                        77,586        77,586        1,283,359

Net loss                           $(1,959,874)  $(5,577,688)  $(3,072,470)

  Net loss per common share        $(25.26)      $(71.89)      $(2.39)




                                        YEAR ENDED DECEMBER 31,

                                    1995          1996          1997



PRO FORMA:
Weighted average common shares
outstanding                        77,596       77,586         1,283,359
Weighted average preferred
shares outstanding                 4,045,295    6,758,094      6,924,947


    Total                          4,122,881    6,835,680      8,208,306


Net loss                           $(1,959,874) $(5,577,688)   $(3,072,470)
Pro forma net loss per share       $(.48)       $(.82)         $(.37)


ARTICLE 5
MULTIPLIER: 1


PERIOD TYPE YEAR
FISCAL YEAR END DEC 31 1997
PERIOD START JAN 01 1997
PERIOD END DEC 31 1997
CASH 3,988,368
SECURITIES 26,884,852
RECEIVABLES 1,641,489
ALLOWANCES 19,276
INVENTORY 957,303
CURRENT ASSETS 33,584,150
PP&E 3,281,216
DEPRECIATION 881,323
TOTAL ASSETS 36,196,569
CURRENT LIABILITIES 1,545,235
BONDS 0
PREFERRED MANDATORY 0
PREFERRED 0
COMMON 48,396,005
OTHER SE (13,744,671)
TOTAL LIABILITY AND EQUITY 36,196,569
SALES 3,723,492
TOTAL REVENUES 3,723,492
CGS 3,935,766
TOTAL COSTS 7,000,825
OTHER EXPENSES 0
LOSS PROVISION 0
INTEREST EXPENSE 0
INCOME PRETAX (3,072,470)
INCOME TAX 0
INCOME CONTINUING (3,072,470)
DISCONTINUED 0
EXTRAORDINARY 0
CHANGES 0
NET INCOME (3,072,470)
EPS PRIMARY (2.39)
EPS DILUTED (2.39)

ARTICLE 5
RESTATED:


PERIOD TYPE 9 MOS
FISCAL YEAR END DEC 31 1997
PERIOD START JAN 01 1997
PERIOD END SEP 30 1997
CASH 770,704
SECURITIES 2,001,429
RECEIVABLES 1,441,206
ALLOWANCES 46,976
INVENTORY 503,815
CURRENT ASSETS 4,768,215
PP&E 2,980,884
DEPRECIATION 767,924
TOTAL ASSETS 7,286,071
CURRENT LIABILITIES 1,709,155
BONDS 0
PREFERRED MANDATORY 0
PREFERRED 19,553,083
COMMON 450
OTHER SE (13,976,617)
TOTAL LIABILITY AND EQUITY 7,286,071
SALES 2,245,415
TOTAL REVENUES 2,245,415
CGS 3,321,288
TOTAL COSTS 5,607,223
OTHER EXPENSES 0
LOSS PROVISION 0
INTEREST EXPENSE 0
INCOME PRETAX (3,304,416)
INCOME TAX 0
INCOME CONTINUING (3,304,416)
DISCONTINUED 0
EXTRAORDINARY 0
CHANGES 0
NET INCOME (3,304,416)
EPS PRIMARY (42.59)
EPS DILUTED (42.59)